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CYTOPLASMIC CYCLIN E MEDIATES RESISTANCE TO AROMATASE INHIBITORS IN
BREAST CANCER

Iman Doostan, M.D.
Supervisory Professor: Dr. Khandan Keyomarsi, Ph.D.

Almost seventy percent of patients with breast cancer have tumors that express hormone
receptors and need hormonal therapy. Aromatase inhibitors (AIs) block estrogen
biosynthesis and are considered as the first line hormonal therapy for ER+ post-menopausal
patients. However, resistance to these drugs remains a major challenge in clinic and the
biology of such resistance is not completely understood. Cyclin E is deregulated in breast
cancer through generation of low molecular weight isoforms that renders patients to a poor
survival. Herein, we show that HR+ patients with LMW-E expressing tumors show
diminished early response to neo-adjuvant AIs as well as poor recurrence-free survival. In
addition, xenografts with LMW-E expression are unresponsive to letrozole. Using LMW-E
inducible model system, we show that LMW-E expression bypasses cell cycle inhibition of
AIs through up-regulation of CDK2, Rb, and phospho-Rb in a reversible manner. Lastly, we
show that LMW-E expressing breast cancer cells respond to dinaciclib but not palbociclib.
Taken together, this study suggests that targeting CDK2 by inhibitors such as dinaciclib in
combination with AIs is a potential therapeutic strategy for HR+ postmenopausal breast
cancer patients with LMW-E expressing tumors.
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CHAPTER 1: INTRODUCTION TO USE OF ANTIESTROGEN THERAPIES
IN BREAST CANCER
1-1 EPIDEMIOLOGY OF BREAST CANCER
Cancer follows cardiovascular diseases as the cause of death in the US (1). In women,
breast cancer (BC) comprises the top site of cancer diagnosed each year excluding skin
cancer (30% of all cancers). Lung and bronchus cancer includes only 12% of all the new
cancer cases in women. About 252,710 of breast cancer cases are estimated in US in 2017
(1). In addition, only lung cancer precedes breast cancer in terms of mortality from a
malignancy in women (1). These statistics show the significance of breast cancer and
highlight the need for new therapeutic strategies to better control this devastating disease.

1-2 SUBTYPES OF BREAST CANCER AND TREATMENT OPTIONS
Breast cancer is a heterogeneous disease. Historically, breast cancer was classified
according to the histopathology of the tumor. Staining of breast cancer tissue samples for
estrogen, progesterone, and Her-2 receptors was the mainstay for this type of classification.
Based on the positivity of each receptor, breast cancer is divided into four subtypes, i.e.,
hormone receptor positive (express ER or PR but lack Her-2), hormone and Her-2 positive
(express both ER/PR and Her-2), Her-2 positive (express Her-2 but not ER/PR) and triple
negative (deficient in three receptors, also called basal like) (2, 3). Perou and colleagues
used cDNA microarray analysis to examine gene expression profile of normal and tumor
tissues from 42 individuals (including breast cancer tissues, DCIS and normal breast tissue)
(4). Based on similarity and variation of gene expression in these samples, they identified
four different subtypes of BC known as “ basal-like, ER positive/luminal, Erb-B2 positive, and
normal breast subtypes” (4). Further studies suggest that such classification based on gene
expression profile has prognostic value (5). Sotiriou et al used microarray analysis to
examine gene expression profile of 99 breast tumors from patients (both node negative and
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positive) with available clinical and histopathological data (5). Hierarchical clustering of
these tumors identified two main groups including luminal (mainly ER positive) and basal
(mainly ER negative) with some minor subgroups including luminal subtype A, luminal
subtype B (or possibly C), normal breast-like, and ERBB2 positive subtypes (5). Correlation
of the subtype clustering with outcome revealed that patients with ER negative tumors
(basal/ERBB2) relapsed earlier and had worse survival in comparison to patients with
luminal-subtype tumors (5). Luminal A tumors express hormone receptors but lack Her-2
and show low expression of Ki67 as proliferation marker. These tumors tend to grow slower
and have the best prognosis of all subtypes. In contrast, luminal B subtypes, overexpress
Her-2 receptor with high Ki67 expression, and tend to have lower survival rates compared to
luminal A (6). Her-2 subtype is detected in younger women compared to luminal types and
have fairly poor prognosis. Finally, tumors with basal-like gene expression profile account for
the majority of the triple negative breast cancer (TNBC) and show aggressive behavior. In
addition, this subtype is more prevalent in African American women and has the worst
prognosis of all subtypes with higher tendency to relapse (7, 8). Analysis of these TNBC
tumors reveals a heterogeneous pattern (9). Lehmann and colleagues analyzed gene
expression profile of 386 triple negative tumors (used as training set) and 201 other TN
tumors (used as validation set) from 21 data sets (9). They clustered these tumors according
to differential gene expression into 6 subtypes including “mesenchymal, mesenchymal
stem–like, immune-modulatory, luminal androgen receptor, basal-like 1, and basal-like 2
subtypes” (9). Each distinct subtype has enrichment of specific sets of genes that can be
clustered into specific pathways. For example, basal like 1 subtype showed enrichment of
genes that are clustered into cell cycle and DNA replication regulatory pathways, while
luminal androgen subtypes were enriched in androgen metabolism pathways (9). This
suggests that although all these tumors are considered as triple negative, they rely on
different pathways and hence individual targeted therapies could have beneficial therapeutic
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value. As a proof of concept, the authors showed that representative cell lines for each
subtype show better response to specific molecularly targeted therapy (9). For example, cell
lines representative of luminal androgen subtype expressed higher androgen receptor both
at mRNA and protein level and these cell lines responded to a lower dose of bicalutamide
(androgen receptor antagonist) (9). Novel therapeutic approaches using targeted therapies
in triple negative population of breast cancer are discussed in further detail in this section.

1-2a Hormone receptor positive breast cancer and treatment options
Hormonal therapies are the main treatment strategies for HR+ cancer subtypes (10). In
early stage hormone receptor positive patients, it is necessary is to recognize patients with
low possibility of recurrence in order to avoid the use of aggressive treatments such as
chemotherapy in this subpopulation. Genomic tools that measure gene expression profiles
with the goal to estimate the benefit of adding chemotherapy to anti-hormonal therapies are
now commonly incorporated into decision-making regarding selection of treatment for HR+
breast cancer patients. Mammaprint and Oncotype DX are examples of these tools that
have been validated for estimation of recurrence of breast cancer (11, 12). Using gene
expression profile, van 't Veer and colleagues identified a signature of poor prognosis in
early stage breast cancer patients (T1 or T2 and N0) (13). The authors performed
microarray analysis on 98 tumors from early stage patients and identified a 70-gene
signature that significantly correlated with 5-year breast cancer relapse (13). Patients with
poor prognosis signature showed up-regulation of genes that play role in biologic processes
such as angiogenesis, invasion and metastasis (13). In this dataset, tumors marked as poor
prognosis signature had 28-fold higher change of metastasis within 5-year in comparison to
tumors with good prognosis signature (13). The same team incorporated this 70-gene
signature in prognostication of 295 stage I/II breast cancer patients including both ER+/ERpatients with or without lymph node involvement (11). Results from this study revealed 10-
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year survival rate of 94.5% (±2.6%) in patients who were considered “good-prognosis”
based on the gene expression signature (11). In contrast, only 54.6% (±4.4%) of patients
with poor-prognosis signature survived within the same period of time. In addition, patients
with poor-prognosis signature had approximately five times higher chance of metastasis
compared to ones with good-prognosis signature (11). This suggests that gene expression
profiles of the initial tumor can inform about the possibility of metastasis during the course of
disease progression. In a similar study, the authors examined the correlation between gene
expression and recurrence in 668 node negative ER+ patients who underwent tamoxifen
treatment (12, 14). RT-PCR was performed on paraffin embedded tissue samples to
measure expression of 21 cancer related genes (OncotypeDX) including genes involved in
proliferation (Ki67, CCNB1 expressing cyclin B1), invasion (matrix metallopeptidase 11),
hormone receptors (ER and PR) and Her-2 to mention a few. They classified patients
according to the score of gene expression into low-risk, intermediate-risk, or high-risk group
(12). Statistical analysis showed that 51% of patients were considered as low-risk and only
6.8% of these patients had distant recurrence within 10 years. This recurrence rate was
significantly lower compared to 30.5% recurrence in the high-risk category (12). Taken
together, these studies show that molecular profile of the tumor at early stage is a valuable
tool for estimation of prognosis in the early stage cancer and thus avoid aggressive
treatment such as chemotherapy in patients who will not benefit from such treatment.
Generally, in the early stage disease, hormone receptor positive patients will receive
anti-estrogen therapy either tamoxifen for premenopausal or aromatase inhibitors in the
post-menopausal settings for five years (15). However, a few studies propose longer
treatment regimens in these patients. For example, a double-blind study examined the
extension of treatment using letrozole in patients who have finished five-year tamoxifen
treatment. The results showed improved disease-free survival by 48% in the letrozole arm
compared to placebo control group (16). Similarly, extension of tamoxifen therapy after five
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years in premenopausal patients significantly reduced recurrence and mortality from breast
cancer (17). However, this benefit should be balanced against the expected side effects
from anti-hormonal therapy such as enhanced risk of endometrial cancer using tamoxifen
and joint pain and fracture with aromatase inhibitors (16, 17). Besides hormonal therapies,
bisphosphonates have shown beneficial effects in breast cancer patients (18, 19).
Bisphosphonates inhibit the activity of osteoclasts and decrease bone resorption (20). In
addition, studies have shown that bisphosphonates have anti-tumor activity by inhibition of
adhesion molecules (21), exert anti-proliferative activity (22), and show pro-apoptotic activity
(23). A meta-analysis of bisphosphonates in breast cancer patients showed that
bisphosphonates not only decrease bone recurrence of breast cancer but also improve
outcome in the post-menopausal patients (24). In contrast to early stage disease, patients
with advanced disease often show inherent (de novo) resistance to anti-estrogen treatments
or advance in spite of early initial response (25). In these situations, addition of other
treatment options such as inhibitors of cyclin dependent kinase 4/6 is needed (See section
cyclin D and CDK4/6 inhibitors in breast cancer). Fulvestrant, which down-regulates and
inhibits ER protein (26), is often used in the metastatic setting alone or in combination with
other hormonal therapies.

1-2b HER-2 positive breast cancer and treatment options
Approximately one fifth of breast cancer patients overexpress the Her-2 receptor (27).
Her-2 is a trans-membrane receptor and part of the EGFR family that can be overexpressed
or amplified in breast cancer (28). Therapies targeting the HER2 pathway are currently used
in the early stage as well as advanced stage of the disease and have improved survival of
Her-2 positive breast cancer patients (29). These inhibitors of the pathway include herceptin,
lapatinib, pertuzumab and T-DM1 (30, 31). Trastuzumab (herceptin) is an antibody that can
recognize and inhibit Her-2 receptor by binding to the extracellular portion of the receptor
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(Figure 1). Clinical trials using the combination of trastuzumab and chemotherapy showed
that addition of trastuzumab to chemotherapy delayed progression of breast cancer by
approximately three months in patients with metastatic disease who overexpress Her-2. In
this study, half of the 235 patients who received combination of chemotherapy and herceptin
showed objective response versus only 32% in the chemotherapy alone group (32). Similar
to other therapies, resistance to herceptin develops overtime limiting its benefit (33). One
such mechanism of resistance is the loss of the extracellular domain of the receptor such
that the receptor can not be detected and inhibited by the antibody (34). Another possible
mechanism of resistance to herceptin is the heterodimer complex formation between Her-2
and Her-3 receptors (35, 36). Clinically, Her-3 expression is detected in a subset of Her-2
expressing breast cancer tumors and overexpression of both receptors is linked with poor
survival (37). Mechanistically, this dimerization process results in continued tyrosine kinase
activity of the intracellular domain of the receptor in spite of herceptin treatment leading to
activation of downstream signaling pathways (36). Pertuzumab is another monoclonal
antibody capable to bind to extracellular domain of Her-2 but at a different site compared to
herceptin. Unlike herceptin, pertuzumab prevents the dimerization between Her-2/Her-3
(38). Preclinical models showed additional antitumor activity of pertuzumab in combination
with herceptin suggesting the complementary action of these two antibodies (39). A phase
III trial in Her-2 positive metastatic breast cancer patients showed that addition of
pertuzumab to herceptin and docetaxel is an effective combination strategy to be used as
first line treatment (40, 41). Another class of Her-2 receptor targeting drugs is tyrosine
kinase inhibitor lapatinib. Since lapatinib blocks the intracellular domain of the receptor, any
modification of the extracellular domain can still be inhibited by the drug (42). Therefore, it is
predicted to be effective in breast cancer tumors resistant to herceptin (43). Combination of
lapatinib with trastuzumab in an in vivo model showed enhanced antitumor activity
compared to individual drugs (44). Another class of Her-2 targeting drug isTDM-1, which
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consists of two components, emtansine (a microtubule inhibitor) linked to trastuzumab. Her2 positive cancer cells are recognized by the Her-2 antibody resulting in uptake and release
of the chemotherapy drug only in the cancer cells while sparing the normal cells. A
preclinical model using the combination of pertuzumab and T-DM1 showed enhanced antiproliferative effect in vitro and prolonged control of tumor volume in vivo (45).
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Figure 1. Anti-Her-2 targeted therapies in breast cancer. Her-2 is a member of the
EGFR tyrosine kinase receptor that can activate intracellular transduction pathways such as
PI3K and MAPK resulting in proliferation and survival of breast cancer cells. Trastuzumab
(herceptin) and pertuzumab block Her-2 by recognizing the extracellular domain the
receptor. Lapatinib binds to intracellular domain and inhibit the tyrosine kinase activity of the
receptor. TDM1 is composed of trastuzumab (antibody) and emtansine (cytotoxic).
Emtansine is released inside the cells when herceptin binds to Her-2 receptor on the surface
of breast cancer cells.
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1-2c Triple negative breast cancer and treatment options
Fifteen to twenty percent of all breast cancers have tumors without expression of ER,
PR and HER-2, considered as triple negative breast cancer (TNBC). Therefore, antiestrogen and Her-2 targeting drugs are ineffective in this subpopulation while chemotherapy
is the major therapeutic option for these patients (46). TNBC patients have the worst
prognosis among all breast cancer patients (7, 47). However, these tumors tend to respond
better to chemotherapies compared to hormone receptor positive tumors in the short term
(48). Lymph node positive TNBC patients will require chemotherapy to control the disease.
Generally, these patients are treated with adjuvant chemotherapy using taxanes and
anthracyclines (7). Retrospective studies have compared these regimens in different
settings. As an example, a randomized trial including early stage node positive breast
cancer patients showed that a regimen including cyclophosphamide, epirubicin and
fluorouracil (CEF) is superior to cyclophosphamide, methotrexate and fluorouracil (CMF).
Follow up for 10 years showed that CEF regimen increased relapse-free survival in
comparison to CMF regimen, 52% versus 45%, respectively (49). TNBC patients who did
not achieve complete eradiation of tumors in their breast and axilla (pathologic complete
response) after chemotherapy have higher relapse rate. In contrast, TNBC patients with a
small tumor (less than 0.5 cm) without lymph node involvement have very good prognosis
and may not benefit much from chemotherapy. Cytotoxic chemotherapy remains the
mainstay treatment in advanced TNBC patients. There is a great interest in the use of novel
targeted therapies in the metastatic settings as described in the next paragraphs (50-52).
Poly ADP ribose polymerase (PARP) inhibitors are examples of such targeted
therapies that have been investigated in recent years in patients harboring TNBC tumors
with BRCA1/BRCA 2 mutations. BRCA-1 mutation is detected in about 10-15% of TNBC
patients and is associated with high-grade tumor and basal like subtype (53). Germline
inheritance of a mutation in the BRCA1 or BRCA2 genes increases the risk of breast and
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ovarian cancer, in a cancer predisposition syndrome known as hereditary breast and
ovarian cancer syndrome (54, 55) and increases oncogenesis in contralateral breast (56).
Sixty percent of individuals having BRCA1 mutation and 55% of those harboring BRCA2
mutation are expected to have breast cancer by the age 70 (56). BRCA1 codes for a protein
with tumor suppressive function that is involved in DNA repair particularly the homologous
recombination pathway (57). Brca1−/− cells were not capable of activating the double strand
break repair mechanisms indicating the important role for BRCA1 function in suppressing
tumorigenesis (57). PARPs are a family of proteins with conserved domains that are able to
bind to DNA at the site of single-strand breaks and recruit other enzymes that play critical
role in DNA repair (58, 59). PARP-deficient mice are very susceptible to DNA damaging
agents and are prone to genomic instability (60). Most xenografts derived from BRCA2deficient cell lines responded to PARP inhibitor (AG14361) as a single agent suggesting that
PARP inhibitors are beneficial in BRCA mutant breast cancer patients (61, 62). Similarly,
PARP inhibitors induce genomic instability, apoptosis, and synthetic lethality in cell lines
deficient in BRCA1/2 repair pathway (63). Further preclinical work using the Brca1−/−,
p53−/− mouse model (representing TNBC tumors) shows that BRCA deficient tumors
respond to PARP inhibitor (64). In this model, breast cancer tumors generated in Brca1−/−,
p53−/− were implanted in wild type mice and treated with vehicle, PARP inhibitor
(AZD2281), cisplatin, or combination of both drugs (64). Results revealed the arm that
received PARP inhibitor showed improved survival compared to vehicle treated arm.
Moreover, the best survival curve was detected in the arm that received combination of
PARP inhibitor with cisplatin suggesting synthetic lethality (64). PARP inhibitor (olaparib)
was shown to have therapeutic benefit in BC patients with advanced recurrent disease who
harbor mutation in BRCA1 or BRCA2 (65). Patients were selected to receive two different
doses of olaparib, high dose (400 mg two times a day) or low dose (100 mg two times a
day) (65). Forty one percent of patients who received high dose and 22% of those with low
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dose of olaparib showed objective response (65). The most common adverse effects
included fatigue, nausea, and anemia (65). In addition, combination of PARP inhibitor with
standard chemotherapy is beneficial for TNBC patients (50). Addition of PARP inhibitor
(veliparib) plus carboplatin to standard neoadjuvant chemotherapy doubled the rate of
pathologic complete response, 52% vs 26% respectively (50). Taken together, these
preclinical and clinical studies show that targeting DNA damage repair pathways using
PARP inhibitors is an important treatment strategy in TNBC patients.
Besides from PARP inhibitors, other strategies such as blocking angiogenesis and
inhibiting cell surface receptors (such as EGFR) are under investigation in TNBC patients
(52, 66). Immunostaining of a panel of invasive breast cancer samples revealed higher
expression of EGFR receptor in TNBC patients compared to non-TNBC patients (67). A
phase II study examined the efficacy of EGFR inhibitor (cetuximab) compared to
combination of cetuximab with carboplatin in stage IV TNBC patients. Results from this
study revealed that only 6% of patients who received cetuximab and 16% of those who
underwent combination treatment responded to therapy (68). Examination of post-treatment
tissue revealed that the majority of patients showed active EGFR pathway possibly through
parallel activation (68). However, more promising results were found in another study in
which a combination of cetuximab and cisplatin increased response rate to 20% compared
to 10% (cisplatin arm) in metastatic TNBC patients and prolonged time to progression, but
increased the rate of severe adverse events (52). Similarly, using quantitative immunoassay
higher level of VEGF is detected in tumor specimens of TNBC patients compared to nonTNBC patients suggesting significance of VEGF in TNBC patients (69). Vascular endothelial
growth factor (VEGF) is a strong stimulator of new blood vessel formation secreted by tumor
tissues and can be blocked by monoclonal antibodies such bevacizumab (70, 71). A phase
III study combining bevacizumab to docetaxel in recurrent or metastatic Her2-negative
patients showed delayed progression of breast cancer without significant addition in the
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toxicity profile (51). In the neoadjuvant setting, bevacizumab increased the rate of pCR
when combined with cyclophosphamide plus docetaxel regimen for TNBC patients (66).
Taken together, these studies demonstrate that addition of targeted therapies to standard
chemotherapy regimens in a personalized approach opens new hopes for the treatment of
TNBC patients.

1-3 ESTROGEN AND ESTROGEN RECEPTOR IN BREAST CANCER
The discovery of estrogen hormone goes back to almost 80 years ago by Adolf
Butenandt when he isolated crystalized estrogen from urine of pregnant women (72).
Nowadays, it is evident that estrogen is mainly produced by ovaries in premenopausal
women. After menopause however, estrogen is produced by conversion of testosterone
through the activity of the aromatase enzyme, which is present in adipose and other tissues
(73, 74). The level of estrogen in plasma influences functions of multiple organs in the body.
In brain, estrogen fluctuation throughout the menstrual cycle affects cognition (75). Hormone
replacement therapy in women decreases the risk of Alzheimer disease suggesting that
estrogen has protective role against Alzheimer (76). Moreover, estrogen treatment
decreased depressive symptoms in post-menopausal women possibly through
enhancement of the serotonergic activities in the brain (77). In cardiovascular system,
estrogen regulates vascular tone, blood pressure, and decreases atherosclerosis formation
in the vessels (78, 79). It regulates turnover of the adult bone and stimulates the growth and
maturity of the skeletal system (80, 81). More importantly in reproductive system and breast
tissue, estrogen stimulates proliferation of the uterus endothelium as well as mammary
epithelial cells (82, 83).
Epidemiologic studies have shown a link between estrogen and breast cancer
formation. A study by Trichopoulus and colleagues found that among 3,887 patients with
long-term follow up, those who underwent surgical ovariectomy had lower risk of breast

12

cancer in comparison to individuals who did not undergo surgery (84). In addition, lifetime
exposure to estrogen is associated with higher risk of tumorigenesis in breast tissue (85,
86). In a prospective study, about 10000 women, aged 40 to 65, were included and followed
at least once a year for any possible breast cancer diagnosis (86). Women filled out
questionnaires regarding their age at menarche, history of pregnancies, breastfeeding and
other information during 1990 and 1991 and updated their information annually. A total of
1718 women were diagnosed with invasive breast cancer during the follow up of the study
until 1997 (86). Statistical analysis revealed the correlation between total number of
menstrual cycles in a woman’s lifetime (and before first pregnancy) and increased risk of
breast cancer (86). Similar epidemiologic studies have indicated that premature menarche,
late menopause, and nulliparity are linked with increased chance of developing breast
cancer suggesting the link between estrogen and breast cancer formation (84, 85). Similar
epidemiologic studies highlight the association between estrogen and breast cancer in
postmenopausal women (87, 88). Misser and colleagues measured estrogen and androgen
serum levels in 322 postmenopausal breast cancer patients and matched controls. Higher
levels of both hormones were detected in breast cancer patients compared to controls (87).
In a similar study, Kaaks and colleagues measured the level of different estrogen forms and
androgen in postmenopausal women before they develop breast cancer and compared that
to their matched controls. In their analysis, women with higher serum level of estrogens as
well as androgens had higher rate of breast cancer formation (88).
Estrogen pathway is activated upon binding of the hormone with two different estrogen
receptors known as ERα and ERβ, which are produced from two distinct genes. Estrogen
receptor is mainly localized to the nucleus and interaction with estrogen further enriches
nuclear localization of the receptor (89). Following interaction of these receptors with the
ligand, they become phosphorylated and form a dimer with another receptor, translocate to
the nucleolus, and bind to DNA to activate ER mediated gene expression (90). This is
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considered as classical ligand-dependent process in which ER functions in concert with
other proteins as a transcription factor. Several regulatory proteins known as coactivators
and corepressors interact with estrogen receptor and influence gene transcription (table 1).
In addition to this classical function, signaling pathways such as MAPK can phosphorylate
ER receptor and activate the pathway in the absence of estrogen (91, 92). Due to significant
role of estrogen pathway in breast cancer, different drugs have been developed and used in
clinic to block this pathway. These anti-estrogen medications are discussed in further detail
in the next section.
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Table 1- Coactivators/corepressors of ERα and their role in breast and other cancers
Name

Coactivator
or
Corepressor
Coactivator

Other name

TIF2(transcriptional
intermediary factor–
2)

Coactivator

GRIP1(glucocorticoid
receptor–interacting
protein 1)

NCO2(nuclear
receptor coactivator
2)

Repressor of
tamoxifen
activity

AIB1(Amplified in
Breast Cancer)

Coactivator

CBP(CREB binding
protein)

Coactivator

RAC3(receptorassociated
coactivator 3)
P300

TRAP220(thyroid
hormone receptor–
associated protein)

Coactivator

DRIP205

CARM1(coactivatorassociated arginine
methyltransferase
1)

Coactivator

PRMT4(protein
arginine Nmethyltransferase 4)

SRC-1(steroid
receptor
coactivator–1)
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Comment/Role

Reference

Recruits
chromatinmodifying
enzymes, link to
prognosis of
Her2+ BC
Fusion with MOZ
in AML,
coactivation of
PR
Overexpressed
in prostate
cancer,
translocated in
sarcoma
Overexpressed,
prognostic value
and EMT in BC
Interact with
BRCA and NFkappaB in BC,
mutated in
ovarian cancer
Link between
ERα and RNA
polymerase II,
interact with
BRCA1, cell
cycle role
through aurora
kinase A
Overexpressed
in BC, role in
growth and
metastasis of BC

(93, 94)

(95-97)

(98-100)

(101-103)

(104-106)

(107-109)

(110, 111)

Table 1 (continued)-coactivators/corepressors of ERα and their role in breast and
other cancers
Name
NCoR (nuclear
receptor
corepressor)

Coactivator or
corepressor
Corepressor

Other name
TRAC-1
(thyroidhormone- and
retinoic-acidreceptorassociated corepressor 1)

Comment/role

Reference

Represses ER
gene
transcription,
recruits
deaetylases

(112, 113)

hPR-A (human
progesterone
receptor A
isoform)
SMRT
(silencing
mediator of
retinoid and
thyroid
hormone
receptors)
REA (repressor
of estrogen
action)

Corepressor

Inhibits NFkappaB
signaling

(114)

Corepressor

(115, 116)

SHP (short
heterodimer
partner)

Corepressor

NR0B2
(nuclear
receptor
subfamily 0 B2)

RIP140
(receptorinteracting
protein 140)

Corepressor

NRIP1
(Nuclear
receptorinteracting
protein 1)
(NRIP1)

DAX-1
(dosagesensitive sexreversal)

Corepressor

RTA (repressor
of tamoxifen
activity)

Corepressor

Prevents
stimulated
growth by
tamoxifen,
regulates ERα
induced
transcription
Competes with
SRC-1 to
repress ERα
transcription
Interacts with
and inhibits ERα
directly,
competitive
inhibitor of AR
coactivators
Interacts with
HDACs,
regulates
activity of
glucocorticoid
receptor
Mutated in
congenital
adrenal
hyperplasia,
represses ERα
and AR
Interacts and
represses ERα

Corepressor
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(117, 118)

(119, 120)

(121, 122)

(123-126)

(127)

1-4 ANTIESTROGEN TREATMENT OPTIONS IN BREAST CANCER
More than 70% of breast cancer tumors express hormone receptors, thus these
patients may potentially benefit from therapies targeted against estrogen pathway. There
are three main options available to tackle against estrogen pathway by targeting different
mechanisms (Figure 2 and table 2). The first anti-estrogen treatment developed in the field
is known as Tamoxifen, considered as selective estrogen receptor modulator (SERM).
Tamoxifen binds to estrogen receptor and inhibits binding of the receptor to its ligand
estrogen (128). The other class of these drugs is known as selective estrogen receptor
downregulator (SERDs) such as Fulvestrant. Fulvestrant is a competitive inhibitor of ER that
not only binds to and blocks the receptor but also degrades it (129, 130). The third class of
antiestrogen treatments is aromatase inhibitors. Aromatase is the rate-limiting enzyme that
is responsible for conversion of androgens to estrogen. In contrast to the other two classes
of drugs that target ER, aromatase inhibitors inhibit generation of estrogen (131). Letrozole,
anastrozole and exemestane are three FDA approved AIs that are currently used in the
clinic in post-menopausal breast cancer patients (132, 133). In spite of improved survival
using anti-estrogen therapies in HR+ patients, some patients do not respond to these
medications (see resistance to aromatase inhibitors section). In addition, patients often
develop acquired resistance after initial therapy. Therefore, it is important to understand the
resistance mechanisms to each of these anti-estrogen treatments. The next sections will
describe the development, clinical use and resistance mechanisms of these drugs
individually in more detail.
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Table 2- Structure and classification of available anti-estrogens in breast cancer
Name

Class

Chemical structure

exemestane

aromatase inhibitors
(steroidal inactivator)

anastrozole

aromatase inhibitors
(nonsteroidal inhibitor)

letrozole

aromatase inhibitors
(nonsteroidal inhibitor)

tamoxifen

SERM
(selective estrogen receptor
modulator)

fulvestrant

SERD
(selective estrogen receptor
downregulator)

References: (134-136)
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Post-menopause

Pre-menopause

Adrenal

Fu

nt
ra
t
s
lve
T

ER
Tamoxifen
AD

Aromatase

E

E

proliferation
E

Aromatase
Inhibitors

Adipose tissue
Breast, Brain

ER

E

ERE

Figure 2. Estrogen production and hormonal therapies in ER+ breast cancer patients.
Estrogen (E) is mainly produced by ovaries in pre-menopausal women and through
aromatase activity in post-menopausal ones. Fulvestrant binds to and degrades estrogen
receptor (ER) while tamoxifen (T) blocks ER from binding to estrogen. AIs reduce estrogen
level by inhibiting converting enzyme known as aromatase.
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1-4a Tamoxifen in breast cancer and resistance mechanisms
Estrogen plays a significant role in breast cancer tumorigenesis. One of the first
approaches (in the 1970s) to control breast cancer was to irradiate ovaries in patients with
advanced breast cancer in order to block hormone production (137). Later on, tamoxifen
was developed which has revolutionized the field of breast cancer treatment. The first trial
using ICI 146474 (later known as tamoxifen) was reported in 1971 when 10 out of 46 breast
cancer patients showed response to the drug (138). Binding of Tamoxifen to ER receptor
may induce both agonistic and antagonistic activity depending on the target tissue. While
tamoxifen acts as an ER-antagonist in breast cancer cells, it stimulates estrogenic effect in
bone tissue leading to prevention of osteoporosis (139, 140). In addition, tamoxifen
decreases cholesterol level and decreases morbidity from myocardial infarction (141-143).
In contrast to these beneficial effects, tamoxifen shows agonistic effect on uterus and results
in higher incidence of endometrial cancer in patients who receive long-term tamoxifen with a
rate of 1.2 per 1000 patients annually (144). Xenograft model systems have been
established to study the beneficial role of Tamoxifen in vivo (145). In these animal models,
nude mice are subcutaneously implanted with HR+ breast cancer cells (such as MCF7 or
T47D) in the presence of estrogen (daily injection or subcutaneous pellets). Once tumors
are formed and reach a certain size, animals are treated with daily dose of tamoxifen (for
example 100mcg/day) and tumor volumes are measured regularly until the end of the
experiment when tumors are analyzed (145). Using this animal model with implantation of
endometrial and breast cancer, the authors show that tamoxifen stimulates endometrial
tumor growth while it shows anti-tumor activity in breast (146). In addition to increased rate
of cancer in uterus, volunteers who were enrolled in tamoxifen prevention studies suffered
from higher rate of hot flashes, vaginal discharge as well as menstrual irregularities
compared to placebo treated ones (147). One other major concern with tamoxifen is the
development of resistance as expected for any targeted agent with long-term use (148).
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Research studies in this field have identified different mechanisms of resistance to
tamoxifen (149, 150). Mutation in the ER receptor, interaction of ER with other signaling
pathways, and loss of ER expression are among such resistance mechanisms (150, 151).
Understanding these resistant mechanisms will allow scientists to find new therapies
available to patients who show limited response to tamoxifen.
ERα loss is one strategy that breast cancer cells adopt in order to become resistant to
tamoxifen (149, 152). Examination of ER in clinical tissue samples taken before and after
development of resistance has confirmed ER loss in 15% to 30% of resistant tumors (149,
151, 153). In theory, restoration of ER is considered a potential therapeutic approach in
tamoxifen resistant patients harboring tumors with loss of ER expression upon treatment
(154). Since the main mechanism of action of tamoxifen is direct binding to ER, the cells
become unresponsive to the drug as a result of ER loss. Epigenetic modification of the ER
gene is involved in silencing of the gene (155, 156). Cancer cells silence ER receptor by
methylation at the CpG islands. Yang and colleagues treated two ER-ve cell lines (MDA-MB231, MDA-MB-435) with inhibitor of the DNA methyltransferase (DNMT) and examined ER
expression in these cell lines (157). DNMTs are enzymes that catalyze methylation of the
DNA such as promoter regions of cancer suppressor genes leading to underexpression or
silencing of these genes (158, 159). Aberrant activity of DNMTs is detected in many human
cancers including colon (160, 161), pancreas (162, 163), and breast (164, 165). In addition,
inhibitors of DNMTs have shown promise in hematologic malignancies (166, 167). Following
treatment with the DNMT inhibitor these ER− cell lines were able to express ER mRNA as
well as ER protein. Combination of DNMT with HDAC inhibitors in this study resulted in ER
expression to almost 50% level of ER detected in MCF7 (ER+) cell line. Taken together,
these studies suggest that ERα loss contributes to resistance to Tamoxifen and restoring ER
may be a beneficial approach to re-sensitize the cells to anti-estrogen treatment.
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Besides ER loss, mutation of the estrogen receptor may play role in mediating
resistance to tamoxifen (148, 150). Fuqua et al reported a Lys to Arg mutation in ER
(K303R) in 20 out of 59 hyperplasia tissues (150). In addition to this premalignant tissue, the
mutation was also found in the adjacent normal tissue. This alteration was not detected in
blood sample suggesting a somatic mutation. In addition, exogenous expression of mutant
ER in MCF7 cells resulted in hypersensitivity to very low levels of estrogen (150). Generally,
ER mutations are often selected for during endocrine therapy rather than being present in
tumors isolated from newly diagnosed patients (148). Mutated ER is able to dimerize
independent of ligand and activates the downstream estrogenic signaling pathway. Under
this condition, development of novel anti-ER medications that can block mutated ER would
be a potential therapeutic option for patients who have ER mutation.
The interaction between estrogen receptor and growth factor signaling pathway is
another mechanism contributing to tamoxifen resistance. Her-2 and EGFR tyrosine kinase
receptors can become activated through interaction with estrogen receptor at the cell
membrane (168). Alternatively, PI3K and MAPK signaling pathways can lead to
phosphorylation of estrogen receptor in the absence of estrogen (169, 170). Activation of
these signaling pathways can promote cancer cell proliferation and survival in spite of antiestrogen treatment (171, 172). Clinically, when patients become resistant to tamoxifen, one
strategy is to switch to a second line of hormonal therapy either to aromatase inhibitors or
Fulvestrant (173). For example, a randomized multi-center study examined switching from
tamoxifen to anastrozole in patients who underwent antiestrogen treatment with tamoxifen
for two years (173). Results this study indicated that patients who received anastrozole had
significantly better overall survival compared to those who remained on tamoxifen (173).
Another feasible approach in the treatment of patients with tamoxifen resistance is to
combine tamoxifen with inhibitors of the growth factor signaling pathways such as herceptin,
or lapatinib. Preclinical models show that her-2 pathway can mediate resistance to
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tamoxifen (174). For example, Benz et al injected Her-2 overexpressing MCF7 cell line
(ER+) and parental cell line into nude mice in order to generate tumors followed by
tamoxifen treatment to assess response to treatment (174). Results revealed that the control
tumors showed tumor regression in response to tamoxifen treatment while her-2
overexpressing tumors continue to grow suggesting resistance (174). Massarweh and
colleagues examined her-2 expression in xenograft tumors that were generated from ER+
MCF7 cell lines treated with tamoxifen (175). Western blot analysis revealed higher level of
EGFR/her-2 expression in tamoxifen resistant tumors compared to sensitive ones (175). In
addition, treatment of the mice with an EGFR inhibitor (gefitinib) delayed emergence of
resistance to tamoxifen (175). Mechanistic studies show that gefitinib inhibits downstream
signaling pathway of her-2 as shown by decreasing phospho-AKT and phospho-MAPK
(175). Clinical studies are in line with these finding suggesting that her-2 pathway inhibition
has beneficial role under tamoxifen resistant conditions (176). For example, A phase III trial
on metastatic breast cancer patients (including previous tamoxifen therapy) who were
randomized to receive trastuzumab in combination with anastrozole showed improved
progression-free survival by 2.4 months in comparison to those who received anastrozolealone treatment (176). Collectively, these studies show that mechanisms of resistance to
tamoxifen are diverse and suggest that understanding and identifying the underlying
resistance mechanism in each patient would guide a personalized therapeutic approach.

1-4b Fulvestrant and breast cancer
Fulvestrant is an analogue of 17β-estradiol, structurally different from AIs. Fulvestrant
selectively interacts with estrogen receptor and prevents binding of ER to estrogen (177).
Binding of fulvestrant to ER prevents dimerization and nuclear localization of the receptor
(130, 178). In addition, this process induces degradation of ER receptor resulting in
inhibition of the pathway (129). Fulvestrant, in contrast to tamoxifen, does not have agonistic
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activity on endometrial tissue (179). Early clinical trials showed efficacy in breast cancer
patients resistant to other therapies (180). Howell and colleagues used monthly
intramuscular injection of fulvestrant in 19 breast cancer patients who progressed in spite of
treatment with tamoxifen. Seven patients showed partial response and six patients had no
change in tumor size suggesting that fulvestrant can extend duration of response to antiestrogens (180). In clinical studies, two different doses of fulvestrant have been used; high
dose (500 mg) versus low dose (250 mg). In a phase III study, a higher dose was
associated with longer progression-free survival compared to low dose without increased
toxicity (181). Early studies have focused on use of fulvestrant in patients who failed prior
tamoxifen or AI therapy (182). Subsequent studies however, have compared fulvestrant in
treatment-naive patients to other therapies (183). A phase II study compared high dose
fulvestrant versus anastrozole in locally advanced or metastatic HR+ post-menopausal
breast cancer patients. Clinical benefit rate was not statistically significant in fulvestrant
versus anastrozole arm (36% versus 35.5% respectively) (183). However, time to
progression was longer in fulvestrant treated patients without any additional side effect
profile suggesting that fulvestrant is at least as good as AIs in the early phase of treatment
(183). Results recently published from a phase III study comparing these two treatments in
HR+ advanced breast cancer patients also support an improved progression free survival for
2.8 months in patients who received fulvestrant (184). Fulvestrant side effects of are similar
to those of AIs including pain in joints, hot flashes and nausea (184). In summary,
fulvestrant is an effective anti-estrogen medication used in ER+ breast cancer patients
specifically in the metastatic setting.

1-4c Aromatase Inhibitors in breast cancer
The third classes of drugs that inhibit estrogen pathway are known as aromatase
inhibitors. According to their structure (Table 2), aromatase inhibitors are divided into two
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different classes. Class I drug, also known as steroidal group, consists of formestane and
exemestane, which covalently bind to and inhibit the enzyme in an irreversible manner (33).
Both drugs resemble in structure to androstenedione as the substrate for estrogen
conversion (131). Formestane was the first drug developed by Dr. Brodie’s lab and later
substituted by exemestane, which is FDA approved and is currently being used in clinic for
postmenopausal HR+ BC patients (185). The second class of AIs, known as non-steroidal
AIs, includes letrozole and anastrozole that are also FDA approved and used clinically as
the standard of care for ER+ post-menopausal patients (132). These inhibitors are
derivatives of anti-fungal azole drugs, bind to the enzyme non-covalently, and inhibit
aromatase in a competitive reversible manner (186). Many clinical studies have shown
advantage of AIs over tamoxifen in post-menopausal BC patients (132, 133, 187). For
example, in a phase III trial (ATAC), HR+ postmenopausal patients were treated with
adjuvant anastrozole (arimidex), tamoxifen, or in combination (132). Results from this study
showed significant improvement in disease-free survival, time to recurrence, and distant
metastasis in the anastrozole group compared to tamoxifen (132). The arm receiving
combination of anastrozole and tamoxifen was discontinued early due to lack of benefit
compared to tamoxifen-alone arm. In addition, more recent studies propose the use of AIs in
the neoadjuvant setting in selected patients before they undergo surgery as discussed in the
next paragraph.
Another similar phase III trial (Breast International Group 1–98), randomized 8010 HR+
BC patients to either letrozole or tamoxifen treatment (133). Results from this study showed
that patients who were treated with letrozole had higher disease-free survival and lower
recurrence of breast cancer at distant sites in comparison to tamoxifen (133). In the letrozole
group, 4.1% of patients died from disease whereas 4.8% of patients died in the tamoxifen
arm (P value did not reach significant level) (133). A higher percentage of patients
developed endometrial cancer on tamoxifen compared to letrozole arm (0.3% versus 0.1%
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respectively, p=0.18) and the thromboembolism rate was higher in tamoxifen arm compared
to letrozole arm (3.5% vs.1.5% respectively, P<0.001) (133). However, letrozole-treated
patients experienced higher arthralgia compared to tamoxifen treated ones (20.3% vs.
12.3%, p<0.001) (133).
Aromatase inhibitors are also shown to be favorable in stage III and IV postmenopausal patients than tamoxifen (187). In a phase III study, 907 advanced breast cancer
patients (Stage IIIB, metastatic, or recurrent patients not candidate for surgery or radiation
therapy) with HR+ (or unknown status) were assigned to letrozole or tamoxifen as first line
therapy (187). Follow up of these patients revealed that letrozole increased median time to
progression and time to treatment failure by 15 weeks in comparison to tamoxifen.
Moreover, letrozole treated patients showed higher rate of objective response compared to
tamoxifen arm (30% versus 20%) indicating the benefit of letrozole over tamoxifen in the
advanced stage of the disease (187). In a similar study, 353 HR+ (or unknown status)
postmenopausal BC patients with locally advanced/metastatic disease received either daily
anastrozole or tamoxifen (188). Anastrozole treatment improved time to progression by 5.5
months in comparison to tamoxifen and was associated with fewer thromboembolic events
(188). Similar to anastrozole, a phase III trial compared exemestane to tamoxifen in a cohort
of locally advanced or metastatic HR+ postmenopausal patients (189). A total of 371
patients were treated with either tamoxifen or exemestane daily until they progressed on
treatment (defined by 25% increase in tumor size, or new lesion) or developed toxicity.
Analysis of the follow up data revealed that patients in exemestane arm had significantly
longer progression-free survival compared to tamoxifen arm, 9.9 months versus 5.8 months,
respectively (189). Patients on exemestane had higher rate of overall response compared to
tamoxifen, 46% compared to 31% respectively. However, exemestane did not change
overall survival of patients in comparison to tamoxifen (189). Taken together, these studies
revealed the beneficial role of aromatase inhibitors in post-menopausal BC patients.

26

1-4d Aromatase inhibitors in the neoadjuvant setting
One feasible clinical approach in treatment of post-menopausal setting using AIs is
treatment in the neoadjuvant setting before patients undergo surgery. An advantage of this
approach is to induce tumor shrinkage such that an inoperable tumor becomes operable.
Consequently, neoadjuvant treatment increases the chance of breast conserving surgery in
patients that were initially considered suitable for total mastectomy. Similar to studies using
AIs in the adjuvant setting, neoadjuvant studies have also shown superiority of aromatase
inhibitors to tamoxifen in HR+ postmenopausal patients. For example, letrozole was
compared to tamoxifen in a neoadjuvant setting study including 337 newly diagnosed postmenopausal HR+ patients (190). Clinical response (complete or partial response by
palpation) was higher in the letrozole arm compared to tamoxifen arm, 55% versus 36%
respectively. While none of the patients were eligible for breast conserving surgery (BCS)
pretreatment, 45% of patients became BCS eligible with letrozole and 35% in the tamoxifen
group after neoadjuvant treatment. Higher efficacy of letrozole compared to tamoxifen in
post-menopausal patients was also confirmed in another neoadjuvant study (191). Another
neoadjuvant study examined response to anastrozole in comparison to tamoxifen during the
12-week neoadjuvant treatment (Pre-Operative Arimidex Compared to Tamoxifen
(PROACT). Higher objective response was detected in the anastrozole arm compared to
tamoxifen arm as measured by ultrasonography, 39.5% versus 35.4%, respectively (192).
Collectively, these adjuvant and neoadjuvant studies highlight the significance of AI
use in treatment of HR+ patients. Unfortunately, resistance is a major obstacle facing these
medications and in this section different mechanisms of AI resistance are discussed in more
detail.
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1-5 RESISTANCE TO AROMATASE INHIBITORS
In spite of favorable response with AIs compared to tamoxifen in BC patients,
resistance to AIs is considered a clinical challenge. Two forms of resistance are detected
clinically in breast cancer patients including primary (de novo or intrinsic) or secondary
(acquired) resistance. In the primary resistance setting, the tumors show innate resistance to
the drugs and patients do not respond to the initial treatment. Results recently published
from non-metastatic HR+ patients undergoing neoadjuvant aromatase inhibitor therapy
suggest primary resistance in almost 20% of patients (193). Forty nine out of 245 (20.8%)
HR+ treatment-naive patients showed primary resistance to AIs as defined by Ki67 more
than 10% in the sample taken after two weeks of treatment (193). Thirty five of these AI
resistant patients were treated with neoadjuvant chemotherapy before undergoing surgery
and analysis of tumors at the time of surgery showed pathologic complete response (pCR)
in only 5.7% of these patients suggesting that these patients are also resistant to
chemotherapy (193). Another neoadjuvant trial revealed only 55% objective response to
letrozole in newly diagnosed breast cancer patients (190). In the newly diagnosed
metastatic setting, the response rate is much lower and almost all patients eventually
succumb to the disease (187). In a phase III trial, only 8% (34 out of 453) of patients with
advanced disease who were randomized to receive letrozole showed complete response
and 23% showed partial response (30% objective response) (187). Similarly, results from
another randomized trial showed overall response to anastrozole in only 20% of patients
with advanced disease (188). Secondary resistance is defined when patients respond to
initial therapy but fail after a long-term initial response. For example, five-year follow up of
HR+ postmenopausal patients showed that more than 10% of patients recurred while on
anastrozole treatment (132). Mechanisms of resistance to these drugs are distinct but
sometimes overlap as described in more detail separately in the next few sections of this
dissertation.
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1-5a Aromatase enzyme and resistance to anti-estrogens
CYP19 (aromatase) is located on chromosome 15 and is responsible for catalyzing the
last step in the conversion of androgens to estrogen (194). Aromatase enzyme is expressed
in many different tissues including brain, placenta, adipose tissue, breast and bone (195).
Tissue specific promoters tightly regulate expression of aromatase in each tissue (196). For
example in placenta, aromatase expression is under control of a promoter that is located
more than 40kb upstream of the translation start site (196). However, in ovaries another
promoter located upstream of the second exon regulates expression of aromatase (197). In
the reproductive system, aromatase is abundant in ovaries and regulates the reproductive
cycle through local production of estrogen in ovaries (198, 199). In males, local production
of estrogen in testis by aromatase enzyme contributes to spermatogenesis (200). In normal
breast tissue, the majority of aromatase is produced by the fibroblasts localized in the fatty
tissue of the breast while adipose cells do not express aromatase gene (201). Increased
estrogen production, through activity of aromatase enzyme in fibroblasts located adjacent to
breast cancer mass, enhances proliferation of cancer cells (202). In addition, in breast
cancer tissue, aromatase is present in both epithelial cancer cells as well as fibroblasts
located in the extracellular matrix surrounding breast tumor cells (203, 204). Studies have
shown interaction between fibroblasts and cancer cells. For example, co-culture of the
fibroblasts with breast cancer cells (MCF7) resulted in higher expression of aromatase in
fibroblasts through production of stimulatory factors by cancer cells (205). Increased
aromatase expression in fibroblasts stimulated by cancer cells can lead to higher local
estrogen production, which in turn increases proliferation of cancer cells in a positive
feedback loop (203, 204). In addition to estrogen-mediated proliferation, increased
aromatase expression enhances survival and metastasis of ER+ breast cancer cells. In one
study, the authors exogenously overexpressed aromatase in ZR75 cell line (ER+) and
compared their tumorigenic as well as metastatic potential to the parental cells (206). These
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aromatase overexpressing cells were able to form tumors when implanted into mammary fat
pad of nude mice without estrogen supplementation suggesting enhanced tumorigenicity. To
investigate metastatic potential of these cells, the authors injected aromatase
overexpressing and control cells into the heart of nude mice and examined metastases
formed in bone. The results showed that aromatase overexpressing cells were capable to
form metastasis in mandible bone (in 80% of mice) and tibia/femur (in 40% of mice). In
sharp contrast to this, none of the mice injected with parental cells formed metastasis (206).
One mechanism of resistance to anti-estrogen treatment is attributed to alteration in
aromatase expression. For example, tamoxifen-resistant MCF7 cells were shown to have
higher aromatase level and activity than parental cells using Western blot and enzyme
activity assay (207). In this study, treatment with a PI3K inhibitor down-regulated aromatase
expression, suggesting a possible interaction between PI3K and aromatase. To translate
these findings, the authors examined aromatase expression by immunohistochemistry in 4
cases who relapsed after adjuvant tamoxifen therapy and compared those to 4 patients who
did not relapse at least within 6 years of follow up. Results revealed that recurrent tumors
had significantly higher percentage of aromatase positive cells compared to non-recurrent
tumors, 57.5% versus 9.8%, respectively. Taken together, these studies show that
aromatase enzyme plays a significant role in ER+ breast cancer and that its enhanced
expression can contribute to resistance to anti-estrogens.

1-5b Androgen receptor and AI resistance
Androgen receptor, similar to ER, is a member of the nuclear receptor family and upon
binding with androgen translocates to the nucleus to bind to the promoter regions of target
genes (208, 209). Collins and colleagues used immunohistochemistry to examine tissue
microarray samples of a cohort of invasive breast cancer patients (210). The investigators
stained 2171 invasive breast cancer tissues for ER, PR, Her-2, cytokeratin 5/6, EGFR, and
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AR to identify molecular subtype of breast cancer. According to phenotype staining the
tissues included luminal A (64%), luminal B (15%), basal-like subtype (11%), Her-2 (6%),
and the rest as unidentified. Overall 77% of all cases were considered positive for AR
expression (210). Luminal A patients had the highest rate of AR positivity (91% of cases)
while basal like had the least percentage of AR expression (32% of cases) (210). Several
studies show the correlation between serum androgen level in postmenopausal women and
higher rate of breast tumor formation (211, 212).
Androgen receptor has been shown to contribute to de-novo resistance to AIs (213).
In this study, AR played role in resistance through activation of ER pathway as well as
parallel growth signaling pathway (213). AR overexpression in ER+ cell line (MCF7) resulted
in increased phosphorylation of IGF-1R receptor and activation of PI3K downstream
signaling pathway (213). In line with this notion, treatment with an IGF-1R inhibitor
(Tyrphostin, AG1024) desensitized the cells to anastrozole by inhibiting androgen receptor
as well as downstream AKT pathway (213). Similarly, AKT inhibitor restored sensitivity to
anastrozole in AR overexpressing cell line (213).
Another mechanism of AR-mediated resistance is linked to its collaboration with ERα
and activation of ER transcription (213). First, using a proximity ligation assays
(immunoassay that detects protein-protein interaction using two specific antibodies detected
by confocal microscopy), the authors found co-localization of ERα-AR in the nucleus of
resistant cells (213). Next, chromatin immunoprecipitation assay (chip) revealed enrichment
of AR at the pS2 (a well-known estrogen responsive gene) promoter region upon
androstenedione treatment (213). In addition, a combination of either an AR antagonist
(abiraterone) or an ER degrader (fulvestrant) with anastrozole restored sensitivity to AI in
AR-overexpressing resistant cell lines (213). These experiments suggest that AR and ER
can collaborate to bypass the effect of aromatase inhibitors. In another study, the
researchers examined primary and AI resistant recurrent tumors from 21 breast cancer
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patients using immunohistochemistry (214). Results from this study revealed higher Ki67
(representative of proliferation) and higher PSA levels (representative of androgen activity)
and lower ER and PR expression in recurrent tumors (214). In addition, higher AR
expression and activity were detected in long-term estrogen deprived cell line (T47D-LTED)
compared to parental cell line (214). These preclinical studies suggest that cancer cells
adapt to low estrogen environment by increasing AR expression and activity leading to
expression of the ER target genes in resistant cells in spite of anti-estrogen treatment.
Additional studies are required to investigate the potential efficacy of anti-androgen
treatment in AI resistant patients who overexpress AR. For example, one proposed study is
to randomize ER+ patients who become resistant to AIs into two arms in which one arm
would receive fulvestrant plus AR antagonist (enzalutamide) based on AR overexpression
while the other arm would receive fulvetsrant plus placebo and follow up these patients for
short-term and long-term response. It is worth noting that feasibility of enzalutamide therapy
in under clinical investigation in early stage AR+ TNBC patients (NCT02750358).

1-5c Her-2 MAPK pathway and AI resistance
Aberrant activity of growth signaling pathways is another known mechanism of
resistance to aromatase inhibitors. In vitro and in vivo studies using acquired AI resistant
models indicate that cancer cells are able to adapt to low estrogen environment in order to
survive (215). One such adaptation is escape from ER signaling by activation of growth
factor signaling pathways (215). Studies in the lab of Dr. Brodie are focused on
understanding AI resistance using in vitro and in vivo models. Her group has generated
letrozole-resistant tumors by injecting aromatase overexpressing cell lines into the
mammary fat pad of ovariectomized mice and treating the tumors with letrozole (216). In
order to develop resistance, tumor-harboring mice were treated with a low dose (10μg/day)
of letrozole for 8 weeks followed by a higher dose (100μg/day) for a total period of 37 weeks
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until the tumors almost doubled in size compared to the initial size (216). They generated in
vitro cell lines from these tumors and showed that these cells are able to form tumors when
implanted into nude mice without androstenedione supplementation. This confirms that the
cells are able to form tumors in the absence of estrogen suggesting resistance to AIs. In
vitro analysis of these cells using Western blot analysis showed that the level of ERα
increased at 4 weeks following letrozole treatment but decreases at 28 or 56 weeks of
therapy when the cells are resistant to letrozole. In contrast, the level of HER-2 as well as
phosphorylated MAPK increased at 28 and 56 weeks (217) suggesting that resistant cells
are dependent on Her-2/MAPK pathway rather than ER signaling (217). To further confirm
dependence of these resistant cells on MAPK pathway, they treated letrozole resistant cells
and parental controls with increasing concentrations of a MEK inhibitor (U0126) or a MAPK
Inhibitor (PD98059) (217). Results from this study revealed that only resistant cells respond
to these inhibitors by decreasing proliferation in a dose-dependent manner (217). In a
similar study, letrozole resistant cells and tumors responded to HER2 inhibitor (trastuzumab)
in a dose dependent manner (215). Western blot analysis indicated that trastuzumab
blocked Her2/MAPK pathway and increased ERα at the protein level. Chip and RT-PCR
assays revealed that trastuzumab increased ER binding to pS2 gene promoter (a known ER
responsive gene) as well as increased pS2 mRNA level (215). Moreover, pre-treatment with
trastuzumab enabled these cells to show exponential growth upon estrogen stimulation
suggesting these cells become hypersensitive to estrogen (215). Brodie’s lab has also
generated anastrozole-resistant tumors and found that HER-2/MAPK pathway was not
activated in these cells (in contrast to letrozole resistant cells) (218). However, they detected
higher expression of insulin-like growth factor type I receptor β (IGF-R1β) as well as upregulation of mTOR and phospho-mTOR rather than HER-2 in this model (218). Using a
xenograft model system, they showed that the tumors respond to a combination of
anastrozole and fulvestrant (218). Taken together, results from these studies show that
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signaling pathways can contribute to AI resistance in a subset of patients and inhibition of
this pathway may re-sensitize resistant cells to anti-estrogen treatment. Comparison of
letrozole to anastrozole resistant cells suggests that resistant mechanisms to each individual
AI could be different and cancer cells may adopt different pathways to survive the pressure
of antiestrogen treatment.

1-5d PI3K pathway and AI resistance
Phosphoinositide 3-kinases (PI3K) is the most frequent signaling pathway that is
aberrantly activated in human cancers (219). PI3K pathway activation initiates when growth
factors bind to the specific cell surface receptors of the pathway such as Her-2 or MET
(220). Upon activation of these receptors, the signal is transmitted through PI3K and
downstream signal transduction proteins such as AKT and mechanistic target of rapamycin
(mTOR) (221). Activation of these kinases eventually transmits the signal to the nucleus and
regulates many hallmarks of the cancer cells such as growth, cell cycle progression, and
survival (222-224). One mechanism of deregulation of the pathway is through mutation in
the PIK3Ca (catalytic unit) leading to hyperactivity of the pathway (219). In addition, PI3K
amplification has been detected in 40% of ovarian cancer patients, and is associated with
higher level of PI3K (225). Amplification of AKT has been detected in ovarian and breast
cancer (226). Bellacosa et al examined 132 ovarian cancer and 106 breast cancer tissues
using southern blot analysis and found AKT2 amplification in 12.1% of ovarian and 2.8% of
breast tumors (226). Phosphatase and tensin homolog (PTEN), a known cancer suppressor
gene, negatively controls the pathway and may become inactivated through mutation or
gene silencing in different cancers (227, 228). Given the significance of this pathway in
human cancer, several targeted inhibitors have been developed that can be used for
cancers with deregulation of this pathway. For example, compounds that can specifically
target downstream molecule in the pathway (mTORC1) such as everolimus are currently
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approved by FDA and used in clinic (229, 230). In a phase III study, HR+ patients who
progressed on anastrozole or letrozole were categorized to exemestane plus everolimus or
exemestane plus placebo regimen. Results from this study revealed that everolimus
significantly improved progression-free survival in this population of patients (229). Orally
available Inhibitors of PI3K such as BKM120 (buparlisib) are another class of inhibitors
currently being investigated in breast cancer (231). In BELLE-2 trial, HR+ patients who were
unresponsive to AIs received fulvestrant for 14 days followed by randomization to receive
fulvestrant alone or fulvestrant plus BKM120. Results revealed that the combination
treatment increased PFS significantly (but modestly) from 5 months (control group) to 6.9
months (combination group) (231).
The link between PI3K pathway and AI resistance has been investigated in a few
studies. Miller et al cultured different estrogen receptor positive cell lines over long period of
time to develop resistant models (known as LTED model). Next, the researchers subjected
these resistant cells along with their parental counterparts to proteomic analysis (232). LTED
cells adapted to survive and proliferate in the media deprived of estrogen and thus are
acceptable model to study AI resistance (232). Comparison of LTED cells with parental
controls revealed increased activity of mTOR as measured by higher phosphorylation of
p70/p85 ribosomal protein S6 kinase (p70S6K), a kinase downstream of mTOR (232).
Higher phosphorylation of AKT was detected in LTED cells suggesting higher activity of
PI3K-AKT-mTOR pathway in resistant cells (232). In addition, treatment of these LTED cells
with a dual inhibitor of PI3K and mTOR (BEZ235) resulted in maximum apoptotic rate and
highest inhibition of proliferation. In contrast, mTOR inhibitor alone (RAD001) or PI3K
inhibition using RTKs Inhibitors (IGFR or Her-2 Inhibitors) resulted in a moderate
suppression of cell growth (232). To translate these findings, the authors examined 64 ER+
tumors using RPPA analysis and stratified them to PI3K-high and low signatures (232).
Presence of PI3K activation signature correlated with shorter recurrence in patients who
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underwent adjuvant therapy with anti-estrogens suggesting the link between PI3K pathway
and resistance to anti-estrogens (232). In another study, the authors examined the
combination of PI3K inhibitor and antiestrogen treatment and detected greatest cell death in
the concomitant treatment condition (233). Individual PI3K inhibition induced less than 20%
apoptosis in the LTED MCF7 cell lines (233). However, combination of fulvestrant with a
PI3K inhibitor resulted in almost 80% cell death. Taken together, these studies show that
PI3K pathway plays role in resistance to AIs and dual inhibition of PI3K and ER pathway can
be a considered beneficial combination therapy in anti-estrogen resistant ER+ breast
cancer.

1-5e Cancer stem cells, epithelial to mesenchymal transition and AI resistance
Caner stem cells (CSCs) are rare population of pluripotent cells within a tumor with
self-renewal capacity (234). It is thought that CSCs are resistant to chemotherapy and
radiation (235, 236). Cancer stem cells are identified in many different cancers such as lung,
colon, ovary and breast (237-240). Al Hajj et al first described and isolated cancer stem cells
in breast cancer using flow cytometry for CD44+ CD24−/low Lineage− cells (237). These
subpopulations of cells were able to generate tumors when as low as 100 cells were
injected in mice. In addition, these cells formed the bulk of non-stem cells within a newly
formed xenograft tumors indication their pluripotent potential. Later on, aldehyde
dehydrogenase (ALDH) was found to be another marker of breast cancer stem cells (241).
Further studies suggest that ALDH+ breast cancer cells are responsible for drug resistance
(241). Tanei et al examined tumor tissues prior to and at the end of neoadjuvant
chemotherapy and found an association between ALDH positivity and resistance to
chemotherapy. ALDH positive tumors showed significantly lesser pathologic complete
response (pCR) in response to therapy in comparison to ALDH-negative ones (242).
CSCs have the capability of transforming from an epithelial phenotype to a
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mesenchymal one (known as EMT) and metastasizing to other tissues. Throughout this
process, epithelial markers such as E-cadherin (CDH1) are attenuated and in contrast
mesenchymal markers such as Vimentin and N-cadherin are increased (243). As mentioned
earlier, cancer stem cells have self-renewal and long-term maintenance abilities. These
capabilities raise the assumption that these cells are able to survive in the metastatic site.
During the EMT process, highly adherent epithelial cells transform into mesenchymal cells
with higher migratory and invasive phenotype (244).
Several studies show the link between CSCs and invasion/metastasis in breast cancer
(245, 246). Liu and colleagues generated an invasive gene signature by comparing
differentially expressed genes in breast cancer stem cells (CD44+ CD24−/low) and normal
epithelial cells (245). In this study “high invasive signature” correlated with higher metastasis
and diminished survival (245). In another study, tumor particles isolated from triple negative
breast cancer patients were implanted into the mammary fat pad in order to track lung
metastasis (246). Examination of the lung metastatic cells revealed CD44+ cancer stem
cells. In addition, these cells retained their tumorigenic potential when transplanted in vivo
suggesting their stemness phenotype (246). In line with these studies, evidence shows the
link between EMT phenotype and stemness where forced expression of Twist and Snail, two
genes with cancer stem cell function, in immortalized mammary epithelial cells induced EMT
and concomitantly shifted the cells toward a cancer stem cell phenotype (higher percentage
of CD44high CD24low cells in experimental cells compared to control ones) (247). In addition,
these transformed cells with EMT phenotype showed higher mammosphere formation ability
in vitro as well as enhanced tumorigenicity in animal models.
A few studies have investigated the link between EMT/CSCs and development of AI
resistance (248). Creighton et al investigated the link between cancer stem cell phenotype
and letrozole resistance (248). To this end, they generated a CSC signature by combining
gene expression signature of CD44+/CD24 -/low subpopulation and a signature of
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mammosphere forming cells. Comparison of post-neoadjuvant samples from 36 ER+
patients treated with letrozole to pretreatment samples shows enrichment of this signature
(248). In addition, gene expression profile of post-letrozole treatment tumors overlapped
with a claudin-low signature characterized by increased expression of EMT related genes
(MMP2 & MMP3) and down-regulation of CDH1 (E-cadherin) (248). This suggests an
enrichment of CSCs and EMT in the letrozole resistant tumors. In a similar study, the
authors examined cancer stem cell markers in letrozole resistant cells isolated from in vivo
tumors treated long-term with letrozole. Letrozole resistant cells had higher subpopulation of
ALDH+ cells compared to sensitive cells (3.9 % vs. 0.6 %) and formed almost two times
higher mammospheres in vitro (249). At the protein level, letrozole resistant cells had higher
breast cancer resistant protein (BCRP) level. BCRP is a trans-membrane protein that is
involved in resistance to multiple chemotherapies and is considered as a marker of stem
cells (250). Treatment of resistant cells with lapatinib, a HER-2 tyrosine kinase inhibitor,
resulted in decreased percentage of ALDH+ cells, decreased BCRP level and diminished
mammosphere formation in vitro suggesting that HER-2 pathway regulates stem cell
behavior of letrozole resistant cells (249). In addition, letrozole resistant cells show
increased HER-2 concomitant with decreased ERα level indicating that resistant cells loose
their dependence on estrogen pathway by adopting a cancer stem cell behavior (249). The
link between HER2 receptor and cancer stem cell has been discussed in a few studies (251,
252). For example, Korkaya et al overexpressed HER-2 in normal mammary epithelial cell
line and showed enhanced mammosphere formation, enriched ALDH+ subpopulation in
vitro and increased mammary outgrowth with dysplasia when implanted in vivo (251).
Similarly, overexpression of HER-2 in two different cell lines, MCF7 (ER+) and SUM159
(triple negative), resulted in higher invasiveness of these cells as assessed by matrigel
invasion assay. Moreover, the authors detected higher expression of genes associated with
stem cell behavior such as Notch1, Notch2, and Oct3/4 in SUM159 cells ectopically
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overexpressing HER-2. In a similar study, tumor-initiating subpopulation of breast cancer
cells had higher expression of HER-2 (252). Treatment of these HER-2 overexpressing cells
with trastuzumab resulted in decreased mammosphere formation ability in vitro and tumor
formation in vivo when serially transplanted into mice suggesting that anti-HER-2 therapy
can specifically target these HER-2 overexpressing tumor initiating cells (252).
In summary, these findings highlight the significance of CSCs and EMT process in
resistance to AIs. Currently, the studies examining cancer stem cells and resistance to AIs
are limited and inconclusive. It is not completely clear whether the subpopulation of cells
that become resistance to AIs are derived stem cells. In addition, the clinical implications of
CSCs in the context of AI resistance are yet to be determined. For example, anti-CD44
monoclonal antibody showed efficacy to decrease repopulation of AML cells when
transplanted into immune-deficient mice and prevented leukemia propagation in serial
transplantation experiments suggesting that anti-CDK44 antibody is able to target cancer
stem cells (253). As mentioned earlier, a CD44 cancer stem cell signature is enriched in
remaining tumors following letrozole treatment (248). Therefore, it is intriguing to study
whether a combination of anti-stem cell therapies (such as CD44 antibodies) are beneficial
in combination with aromatase inhibitors.

1-5f Gene alterations/mutations and AI resistance
Gene mutations are often detected in human cancers. Some of these mutations are
detected in early phase of oncogenesis. However, some mutations are found as a response
to targeted therapies leading to resistance to therapies. The most relevant example of such
mutation is the BCR-ABL gene mutation leading to resistance to BCR-ABL inhibitor imatinib.
BCR-ABL is an oncogenic protein detected in CML patients that can be targeted with
specific kinase inhibitors (254). The discovery of the BCR-ABL inhibitor imatinib has
dramatically changed the landscape in CML, due to significantly improving overall patient
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survival (254, 255). However, resistance to imatinib is a great challenge partially attributable
to mutation in the trans-located gene (256, 257). Another well-known example in this context
is the secondary mutation in EGFR gene following treatment with its specific inhibitor in nonsmall cell lung cancer (NSCLC). NSCLC is a malignant disease of the lung with very poor
prognosis. EGFR is often overexpressed or mutated in NSCLC and these patients benefit
from anti EGFR targeted therapy (258). However, secondary mutations in the gene develop
upon treatment, which limit the effect of targeted therapies (259, 260). Therefore,
identification of secondary mutations that can cause resistance to targeted therapies is an
important aspect to consider when these medications are used.
A few studies in breast cancer have investigated association between gene mutation
and response to anti-estrogen treatment. As an example, Veeraraghavan et al detected
gene rearrangement between ESR1 (gene encoding ERα protein) and CCDC170 (gene
encoding a protein with unknown function) in 8 out of 200 ER+ breast cancer tumors (261).
The authors screened a series of BC cell lines and detected this fusion in three ER+ ones
that were isolated from metastatic patients namely MCF7, HCC1428, and ZR-75-1. They
further show that introduction of ESR1-CCDC170 into mammary epithelial cell line
(MCF10A) resulted in higher migration and invasion (assessed by Boyden chamber),
enhanced cell proliferation, and increased colony formation. Mutant variant of ER was first
reported by Fuqua et al by examination of 5 tumors isolated from ER-/PR+ BC patients
(262). ER mutations are rare in primary tumors but more frequent in the metastatic setting
(148). DNA Sequencing of specimens isolated from patients who progressed while on antiestrogen therapy revealed mutation in 14 out of 80 samples. These mutations were mainly
localized in the ligand-binding domain of estrogen receptor and incorporation of these
mutant constructs resulted in estrogen-independent activity of mutant ER (148).
Another important related aspect in the context of resistance to AIs is to examine
tumors from treatment-naive patients for mutational patterns that can predict response to

40

treatment. Ellis et al applied a whole genome analysis approach using whole-genome or
exome sequencing of 77 biopsy samples isolated from ER+ patients to examine correlation
between mutations and response to treatment. Tissue samples before and after treatment
with neoadjuvant AIs were examined (263). Cases were considered resistant when Ki67
positivity remained more that 10% after neoadjuvant treatment with AIs. On average, they
detected 16.8 mutations in each tumor. Genes encoding for PI3K-α subunit, p53, Ecadherin, Rb and p27 were among the significantly mutated genes in their samples with
PI3K being the highest mutated genes (41.3%) followed by p53 (16.1%). Mutation in p53
correlated with higher Ki67 in both samples before and after neoadjuvant AI therapy (263).
Combining these mutated genes into pathway analysis and comparison between resistant
and sensitive cases revealed enrichment of DNA replication, mismatch repair and p53
signaling in resistant cases (263). Taken together these studies suggest that examination of
mutations at the DNA level could be beneficial for the selection of specific targeted therapies
along with anti-estrogen treatment. However, more studies with longer follow up are needed
in order to validate the clinical significance of these findings and apply therapeutic strategies
based on available druggable targets that are mutated.

1-5g Gene expression analysis and AI resistance
Cancer cells often alter their gene expression profile to tolerate the pressure of
chemotherapy and other targeted therapies. A few studies have investigated gene
expression changes upon AI treatment using model systems that are resistant to AIs.
Chen’s team has established acquired resistance models of aromatase inhibitors by
culturing aromatase-overexpressing cells in the presence of aromatase inhibitors for a long
period of time (264). In addition, his lab has generated LTED and tamoxifen resistant cell
lines (264). In order to identify mechanism of resistance, they performed Affymetrix
microarrays on these cell lines. Comparison of gene expression changes compared to
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parental cell lines showed that all the three cell lines resistant to individual AIs (letrozole,
anastrozole, exemestane) were clustered together in one group but different from tamoxifen
or LTED clusters suggesting distinct mechanism of resistance (264). Even within the AI
cluster, the authors found almost 50% similarity between up-regulated or down-regulated
genes. The top 20 up-regulated genes in resistant cells were categorized as estrogen
responsive genes suggesting an ER-mediated transcriptional activity in the resistant cells.
Further molecular analyses using ER luciferase reporter assay and Western blot in resistant
cells showed constitutive ER transcription activity and phosphorylation of ERα protein (264).
This is consistent with the notion that combining an ER downregulator (fulvestrant) with an
AI is beneficial to overcome resistance. Furthermore, Ingenuity Pathways Analysis (IPA) of
resistant cells compared to their parental cell line revealed enrichment of pathways involved
in DNA replication, DNA repair, as well as cell cycle control (264). In another similar study,
the authors established LTED models from 4 different ER+ cell lines including MCF7, ZR751, MDA-361, HCC-1428. Comparison of gene expression profile of LTED versus parental
cells revealed a total of 86 down-regulated genes and 13 up-regulated genes that were
similarly altered across all cell lines (265). Next, they examined the correlation between
LTED signature and response to aromatase inhibitors in tumors isolated from patients
treated with neoadjuvant letrozole (266). To this end, they assigned “LTED score” to each
tumor before and after therapy based on the available microarray data of these tumors.
Results showed that high LTED signature correlated with high Ki67 in post-treatment
samples as a marker of proliferation. Furthermore, high “LTED signature” correlated with
poor long-term survival in a separate data set where patients were treated with tamoxifen.
Taken together, these studies suggest that gene expression profile derived from resistant
cell lines has clinical implications and can inform response to anti-estrogen treatment.
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1-6 THE CELL CYCLE AND CANCER
Cell cycle is a very orchestrated phenomenon resulting in generation of two daughter
cells from an individual cell. Each cell goes through multiple phases in order to divide. These
are known as interphase: a period in which cells grow and replicate their DNA content, and
Mitosis: when the replicated DNA is separated along with cytoplasm into two daughter cells.
During interphase the cells go through G1 phase in which the cells metabolically prepare for
DNA synthesis, S phase the actual duplication of the DNA content, and finally G2 phase
when the cells prepare for mitosis. In addition, there are checkpoints between cell cycle
phases when the cells decide to move forward to the next phase considering the internal
and external stimuli. In addition, normal cells have capacity to pause at the checkpoints with
any aberration in the natural progression of cell cycle with potential to activate repair
mechanisms. The most significant checkpoint is at the time of transition between G1 to S
phase, as the cells are committed to continue through cell cycle and divide after passing this
checkpoint while no longer rely on external stimulation. Cell cycle progression requires
appropriate interaction and activity of different proteins known as cyclins and cyclin
dependent kinases (CDKs) (267) (Figure 3). CDKs are the active components that fuel
progression of cell cycle and have constant levels throughout different phases of the cell
cycle. In contrast, cyclins oscillate throughout different phases, form complex with CDKs,
and initiate their kinase activity. On the other hand, cyclin dependent kinase inhibitors (CKIs)
inhibit the activity of CDKs through binding with the cyclin-CDK complex (268). Two families
of CKIs include INK proteins such as p15, p16, p18 and p19 that can inhibit CDK4/6
kinases. The other family know as Cip/Kip family entails p21, p27 that are responsible to
inhibit CDK1 and CDK2 kinases (269), (270). G1 checkpoint is mainly regulated by Rb
protein, a well-known tumor suppressor. Under hypo-phosphorylated state, Rb protein
keeps E2F transcription factor in the inactive form. Cyclin D CDK4/6 complex initiates
phosphorylation of Rb protein during the early G1 phase. This phosphorylation is further
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resumed by cyclin E/CDK2 resulting in inactivation of Rb protein as a tumor suppressor
gene. Hyperphosphorylated Rb can no longer bind to E2F, releasing it to transcriptionally
activate genes required for DNA synthesis (271, 272). Expression of Cyclin E as well as
cyclin A is also affected by E2F transcription factor. As a result of this process, cyclin E level
increases throughout G1 phase reaching its peak level at the time of G1 to S transition.
Cyclin E activity is required for initiation of S phase (273). Cyclin A expression continues
through G2 phase of the cell cycle and replaced by cyclin B during mitosis. In fact, cyclin B
level peaks at the end of G2 and early mitosis. Cyclin B forms a complex with CDK1 and
allows the cells to pass G2/M checkpoint and start mitosis (274). Lastly, cyclin B degradation
is required for the cells to progress out of mitosis. Any defects in this orchestrated process
can result in abnormal progression of the cell cycle, enhanced proliferation, DNA damage,
and tumor formation.
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Figure 3. Cell cycle phases and regulation of cell cycle in human. A single cell passes
through multiple phases including Gap 1 (G1), DNA synthesis (S), Gap 2 (G2), and Mitosis
(M) in order to divide. This process is tightly regulated by interaction of complexes including
cyclin dependent kinases (CDKs), cyclins as binding partners, and CDK inhibitors such as
p16, p21 and p27. Rb phosphorylation releases E2F allowing gene transcription and
bypassing the restriction point between G1 and S.
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Deregulation of cell cycle is a very common phenomenon in many cancers. Alterations in
many components of cell cycle regulators have been detected in many cancers. For
example, translocation and amplification of cyclin D is detected in breast cancer patients
(see section cyclin D and breast cancer). At the protein level, cyclin D is overexpressed in
breast, GI malignancies, head and neck cancers (275). Cyclin E is deregulated in breast
cancer as discussed in the next chapters. Alteration of CDKs also can play role in abnormal
growth of cancer cells. In melanoma, CDK4 mutation results in inability of CKIs to bind and
inhibit CDK4 leading to proliferation of the cells (276). Rb protein is a well-known cancer
suppressor gene that is frequently altered in human cancers including breast cancer. Rb
dysfunction is linked to resistance of breast cancer to tamoxifen (277). Loss of inhibitory role
of CKIs such as p16 is implicated in oncogenesis. P16 knock out animal models tend to
develop cancers suggesting the cancer suppressive role of this gene (278). CKIs can be
inactivated through methylation at the promoter region of the genes, as well as mutations of
the gene (279). Similarly, loss of p27 in breast cancer is correlated with decreased survival
(280).
In the context of AI resistance, a few studies have shown deregulation of the cell cycle
in AI-resistant cell lines. These studies are described in detail in chapter 3 of this
dissertation. Given the significance of cell cycle in cancer, many different CDK inhibitors
have been developed. Most of these drugs are able to bind to ATP-binding pocket of CDKs
in a competitive manner and inhibit their activity (281). The initial CDK2 inhibitors that were
developed did not have specificity to specific CDKs with unknown mechanism of actions. In
addition, these inhibitors were used in clinical trials without a potential biomarker for patient
selectivity and therefore resulted in early termination of trials (see CDK2 inhibitors and
breast cancer section). With promising results from the current CDK4/6 inhibitors, there is a
great interest in clinical use of these CDK inhibitors in other cancers. The clinical
development of each of these CDKs is discussed in the next few paragraphs.
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1-7 CYCLIN D AND CDK4/6 INHIBITORS IN BREAST CANCER
The first evidence of cyclin D (previously known as PRAD1) involvement in cancer
originates from studies performed on parathyroid adenomas (282). In parathyroid tumors, a
gene rearrangement between an upstream regulatory sequence of parathyroid hormone
gene and unknown DNA sequence from chromosome 11 was detected (282). Motokura and
colleagues first cloned PRAD1 cDNA, detected homology of its sequence with other cyclin
family, and found oscillation through cell cycle phases indicating a cell cycle regulatory
action (283). The same group found that PRAD1/cyclin D is overexpressed in parathyroid
and breast tumors (284). Jiang et al identified cyclin D amplification in 25% of human
esophageal cancers (285). Cyclin D is deregulated in many other tumors such as lung, head
and neck, and bladder cancer to mention a few (286-288). Schuuring et al examined tissues
from 226 stage I-III patients and detected amplification of cyclin D region in 16% of these
patients. Importantly, in this cohort, cyclin D amplification correlated with lymph node
involvement and poor survival (289). While cyclin D gene amplification is detected in about
20% of tumors, overexpression is seen in almost half of all BC patients (290). This suggests
deregulation at the transcriptional and post-transcriptional level. Transgenic animals with
cyclin D1 overexpression form breast tumors indicating an oncogenic role of cyclin D1 (291).
While the canonical interaction of cyclin D with CDK4/6 to inactivate Rb protein has been
accepted as the major contributor of cyclin D in tumorigenesis, other evidence argues a
CDK4/6 independent function of cyclin D (292, 293). As an example, exogenous expression
of cyclin D1 in BC cells not only interacted directly with estrogen receptor but also activated
ER signaling in a CDK4/6-Rb independent manner (292, 293). On the other hand, estrogen
receptor and Her-2 receptor can induce cyclin D expression indicting interaction between
cyclin D and these receptors. Moreover, major signaling pathways such as PI3K and MAPK
can increase cyclin D level at both mRNA and protein levels, as well as phosphorylate CDK4
protein resulting in cell cycle progression (294). These findings raise the question whether
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cyclin D can overcome the effect of AIs by activating unliganded ER. Clinical trials including
ER+ BC patients reveled an important role for cyclin D and CDK4/6 (295, 296). A
combination of a CDK4/6 inhibitor (palbociclib) with letrozole has shown promising results
leading to approval of palbociclib combined with letrozole by FDA in advanced ER+ breast
cancer patients. In the next section of this dissertation, I will review development of CDK4/6
inhibitors in further detail.

1-7a CDK4/6 inhibitors in breast cancer
PD-0332991, also known as palbociclib, is a novel CDK4/6 inhibitor. ER+ cell lines
showed the highest sensitivity to palbociclib when different subtypes of BC cell lines were
exposed to the drug (297). In this study, sensitive cell lines (IC50<150nM) had higher level
of cyclin D1 and Rb1 when gene expression was compared to resistant cell lines
(IC50>150nM). Mechanistic studies showed that PD diminished phosphorylation of Rb
protein associated with cell cycle arrest at G1 phase specifically in sensitive cells (297).
Moreover, PD was shown to have synergistic activity when combined with tamoxifen.
Sensitivity to palbociclib was further studied using an explant model of breast cancer (298).
11 out of 13 explants responded to palbociclib as measured by significant decrease in Ki67
positivity whereas 2 explants did not show decrease in Ki67. In this study, loss of Rb protein
was linked to insensitivity to palbociclib. Knudson et al examined the gene expression
changes in MCF7 cell line upon palbociclib treatment and compared the profile with
estrogen-deprived condition (299). In contrast to estrogen deprivation, palbociclib treatment
did not affect the ER target genes. However, long-term treatment with palbociclib altered the
gene expression profile of MCF7 cell line by suppressing the cell cycle regulatory genes
(299). Analysis of PAM50 genes following palbociclib treatment revealed a shift from
luminal-B to a luminal-A molecular subtype. Similar gene suppression was detected when a
xenograft model of MDA-MB-231 cells (triple negative) were treated with palbociclib
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highlighting the gene alterations induced by palbociclib is not restricted to HR+ breast
cancer. Taken together, these results suggest that beneficial role of palbociclib in HR+
breast cancer patients.
To advance the clinical development of palbociclib, a cohort of patients with advanced
disease were treated with palbociclib (300). In this study, patients received escalating doses
of palbociclib with three-week on-treatment and one week off-treatment schedule. Based on
this study, a dose of 125 mg of palbociclib was suggested for the phase II trial. Neutropenia
was found to be the only significant toxicity in this trial (300). Later on, DeMichele and
colleagues tested palbociclib in a single-arm phase II trial on 37 advanced BC patients who
had failed at least two lines of anti-hormonal therapy. A similar dose of 125 mg for threeweek on-treatment regimen was used. Results showed that two patients showed partial
response to treatment and five patients had stable disease. Neutropenia was detected in
half of patients, however only one patient developed fever and sepsis. This shows that
palbociclib is generally a well-tolerated drug while the bone marrow suppression is
reversible. In fact, in spite of neutropenia most patients were uncomplicated suggesting that
the bone marrow is still functional (301). As far as biomarkers are concerned, the
investigators examined tumor tissues for expression of Rb, p16 and Ki67 using
immunohistochemistry and cyclin D1 amplification using FISH. Surprisingly, no correlation
was detected between response to treatment with and any of these molecules (301). The
authors suggest that these biomarkers need to be tested at a larger sample size. In addition,
other biomarkers such as PI3K pathway or Rb mutation could potentially be involved
requiring further investigation.
PALOMA-1, phase 2 clinical trial, investigated response to letrozole monotherapy or
letrozole plus palbociclib in postmenopausal ER+ BC patients with advanced disease (296).
Patients in this study were treatment naïve and were recruited in two different cohorts where
cohort 1 included only advanced ER positive/Her-2 negative patients and cohort 2 included
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those with cyclin D amplification and/or p16 loss (296). In cohort 1, palbociclib addition to
letrozole improved median progression-free survival from 5.7 months to 26.1 months. In
cohort 2, combination treatment enhanced median progression-free survival from 11.1
months to 18.1 months. Taken together, addition of palbociclib to letrozole improved median
progression-free-survival from 10.2 months to 20.2 months (296). The most significant side
effect was neutropenia (54%) of patients who were treated with both drugs, whereas only
1% of cases treated in the letrozole arm developed neutropenia. However, addition of
palbociclib to letrozole did not statistically change overall survival of patients, 33.3 months in
the letrozole arm versus 37.5 months in the combination group (296). While preclinical
studies suggest that an intact Rb pathway could be a predictor of response to palbociclib,
translating such findings to clinical samples is difficult since loss of Rb is uncommon in
ER+/HER2- breast cancer patients. In addition, it is required to examine whether the level of
Rb protein could potentially be used as a predictive marker of palbociclib sensitivity. Results
recently published from the phase III trial (PALOMA-2) also confirmed improved
progression-free survival in patients who received palbociclib plus letrozole in comparison to
placebo plus letrozole arm (295). In this phase III trial, 666 ER positive/Her-2 negative
patients were randomized to receive letrozole or letrozole plus palbociclib. Analysis of the
data revealed that addition of palbociclib increased progression-free survival by
approximately fourteen months. Although neutropenia was detected in a majority of patients
who received combination treatment (79.5%), febrile neutropenia was only found in 2% of
patients. These results confirm the clinical benefit of palbociclib found in previous phase II
trial and signifies role of cell cycle regulatory proteins such as cyclin D and CDK4/6 play in
breast cancer. In the PALOMA-3 study, a total of 521 advanced ER positive/Her-2 negative
patients with prior relapse or progression on endocrine therapy were assigned to receive
either fulvestrant and placebo or fulvestrant in combination with palbociclib on a 3-week on
and 1-week off treatment schedule for palbociclib (302). Most patients recruited in this study
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were post-menopausal patients (79.3%). Results revealed that patients who received
palbociclib-fulvestrant regimen had longer median progression-free survival compared to
those who were treated with fulvestrant alone, 9.2 months versus 3.8 months, respectively
(302). Grade 3 and 4 neutropenia was detected in 62% of patients who received palbociclibfulvestrant treatment but most patients were uncomplicated and did not require
discontinuation of therapy.
In addition to palbociclib, two other CKD4/6 inhibitors are under development; one by
Lilly known as abemaciclib (LY2835219) and the other one by Novartis company ribociclib
(LEE011). Ribociclib is another CDK4/6 inhibitor that can prevent phosphorylation of Rb and
induce cell cycle arrest. Radet et al tested ribociclib on a panel of neuroblastoma cell lines in
vitro and xenograft tumors and showed that ribociclib induced cell cycle arrest and delayed
tumor growth (303). Mechanistic analysis by Western blot revealed that ribociclib decreased
phosphorylation of Rb protein at S780 as early as 6 hours. In addition, ribociclib decreased
mRNA level of FOXM1, a transcription factor recently found to be a target of CDK4/6
pathway, in the sensitive cell lines. In addition, ribociclib showed antitumor activity in
xenograft models alone or in combination with other agents such as MEK inhibitor (304). A
phase I trial studied ribociclib in a cohort of patients with advanced malignancy (18 BCs)
(305). Similar to palbociclib treatment, most patients received a 3-week on and 1-week off
treatment with neutropenia being the most common side effect. Results from a recent phase
III trial shows the efficacy of ribociclib in combination with letrozole in advanced ER+ breast
cancer patients (306). In this multi-center study, post-menopausal patients with advanced or
metastatic disease were randomized to receive either letrozole (daily) in combination with
ribociclib (21 out of 28-day cycle) or letrozole plus placebo as control arm (306). Results
from this study showed than ribociclib significantly delayed the progression of breast cancer
when combined with letrozole (306). Overall response was significantly higher in the
combination group compared to letrozole-alone treated patients (52.7% VS 37.1%,
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respectively). Other studies combining ribociclib with endocrine therapies such as tamoxifen
in premenopausal women (MONALEESA-7 NCT02278120) and fulvestrant in
postmenopausal women (NCT02422615) are currently undergoing.
The third CDK4/6 inhibitor under clinical investigation in this class is abemaciclib.
Pantaik and colleagues have recently published results of a study using abemaciclib as
monotherapy which included fourty seven BCs (307). Unlike the other two CDK4/6
inhibitors, patients received continuous daily or twice a day regimens. Results from this
study revealed that abemaciclib is generally safe when dosed continuously. More
importantly, overall response was detected in almost one third of breast cancer patients
(307). Bone marrow suppression and high-grade neutropenia are less commonly detected
with abemaciclib compared to palbociclib and ribociclib. However, abemaciclib is associated
with higher fatigue and diarrhea. Examination of breast cancer tumors from HR+ patients
treated with abemaciclib showed that the drug was able to inhibit proliferation of breast
cancer as measured by decreased Ki67 (308). One important aspect of abemaciclib is the
detection of the drug in the CSF when animal models where examined suggesting that it can
pass the blood brain barrier. In fact, abemaciclib increased survival of rats harboring
orthotopic brain tumors (309). This raises the question whether abemaciclib could be
effective in treating brain metastasis. Besides breast cancer, preclinical models show
promising results with abemaciclib in mutant BRAF melanoma and glioblastoma (309, 310).
While the use of CDK4/6 inhibitors in breast cancer has gained a lot of attention recently,
CDK2 inhibitors are still not well studied. In the next section, the role of CDK2 in breast
cancer and development of specific inhibitors are discussed in further detail.
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1-8 CYCLIN E AND CDK2 INHIBITORS IN BREAST CANCER
Cyclin E, an important regulator of cell cycle, is deregulated in many human cancers.
Overexpression of cyclin E is detected in different cancers such as stomach, breast, ovary,
to mention a few. Immunohistochemistry staining of cyclin E showed overexpression of
cyclin E in gastric adenocarcinoma in comparison to adenomas (311). In addition, in gastric
tumor tissues, the level of cyclin E expression correlated with increased proliferation as
measured by Ki67 using IHC (311). Lindhal and colleagues examined cyclin E expression
using immunohistochemistry in 270 breast cancer patients with known p53 status (312).
Cyclin E status was divided into three categories based on the percentage of positive cells
in IHC; low (less than 4%), intermediate (5-49%), or high (more than 50% positivity) (312).
Patients with high cyclin E staining tumors had more frequent point mutations, deletions and
insertions in p53 as well as decreased survival (312). Comparison of BC cell lines (including
MCF7, T47D, MDA-MB 231, and MDA-MB 436) to normal mammary epithelial cells (70N
and 76N) revealed overexpression of different cyclins such as cyclin E in breast cancer cells
(313). Amplification of cyclin E is detected in breast cancer cell line (MDA-MB-157 cell line)
compared to normal mammary epithelial cells (76N) using southern blot analysis (313). In
addition, comparison of these two cell lines using northern blot and Western blot analyses
revealed one similar mRNA in both cell lines (2.1 kb) but three different overexpressed
“cyclin E (-like)” bands exclusively in cancer cell line suggesting modification at the post
translational level (313). Further studies using Western blot analysis revealed presence of
cyclin E isoforms in breast cancer tumor tissues but not normal breast tissue samples (314).
Several studies using both cell culture as well as animal models in our lab have focused on
understanding the mechanism by which low molecular weight cyclin E (LMW-E) is produced.
In one such study flag-tagged cyclin E constructs were introduced into different cell types;
two normal breast cell lines and two BC cell lines (MDA-MB-157, MDA-MB-436) followed by
examination of cyclin E expression using Western blot (315). Results indicated generation of
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LMW-E forms exclusively in the cancer cells suggesting higher activity of cyclin E
processing in breast cancer cells. Moreover, cancer cells showed higher cyclin E and CDK2
kinase activities. Western blot analysis using antibodies against flag tag showed cyclin E
expression suggesting that the cleavage occurs at the N-terminal of the protein because flag
tag was located at the C terminal of the protein. These findings propose that cancer cells
activate a protease system that gives the cells capacity to cleave cyclin E into LMW-E
isoforms.
Elastase is a member of serine proteases that is able to cleave full length cyclin E into
LMW-E forms. Five different isoforms of cyclin E are generated in tumor cells (Figure 4).
Four of these isoforms are formed by elastase, which is able to cleave full-length cyclin E
(Figure 4). Western blot analysis showed production of the two doublets at 45 KD (EL2)/44
KD (EL3) collectively considered as trunk 1 (T1) and 35 KD (EL5)/33 KD (EL6) collectively
considered as Trunk 2 (T2). The last isoform (EL4) is produced through an alternate start
site (Figure 4). Mull et al showed that phosphorylation of cyclin E is required for generation
of LMW-E forms (316). Our lab has applied a mutagenesis approach to alter the
phosphorylation site of cyclin E in order to further study the generation of these LMW-E
forms. Results from this approach showed that EL2 band represent the phosphorylated form
of EL3 and similarly EL5 band is phosphorylated form of EL6 at T395 (Figure 4).
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Figure 4. Generation of low molecular weight cyclin E in breast cancer. Full length
cyclin E (EL1, referred to as EL in this dissertation) is cleaved by the activity of the elastase
enzyme at indicated sites generating two truncated proteins (EL3 and EL6). These two
isoforms can be phosphorylated at T395 site representing a higher band on Western blot
(EL2 and EL5). These truncated proteins (T1 and T2) are considered LMW-E isoforms of
cyclin E and are mainly localized in the cytoplasm. EL4 is a 40 KD protein produced from an
alternate start site.
Adapted by permission from Macmillan Publishers Ltd: Oncogene, Mull, B. B., J. Cox, T.
Bui, and K. Keyomarsi. 2009. Post-translational modification and stability of low molecular
weight cyclin E. Oncogene 28: 3167-3176, copyright 2009, License Number
4222210891922
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To further study the biologic role of LMW-E, EL and LMW-E constructs were
overexpressed in insect cells separately along with CDK2 expressing vector (317). Kinase
assay showed that LMW-E constructs induced higher CDK2 kinase activity compared to EL.
This increased kinase activity is partially related to higher binding affinity of LMW-E forms
with CDK2 as examined by immunoprecipitation assay. In addition, although LMW-E and EL
both showed similar binding pattern to p21 and p27, LMW-E kinase activity was less
affected by these inhibitors indicating resistance of LMW-E to endogenous inhibitors (Figure
5). It is worth noting that LMW-E forms are able to sequester endogenous inhibitors away
from EL. This increased kinase activity was similarly detected in breast cancer cell lines and
tumor tissues. To investigate the differential activity of EL versus LMW-E, in vitro translated
forms of both proteins were mixed with cell extracts of breast cancer cells (MDA-MB-157),
pulled down with antibody and subjected to CDK2 Western blot and kinase assays (318).
Results from this experiment revealed that EL and LMW-E have the capability to bind to
CDK2 and induce kinase activity. Of particular note, addition of cyclin E increased
phosphorylated active form of CDK2 and resulted in higher CDK2 kinase activity (Figure 5).
In another similar study, EL and LMW-E constructs (both T1 and T2) were overexpressed in
ER+ cell line (MCF7) followed by assessment of kinase activity in these cells (319).
Comparison of LMW-E overexpressing clones to EL ones revealed higher cyclin Eassociated and CKD2 kinase activities in LMW-E overexpressing cells. Taken together,
these studies suggest that LMW-E can bind to CDK2 and is biologically active. However.
LMW-E isoforms are resistant to p21 and p27 inhibitors highlighting the specific behavior of
LMW-E.
Biologic significance of LMW-E goes beyond increasing CDK2 and cyclin E kinase
activities. Studies in our lab have shown that in contrast to full length cyclin E, LMW-E
isoforms are mainly localized to the cytoplasm. Subcellular localization of cyclin E was
assessed in a panel of different cell lines including immortalized mammary epithelial cells as
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Figure 5. LMW-E is more hyperactive than EL and is mainly localized in the
cytoplasm. Low molecular weight cyclin E (LMW-E), compared to full length cyclin E (EL) is
mainly localized in the cytoplasm, have higher CDK2 kinase activity, is resistant to
endogenous cyclin dependent kinase inhibitors (P21, P27), and is less affected by F box
protein (Fbw7).
Adapted from Cancer Res, 2009, 69: 2817-2825, Delk, N. A., K. K. Hunt, and K. Keyomarsi,
altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent
kinase 2 complex formation and proteasomal regulation, with permission from AACR.
License number 4222220357990
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well as breast, ovarian and osteosarcoma cell lines (320). Fractionation and Western blot
analyses revealed LMW-E expression exclusively in the cancer cells with higher localization
in the cytoplasm. Cytoplasmic cyclin E component is able to bind to cytoplasmic CDK2 and
is active as measured by its kinase activity. To confirm localization of LMW-E, a protein
complementation assay with tagged cyclin E (or LMW-E) and CDK2 was used which
revealed localization of LMW-E mainly in the cytoplasm or perinuclear membrane. In
contrast to this, full-length cyclin E was mainly localized in the nucleus. This specific
localization prevents the LMW-Es to be degraded by F box protein which normally
ubiquitinate and target full length cyclin E for degradation in the nucleus. These specific
LMW-E features enable these isoforms to be more stable than the full-length cyclin E. These
experiments suggest that LMW-E is more hyperactive than EL cyclin E contributing to its
biologic significance in breast cancer.
Several other studies have shed light on the significance of cyclin E in breast cancer
patients. Cyclin E status was first examined in tissue samples isolated from breast cancer
patients. To this end, expression of cyclin E and cyclin D were examined in extracts isolated
from breast cancer as wells as normal adjacent tissues. Results revealed abnormal
expression of cyclin E in 8 out of 9 patients exclusively in breast cancer tissue but not the
normal breast tissue (321). In comparison, cyclin D overexpression was seen only in 2 out of
9 patients. Cyclin E deregulation was associated with higher stage and grade but was
independent of proliferation (PCNA level by Western blot). To further explore the role of
cyclin E in the early phase of breast cancer, tumor tissues containing in situ carcinoma (128
samples) and invasive tumor (177 samples) from a cohort of stage I/II breast cancers were
stained with cyclin E antibody (322). Cyclin E was considered positive when more than 5%
positive cells (intensity >1) were detected in each specimen. This analysis revealed cyclin E
overexpression in almost one third of in situ carcinoma, one third of invasive tumors, as well
as 45% of normal breast epithelial cells adjacent to tumor tissue. Staining with γH2AX
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revealed high percentage of DNA damage (77% of samples) in cyclin E overexpressing
normal breast epithelial cells suggesting that cyclin E overexpression is (1) real and (2)
induces genomic instability in normal cells. In addition to overexpression, abnormal
cytoplasmic localization of cyclin E was detected in both breast cancer tissues and breast
cancer cells. These results suggest that cyclin E deregulation is an early process during
breast cancer formation and occurs through both overexpression and altered subcellular
localization. In another study, cyclin E status was examined in frozen tissue samples of 395
breast cancer patients using Western blot and immunohistochemical analysis (323). EL or
LMW-E levels were defined as low or high in comparison to normal breast tissue. Statistical
analysis showed that patients with high levels of full-length cyclin E and LMW-E had poor
overall and disease-specific survival than those with low levels. In a similar fashion, patients
with high cyclin E expression, as per IHC, in their breast tumor had poor survival. In addition,
when cyclin E was examined in stage I-III patients, higher cyclin E level in each stage
correlated with poor survival from breast cancer. Our lab has recently published the use of
immunohistochemistry as a feasible method to identify cytoplasmic cyclin E in breast cancer
tumors (324). Examination of tumor tissues from 1676 breast cancer patients (stage I-III)
revealed that 40% of patients expressed cyclin E exclusively in the cytoplasm representing
the LMW-E expression (324). Moreover, the majority of patients with cytoplasmic cyclin E
expression were also positive for cytoplasmic p-CDK2 (85.1%). On the other hand, almost
80% of patients who were negative for cytoplasmic cyclin E staining were also negative for
cytoplasmic phospho-CDK2 indicating that abnormal expression of cyclin E in breast cancer
tumor deregulates cell cycle by activation of CDK2. More importantly, patients with
cytoplasmic expression of cyclin E and p-CDK2 in their tumors had higher histologic grade
and worse prognosis compared to patients who stained negative for these two markers
(324). Similar to this study, cytoplasmic cyclin E was detected in almost 40% of patients with
inflammatory breast cancer (IBC) (325). IBC is an aggressive type of BC often with poor
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response to chemotherapy and poor prognosis indicating that novel therapies are urgently
needed for this subtype of breast cancer (326). In vitro analysis using IBC cell lines in our
lab has shown that IBC cell lines are very sensitive to dinaciclib and meriolin 5, two potent
CDK2 inhibitors (see CDK2 inhibitor section) (325). Mechanistic studies showed that
dinaciclib induced apoptosis in IBC cell lines as measured by percentage of annexin V
positive cells, cleaved caspase 3, and cleaved poly ADP ribose polymerase (PARP)
(indicators of apoptosis) (325). In addition, a combination of dinaciclib given prior to DNA
damaging agents such as epirubicin and carboplatin showed synergistic activity in IBC cells
through enhancing DNA damage (325). These results suggest that cyclin E/CDK2 pathway
is a potential target to be considered in the treatment of IBC patients. Prognostic value of
cytoplasmic cyclin E is not subtype dependent (327). Cytoplasmic staining of cyclin E
correlated with LMW-E forms detected by Western blot when 152 tumor samples were
examined (327). Examination of tissue samples from 2494 patients including all molecular
subtypes from four different cohorts revealed that cytoplasmic staining correlated with poor
survival and its prognostic value was superior to all clinical variables as well as Ki67 (327).
Taken together, these results show the significance of cyclin E as a prognostic marker and
suggest that targeting LMW-E/CDK2 has potential therapeutic value in patients with
cytoplasmic expression of cyclin E.
To interrogate the tumorigenic activity of LMW-E, Duong et al introduced LMW-E and
EL in hMEC cells and showed that only the LMW-E harboring cells were able to form tumors
(328). Serial transplantation of these LMW-E expressing cells in vivo showed enrichment of
EMT phenotype by downregulating endothelial markers (E-cadherin) while upregulating
mesenchymal and stem cell markers N-cadherin, Twist, and Slug. LMW-E expressing cells
showed higher migratory ability compared to EL cells when subjected to a scratch assay.
Expression of LMW-E in hMECs almost doubled the subpopulation of CD44high/CD24low cells
(Marker of CSCs) as compared to EL. Moreover, serial transplantation of LMW-E cells was
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associated with enrichment of the CD44high/CD24low subpopulation. Additionally, LMW-E
expressing cells formed more and bigger mammospheres in vitro and showed higher ALDH
activity as two characteristics of CSCS. To further study the significance of LMW-E in breast
cancer, transgenic animal models of LMW-E and EL cyclin E were generated (329). In this
model, the LMW-E and EL transgenes were expressed under the MMTV promoter.
Examination of the mammary gland in ten-day-old lactating mice revealed abnormal
morphology of the alveolar cells (variable size nuclei) specifically in the LMW-E expressing
model. Longer follow up of the mice for tumor formation showed higher incidence of
mammary tumor in LMW-E expressing animals than the EL ones, 25% versus 8.3% of mice,
respectively. More importantly, LMW-E transgenic mice harbored higher metastasis rate
(25%) with a mean latency of 17.2 months. Lungs were the main sites of metastasis in these
animals. Mechanistic studies showed that LMW-E did not induce proliferation or
chromosomal instability in this transgenic model. However, loss of the wild-type p53 allele
increased mammary tumor formation and decreased latency suggesting the cooperation
between LMW-E and p53 for carcinogenesis. These studies highlight the significance of
cyclin E in driving mammary tumor formation and metastasis in animal models.
Using animal models, our lab has also shown that LMW-E-mediated mammary tumor
formation requires the activity of CDK2 within the mammary tissues. To address this,
transgenic animals with CDK2 deficient background were generated (330). CDK2-deficient
mice showed decreased branching morphology of the breast tissue at an early stage.
Longer follow up of the animals revealed that LMW-E expression under MMTV promoter
induced tumor formation in CDK2+/+ or CDK2+/- mice with latency between 16 to 19.5
months. In contrast, CDK2 deficient mice (CDK-/-) did not form any tumors within a two-year
follow up. In a similar fashion, pharmacologic inhibition of CDK2 by two different CDK2
inhibitors (roscovitine and meriolin 5) delayed mammary tumor formation in LMW-E
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expressing mice and improved survival of these mice. Taken together, these results
highlight targeting CDK2 as a potential therapeutic strategy in LMW-E expressing tumors.
The significant role of LMW-E in breast cancer raises the question whether targeting
cyclin E could have potential therapeutic role. To explore this, inducible model systems of
LMW-E and EL in ER positive MCF7 cells were generated. Using this system, our lab has
examined the differential kinetics of EL and LMW-E over time (331). Comparison of LMW-E
versus EL expressing cells showed that LMW-E does not alter rate of proliferation compared
to EL. However, LMW-E expression was associated with enhanced cyclin E associated
kinase activity and higher chromosomal instability including higher chromosomal breaks,
fusions and polyploidy. Next, our lab planned to find specific inhibitors that can target LMWE expressing cells. Roscovitine that targets CDK2 was not effective to inhibit LMW-E
inducible cells individually (IC50 15µM), however, a combination of roscovitine followed by
doxorubicin showed synergistic activity in LMW-E inducible MCF7 cells. This sequential
combination also showed synergistic activity in a triple negative cell line with high
endogenous level of LMW-E (MDA-MB-436). The potential efficacy of roscovitine combined
with doxurubicin was further explored in TNBC. As mentioned earlier, TNBC tumors do not
express hormone receptors nor Her-2 receptor and thus will not respond to targeted
therapies against these receptors. In a recently published study, our lab has shown that
roscovitine alone induces higher G2-M arrest specifically in p53 mutant TNBC cells (332).
Similar to the previous study in inducible MCF7 cells, administration of roscovitine before
doxorubicin showed synergistic cell killing in TNBC cells. This sequential combination
induced apoptosis in 30% and 45% of MDA-MB-157 and MDA-MB-468 cell lines (TNBC cell
lines), respectively. In terms of mechanism, this combination increased doxorubicin-induced
DNA damage as measured by γH2AX foci and phospho-H2AX expression. Additionally, the
sequential combination of roscovitine with doxorubicin controlled tumor growth and
improved survival of mice implanted with triple negative breast cancer cells.
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Further studies show the link between cyclin E and response to platinum-based
therapy in ovarian cancer. Cyclin E, p27 level, and cyclin E associated kinase activity were
measured in 75 tumor tissues isolated from ovarian cancer patients who underwent
chemotherapy with platinum based drugs (333). In this sample set, cyclin E level did not
correlate with cyclin E associated kinase activity. However, cyclin E associated kinase
correlated with clinical response to platinum based therapy. Mechanistically, higher cyclin E
kinase activity resulted in higher inactivation of Rb protein through hyper-phosphorylation
leading to higher S phase entry and thus more susceptibility to platinum chemotherapy.
Taken together, these studies suggest that LMW-E is a potential biomarker to select
patients who would benefit from cyclin E/CDK2 targeting drugs.

1-8a CDK2 Inhibitors in breast cancer
Cell cycle deregulation is a common process during tumorigenesis. Therefore, targeting
cell cycle component by specific CDK inhibitors is a potential therapeutic approach. CDK
inhibitors are small molecule inhibitors that can bind to CDKs and inhibit their kinase
activities (281). Flavopiridol was a first generation of CDK inhibitor that reached clinical
trials, but was not able to be developed into a marketed drug because of toxicity profile.
Flavopiridol can inhibit different CDKs including CDK1/2, CDK4/6, CDK7 and CDK9 (334).
Flavopiridol induced G1/G2 cell cycle arrest when two cell lines (MCF-7 and MDA-MB-246)
were challenged (334). In addition, flavopiridol was induced cell death in bladder cancer cell
lines at a concentration as low as 50nM as measured by increased annexin V positive cells
(335). Flavopiridol went into a phase I trial on a cohort of 34 patients with advanced disease
(2 BC patients) (336). Neither of these two breast cancer patients responded to this
treatment regimen (336). Results from another study using flavopiridol in combination with
docetaxel in breast cancer patients were not sufficiently promising to support further drug
development. This was due to the high rate of toxicity such as neutropenia in the majority of
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patients (337). Similar to previous studies using flavopiridol most patients experienced
fatigue and diarrhea, 82% and 64% respectively. However, in colorectal cancer, flavopiridol
reached to a phase II study which was not further pursued due to lack of objective response
and toxicities such as diarrhea (21% of patients) and fatigue (11%) (338). Similarly,
flavopiridol did not reach beyond phase II in malignant melanoma (339) or androgen
insensitive metastatic prostate cancer patients (340).
Another first generation CDK2 inhibitor that was advanced into clinic is known as
roscovitine (seliciclib) (341). In vitro analysis of roscovitine using ER+ MCF7 cell line
revealed both G2 arrest as well as apoptosis (342). Furthermore, anti-proliferative activity of
roscovitine was enhanced when the cells were concomitantly treated with tamoxifen (342).
Antitumor activity of roscovitine was examined in a xenograft model of breast cancer using
MCF-7 cells implanted in the subcutaneous tissue of nude mice (343). Results revealed that
roscovitine or doxorubicin induced almost 50% tumor regression individually compared to
vehicle treated mice (343). However, a combination of both drugs induced almost 70%
tumor shrinkage in this model. Mice treated with concomitant treatment showed higher areas
of necrosis with diminished proliferating cells in the remaining tumors in comparison to
single treatments (343). In a phase I study, 21 patients (none had breast cancer) with
different tumors were treated with roscovitine at a dose range from 100 mg to 800 mg twice
daily (344). None of treated patients showed objective response to roscovitine but 8 out of
21 patients had stable disease on treatment (344). Nausea, fatigue and electrolyte
abnormalities were detected in patients who were treatment with roscovitine. In general,
these two inhibitors lacked specificity against CDKs with possible off-target effects resulting
in toxicities when used clinically.
Dinaciclib is the next generation CDK2 inhibitor (IC50 1nM) with potential to inhibit
others CDKs such as CDK1 or CDK9 but at higher IC50 values (345). In addition, dinaciclib
can block DNA replication at very low nanomolar range. Mechanistic studies using
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increasing concentrations of dinaciclib on A2780 cells (Human ovarian carcinoma cell line)
indicated that dinaciclib inhibited phosphorylation of Rb protein (S801/811) at a
concentration as low as 6nM and induced cleavage of PARP (marker of apoptosis) at 12nM.
Furthermore, in vivo studies using xenograft model of A2780 showed antitumor activity of
dinaciclib with only 5% body weight loss when maximum dose (48 mg/kg) was used. The
authors detected a decrease in the neutrophil and reticulocyte counts at day 6 following
therapy which was reversible at day 13. Dinaciclib efficacy has also been tested in triple
negative cell lines. Dinaciclib has apoptotic activity in TNBC specifically in those with MYC
overexpression. Furthermore, dinaciclib induced tumor regression in xenograft tumors
derived from two TNBC cell lines (MDA-MB-231 and HCC-3153) (346). These preclinical
studies suggest that dinaciclib is a valuable drug to be tested in breast cancer patients.
The clinical efficacy of dinaciclib has been investigated in different studies. Results of a
phase I study including 3 patients with BC indicated general safety of dinaciclib (347).
Patients were treated with increasing concentration of dinaciclib (range from 0.33 to 14
mg/m2) once every week for three weeks followed by one week of recovery. Results of this
study indicated that 10 out of 48 patients showed prolonged stable disease and confirmed
that the drug is well tolerated. To advance clinical development of dinaciclib, a cohort of BC
patients with history of chemotherapy failure were categorized to treatment with dinaciclib or
capecitabine. The trial was stopped since lower time to progression was detected in the
dinaciclib arm (median 2.7 months) compared to the capecitabine arm (median 4.1 months)
(348). However, antitumor activity was reported in 2 out of 7 ER+ breast cancer patients.
47% of patients on dinaciclib treatment showed significant drop in neutrophil count and 21%
showed significant decrease in the total number of leukocytes. Another study using
dinaciclib plus epirubicin in a cohort of metastatic TNBC was terminated early due to severe
neutropenia in spite of growth factor use suggesting that this combination modality is not
satisfactory for TNBC patients (349). Therefore, studies using dinaciclib in breast cancer are
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very preliminary and inconclusive. However, promising results have been detected in other
cancers as discussed in the next paragraphs suggesting that the drug could be potentially
tested in more clinical trials including breast cancer patients.
Dinaciclib has shown promise in hematologic malignancies and is further studied in
lung cancer. Dinaciclib at those of 12 mg/m2 was administered IV at days 1,8, and 15 within
a 28-day cycle for lymphoma patients (350). Most patients tolerated a few cycles of
treatment using such dose while adjustment in dose (decrease to 10mg/m2) was required for
two patients. The authors reported clinical response in some of these highly pretreated
patients. In patients with refractory or relapsed CLL, a combination of dinaciclib (started at
7mg/m2 and increased to 10 mg/m2 in further cycles) with rituximab was well tolerated (351).
A more recent study reported administration of different concentrations of dinaciclib (a range
from 7mg/m2 to 17 mg/m2) to 52 refractory or relapsed CLL patients with at least 4 previous
treatments. Dose limiting toxicity was set as 17 mg/m2 and was further tested in an
expansion study. Response was detected in 54% of CLL patients with administration of
dinaciclib as monotherapy (352). A phase II study compared the efficacy of dinaciclib
(50mg/m2) with erlotinib, a standard of care EGFR inhibitor used in advanced NSCLC, in a
cohort of pretreated non-small cell lung cancer patients. Although dinaciclib was well
tolerated, it did not improve time to progression in comparison to erlotinib suggesting that it
is not effective as single agent therapy for these patients (353). Taken together, the studies
using dinaciclib in human cancers show that it is fairly well tolerated drug. However,
appropriate selection of patients and dosing are required to identify patients who would
benefit from dinaciclib treatment. Using cyclin E as a predictive biomarker of response could
be a feasible approach to identify and select patients. Additionally, a combination of
dinaciclib with AIs may have beneficial role in ER+ patients with abnormal cyclin E pathway.
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1-9 GAP IN KNOWLEDGE
Approximately 75% of all breast cancer patients express hormone receptor on the
surface of their tumors requiring anti-hormonal therapies. Resistance to anti-estrogen
therapies develops overtime during treatment as patients are often treated for five years. In
the neoadjuvant setting only half of patients showed objective response to letrozole (190). In
addition, the majority of BC patients with metastatic disease show resistance to these drugs
(187). As discussed earlier, different mechanisms have been implicated in resistance to antiestrogens including aromatase inhibitors. Studies have shown that Her-2 is overexpressed
upon resistance to aromatase inhibitors. However, theoretically only a minority of patients
would express both ER and Her-2 receptor on the surface of their tumors and thus would
benefit from the dual inhibition of these receptors. In addition, resistance to Her-2 targeted
therapies develops as mentioned earlier (33). Aberrant activity of signaling pathways can
contribute to resistance to hormonal therapies. For example, different clinical trials have
investigated the beneficial role of mTOR inhibition in HR positive breast cancer patients
(229, 354). Among these however, everolimus is the only signal transduction-targeting drug
that has gained FDA approval to reverse resistance to endocrine therapy in BC patients with
advanced disease (229). Further novel therapies are urgently needed to tackle against
resistance to AIs. Recent clinical trials combining CDK4/6 inhibitors with letrozole have
shown promising results indicating the significance of G1 cell cycle component in promoting
breast cancer (295). Cyclin E is deregulated in breast cancer and abnormal cyclin E
expression has prognostic value (323). LMW-E isoforms are specifically generated in cancer
cells and deregulate cell cycle by enhancing G1 to S transition. However, the significance of
cyclin E deregulation in patients treated with aromatase inhibitors is not yet studied. The
goals of this study are to investigate the correlation between cytoplasmic cyclin E and
response to AI in HR+ BC patients, investigate resistance mechanisms to AIs, and
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determine whether CDK2 inhibitors such as dinaciclib (as binding partner of cyclin E) may
be successful in reversing resistance to AIs.
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CHAPTER 2: CYTOPLASMIC CYCLIN E MEDIATES RESISTANCE TO AROMATASE
INHIBITORS
2-1 INTRODUCTION
The majority of breast cancer patient harbor tumors that express hormone receptors
(70-80% of all patients) (2, 3). These patients harbor tumors with ER or PR expression and
may benefit from the anti-estrogen treatments including aromatase inhibitors, tamoxifen, or
fulvestrant (128-132). Aromatase inhibitors are considered as the first line treatment in postmenopausal BC patients. Clinical studies have shown superiority of AIs to tamoxifen in postmenopausal patients (187,188). However, some patients show de novo resistance to these
medications and oftentimes tumors relapse in spite of initial response after long-term
treatment with aromatase inhibitors (187,193). In spite of numerous studies aimed at
understanding the biology of such resistance, current combination treatments are not
completely successful to eradicate tumors resulting in progression of the disease.
Multiple mechanisms have been discussed in the literature contributing to resistance to
these hormonal therapies. Examples of these alternative mechanisms include increased
aromatase expression (207), alteration of ER expression including epigenetic silencing or
mutation of the gene (148), independent activation of ER through growth factor signaling
pathway (169,170), induction of ER transcription by androgen receptor (213),
overexpression of growth factor receptors such as Her-2, and activation of intracellular
cascades such as MAPK and PI3K (217). In addition to these mechanisms, there is new
evidence on the role of cell cycle regulators in resistance to aromatase inhibitors. For
example, AI resistant cells show abnormal expression of aurora kinase A and B (mitotic cell
cycle regulator) or polo-like kinase 1 (G2 phase regulator) and respond to aurora or polo-like
kinase inhibitors (355, 356). Results from combination of CDK4/6 inhibitor (palbociclib) with
letrozole revealed improved median progression-free-survival in HR+ postmenopausal
patients diagnosed with advanced stage (296). These results confirm the significance of cell
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cycle targeted therapy in HR+ breast cancer patients. However, further studies are needed
to identify biomarker of response to CDK4/6 inhibitors.
Cyclin E is a major regulator of G1/S checkpoint and is deregulated in many
malignancies including breast cancer (311). Studies in our lab have shown that cyclin E is
cleaved into oncogenic LMW-E specifically in the cancer cells but not normal breast cells
(314, 315). In comparison to full length cyclin E, LMW-Es are biologically hyperactive, bind
more tightly to its kinase partner CDK2, are resistant to endogenous inhibitors of cyclin
dependent kinases, and are mainly localized to the cytoplasm of the breast cancer cells
(317, 319, 320). More importantly, examination of cyclin E status in tissue samples of 395
BC patients using Western blot analysis showed correlation between cyclin E and poor
survival. Subcellular localization of LMW-E in the cytoplasm as detected by
immunohistochemistry assay also enables identification of patients who express LMW-E in
their tumor tissues (324). The majority of these patients with cytoplasmic cyclin E expression
also showed phosphorylated CDK2 expression in the cytoplasm associated with higher
histologic grade and worse prognosis (324). Animal models using LMW-E expression
hMECs showed that only LMW-E but not full-length harboring cells are capable to generate
tumors in vivo (328). Moreover, serial transplantation of these LMW-E expressing cells
resulted in enrichment of cancer stem cells (331). Given the important role of cyclin E and
CDK2 pathway, combination treatments including inhibitors of CDK2/cyclin E pathway may
have beneficial role in breast cancer.
Combination of a CDK2 inhibitor (dinaciclib) with epirubicin or carboplatin has
synergistic activity in IBC cell lines (325). Similar synergistic activity has been detected when
combining roscovitine with doxorubicin in preclinical models using ER+ MCF7 cell line or
triple negative cell lines (332). In preclinical animal models, dinaciclib was able to regress
xenograft tumors derived from triple negative cell lines (346). Although clinical studies using
dinaciclib combination in breast cancer are limited and preliminary, promising results have
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been observed in hematologic malignancies (350) (351). Considering the important function
of LMW-E in BC, we propose that targeting this pathway with CDK inhibitors such as
dinaciclib is a potential combination therapy that needs to be considered along with
aromatase inhibitors. Therefore, we hypothesize that LMW-E expression deregulates
cell cycle and mediates resistance to aromatase inhibitors. To address this hypothesis,
we examined three different aims in this study:
1) Determine response to neoadjuvant AIs in post-menopausal BC patients with or without
LMW-E expression
2) Investigate mechanism of resistance to aromatase inhibitors using LMW-E inducible
model system
3) Determine LMW-E medicated response to letrozole in xenograft model of hormone
receptor positive breast cancer

2-2 MATERIALS and METHODS
2-2a Cell lines and cell culture
We purchased ER+ cell lines (MCF7& T47D) from the American Type Cell Culture
Collection (ATCC, Manassas, VA). Aromatase overexpressing MCF7 cells were cultured as
previously described (357). Briefly, we cultured the cells in Dulbecco’s modified Eagle
medium (DMEM)(Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Flowery Branch, GA) and G418 purchased from Teknova
(Hollister, CA) at 600μg/ml concentration. We generated cyclin E inducible MCF7Ac1 cells
using transcripts expressing full-length cyclin E, LMW-E, or empty vector and maintained
them in DMEM supplemented with 10% tetracycline-free FBS, 600 μg/ml G-418, and 4
μg/ml blasticidin from InvivoGen (San Diego, CA). T47D cells were cultured as previously
described in minimum essential medium alpha modification from Sigma-Aldrich (St. Louis,
MO) supplemented with sodium pyruvate (1 mM), non-essential amino acids (0.1 mM), L-
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glutamine (2 mM), and HEPES (0.01 M) (358). Full-length and LMW-E expressing T47D
cells, previously generated in our lab, were maintained in the same media as T47D but
supplemented with 200 μg/ml of G418. All plates were kept in incubators at 37° C containing
6.5 % CO2 with fresh media being replaced every 2-3 days. Cell lines were tested for
mycoplasma and if positive, treated accordingly with plasmocin (InvivoGen, San Diego, CA)
until eradication before using them for experiments.

2-2b Cyclin E expression model system
We generated cyclin E inducible system in MCF7Ac1 cells and cyclin E stable system
in T47DAc1 cells. For this purpose, we transfected 293T cells with a vector containing
tetracycline repressor and blasticidin-resistance cassette (pBMN-BSR-TetR) to generate
viral particles harboring Tet repressor gene. Next, MC7Ac1 cells were infected with the viral
particles and cells were screened with blasticidin 48 hours after infection. We performed
Western blot analysis to confirm expression of Tet repressor. We repeated the same
infection using cyclin E constructs harboring TetO upstream of full-length, LMW-E, or empty
vector expression vector and selected the cells using puromycin 1 μg/ml (InvivoGen, San
Diego, CA). Generation of cyclin E constructs (CMV-TetO-Cyclin E) are described
elsewhere (359). Cells were plated in small quantity to allow single colony growth. Next, we
picked and expanded single colonies, harvested cells with or without doxycycline, and
confirmed cyclin E expression in the individual colonies using Western blot analysis. At least
two colonies for each cyclin E isoform were selected to perform our experiments. Colonies
that were leaky or non-inducible were excluded. We used the same protocol and infected
T47D LMW-E and vector control cells with viral particles harboring human aromatase
construct and a blasticidin resistant cassette (Clone ID: PLOHS_ccsbBEn_06078,
ORFeome core at MD Anderson). Western blot analysis was performed to confirm
aromatase expression.
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2-2c CDK2/Rb knock down experiments
In order to knock down Rb or CDK2, we first transfected 293T cells with constructs
harboring shRNA targeting CDK2 or Rb fused with GFP. We next infected inducible
MCF7Ac1 cells with viral particles and sorted GFP+ cells using flow cytometry 48 hours after
infection. To maximize knock down efficiency, we repeated the sorting process followed by
Western blot analysis to confirm efficient knock down. Multiple independent shRNA
constructs were used and two clones with the best knock down efficiency were selected for
further experiments. shRNA constructs were purchased from shRNA core facility at MD
Anderson Cancer Center, CDK2 (Clone ID: V3LHS_637569 and V3LHS_637573) or Rb
(Clone ID: V2LHS_130606 and V3LHS_340825).

2-2d Proliferation and cell viability assays
To measure proliferation, we deprived the cells of estrogen for four days before each
experiment. To remove estrogen from media, we added dextran-coated charcoal (SigmaAldrich, St. Louis, MO) to tetracycline-free FBS followed by shaking overnight at 4°C and
filtration the next day to remove charcoal. This process removes most of the estrogen from
the FBS. Next, we cultured the cells in phenol red-free improved minimum essential medium
(IMEM; Corning, Corning, NY) supplemented with 10% of tetracycline-free charcoal-treated
FBS for 4 days before each experiment. We plated equal number of inducible MCF7Ac1
cells in 6-well plate and exposed for twenty four hours to doxycycline at a concentration of 1
ng/ml in order to induce cyclin E followed by drug treatment. Fresh media containing drug
and doxycycline was replaced every 48 hours. Control conditions containing only vehicle
without doxycycline were included for each experiment. At the end of experiment, we
washed the cells with cold phosphate-buffered saline (PBS) followed by trypsinization to
detach the cells and counting using an automated cell counter (Biorad, Hercules, CA) or
Coulter Counter (Z series; Beckman Coulter, Brea, CA). To measure proliferation of
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aromatase overexpressing T47D cells, we deprived the cells from estrogen by culturing
them in phenol red-free MEM (Corning, Manassas, VA) supplemented with 10% charcoal
dextran-stripped FBS (Gemini, Sacramento, CA) for four days. Next, we measured
proliferation of the cells by counting cell number after treatment with aromatase inhibitors for
three days. Androstenedione was purchased from Sigma-Aldrich (St. Louis, MO) and
dissolved in ethanol as vehicle and maintained at 4°C. We purchased both AIs from SigmaAldrich (St. Louis, MO) and diluted them in ethanol. We measured cell viability using a high
throughput survival assay described previously (331). We deprived the cells from estrogen
for four days as explained earlier and plated equal number of cells in 96-well plate. The next
day, we changed media to an estrogen-deprived media with or without doxycycline to induce
cyclin E expression in inducible cells. Next, we treated the cells with or without
androstenedione and AIs for a total of 12 days. Fresh media containing drugs was replaced
every other day. At the end of the experiment, we washed the cells in PBS, stained them
with crystal violet, washed the cells again to remove extra crystal violet, solubilized the cells,
and finally measured absorbance at 590 nm using an Epoch spectrophotometer (BioTek,
Winooski, VT). For dinaciclib and palbociclib treatment, we deprived inducible cells of
estrogen, challenged with/without doxycycline, treated with palbociclib or dinaciclib, followed
by culture in drug-free media until analysis at day 12.

2-2e Cell cycle analysis
To analyze cell cycle, we deprived the cells of estrogen for 4 days and plated 1 × 106
cells followed by treatment as indicated in each figure. Following drug treatment at indicated
date, we washed the cells in cold PBS, harvested them and maintained the cells in 70%
ethanol at 4°C overnight. Next, we centrifuged the cells, removed ethanol, washed them
with PBS, and maintained them in PBS solution containing 0.5% Tween-20 and bovine
serum albumin, 20μg/mL ribonuclease A, and 10 μg/mL PI overnight to stain the cells. We
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then incubated the cells at 37oC for an hour, filtered them to avoid pellet formation, and
subjected a minimum of 10000 cells to flow cytometry analysis at MD Anderson flow
cytometry facility as previously described (360).

2-2f Western blot analysis and in vitro kinase assay
Following drug treatment, we washed the cells with PBS, trypsinized the cells to
separate them from the plates, neutralized trypsin using the same volume of inhibitor, and
centrifuged to precipitate the pellet. Next, we washed the cells twice in ice-cold PBS and resuspended them in the same volume of phosphatase/protease inhibitor, sonicated
(Sonicator XL; Misonix Inc) followed by ultracentrifugation to clear the lysate. We determined
total concentration of protein in each sample using the Bradford assay. We loaded equal
amount of protein on SDS-polyacrylamide gel and subjected them to electrophoresis at 120
V, followed by overnight transfer to Immobilon P membrane (Millipore) at 35 V at 4°C. The
next day, we stained the membrane with ponceau for 5 minutes, de-stained with 5% acetic
acid for visualization of protein, washed in TBST, and blocked the membrane in BLOTTO
milk at room temperature. We incubated the membrane with primary antibodies for 2 hours
and appropriate secondary antibodies for 1 hour at room temperature with multiple washes
in between. Primary antibodies used for this assay included cyclin E (HE12; Santa Cruz
Biotechnology, Santa Cruz, CA), CDK2 (Santa Cruz Biotechnology), pCDK2 (Cell Signaling
Technology, Danvers, MA), Rb (BD Pharmingen, San Jose, CA), pRb (S807/811; Cell
Signaling Technology), CDK4 (BD Pharmingen), CDK6 (Santa Cruz Biotechnology),
aromatase (Biorad), actin (Millipore, Billerica, MA), and vinculin (Sigma-Aldrich). Secondary
antibodies were goat anti-mouse or goat anti-rabbit immunoglobulin conjugated with
horseradish peroxidase (Pierce, Rockford, IL). After the final wash, we developed the
membranes using a Renaissance chemiluminescence system (Perkin Elmer Life Sciences,
Inc., Boston, MA) according to the manufacturer’s instructions.
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2-2g Aromatase activity assay
To measure aromatase activity, we used an in vivo assay using radiolabelled
androstenedione as the substrate. To this end, we deprived the aromatase overexpressing
inducible cells of estrogen for four days, plated them into 6-well plates and challenged the
cells with or without doxycycline (1ng/ml) for 24 hours to induce cyclin E expression. The
next day, we treated the cells with 100nM of radiolabelled androstenedione (PerkinElmer,
Waltham, MA) with different concentrations of letrozole for 4 hours. Next, we collected 1ml
of the media containing radiolabelled H2O and mixed with 2 ml of chloroform. We removed
any extra steroid by treating the upper aqueous phase with 2.5% charcoal for 30 minutes,
centrifuged each sample for 10 minutes at 2000 g, and measured radioactivity using a liquid
scintillation analyzer. To normalize radioactivity in each sample, we measured protein
concentration using the Biorad assay following solubilizing the remaining cells in each well
by 0.5M NaOH and adjusted the activity to the level in each well.

2-2h Real-time PCR
We extracted RNA from cells at the end of treatment experiments using the RNeasy kit
(QIAGEN, Hilden, Germany) following the instructions of the manufacturer. RNA from each
sample (2 μg per sample) was reverse-transcribed to generate cDNA using the cDNA
synthesis kit (Applied Biosystems, Foster City, CA). We subjected each sample to
quantitative PCR analysis using SYBR Green Master Mix (Applied Biosystems) and
normalized the value to the level of GAPDH expression. Primers used were as following:
pS2 F 5'-GTACACGGAGGCCCAGACAGA
pS2 R 5'-AGGGCGTGACACCAGGAAA
Progesterone F 5'-ACCCGCCCTATCTCAACT
Progesterone R 5'-AGGACACCATAATGACAGCCT
GAPDH F 5'-ACCCAGAAGACTGTGGATGG
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GAPDH R 5’-CTGGACTGGACGGCAGATCT

2-2i Establishment of xenograft model
We developed a xenograft model systems representing aromatase inhibitor treatment
by injecting aromatase-overexpressing inducible MCF7 cells into mammary fat pads of 4-6week-old female nude mice. We purchased animals from the colony of the Department of
Experimental Radiation Oncology at MD Anderson and performed ovarian removal surgery
before cell injections. Since these mice are deficient in androstenedione production, we
supplemented them with subcutaneous androstenedione pellets in the neck (7.5 mg/pellet,
60-day release; Innovative Research of America, Sarasota, FL). We harvested aromatase
overexpressing inducible cells, centrifuged them with final wash in PBS, diluted to 50%
Matrigel (Corning, Tewksbury MA), and maintained on ice before injection (100 μl per
injection). We measured tumors using calipers twice a week starting from the time that
tumors reached a measurable size. We randomized the mice to treatment arms such that
there were no differences between initial tumor volumes (150 mm3). We diluted letrozole in
hydroxypropyl cellulose (vehicle, Sigma-Aldrich, St. Louis, MO) and supplemented drinking
water with doxycycline in the experiment arms (1 mg/ml plus 5% sucrose) to induce cyclin E
expression throughout the treatment period. We randomized the mice to treatments; vehicle,
vehicle plus doxycycline, letrozole (10 μg/day, 5 days per week), or letrozole plus
doxycycline until the end of the experiment when we sacrificed the mice and collected
tumors for Western blot and immunohistochemistry assays.

77

2-2j Patient data
We collected data from a cohort of newly diagnosed ER+ postmenopausal patients
(stage II & III) who were recruited as part of The American College of Surgeons Oncology
Group (ACOSOG)-Z1031 study (361). Core biopsy was performed initially to diagnose
breast cancer and to ascertain hormonal status and Her-2 expression (Her-2 negative
patients were included). Patients were randomized to receive neoadjuvant treatment with
AIs for 16-18 weeks before undergoing tumor resection. All patients who participated in the
study signed an informed consent approved by the Institutional Review Board and in
accordance with federal and institutional guidelines. We also obtained IRB approval at MD
Anderson for this study. Paraffin-embedded tumor tissues following neoadjuvant treatment
were obtained from the pathology bank at MD Anderson Cancer Center and used for
immunohistochemistry analysis. Further clinical information is provided in the result section
of this chapter.

2-2k Immunohistochemistry staining and scoring system
Immunohistochemistry analysis and scoring system were performed as previously
described. We cut 5-μm-thick sections from xenograft tumors or patient samples, deparaffinized, and rehydrated the slides by immersing them in Histoclear (National
Diagnostics), alcohol series (100%, 90%, 70% for 5 minutes each), PBS (5 minutes), and
ddH2O (5 minutes). We immersed the slides in Vector antigen unmasking solution for 20
minutes at 90°C and 20 minutes at room temperature to retrieve antigens. We washed the
slides in ddH2O three times (5 minutes each), soaked them in 3% hydrogen peroxidase
(diluted in methanol) for 15 minutes at room temperature followed by incubation with goat
blocking serum for 1 hour at room temperature in order to block endogenous peroxidase
and nonspecific binding. We washed the slides in PBS at room temperature 3 times (5 min
each) and incubated with primary antibodies in a humid chamber at 4°C overnight. Primary
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antibodies used in this analysis included polyclonal cyclin E (Santa Cruz Biotechnology),
polyclonal pCDK2 (Thr160; Cell Signaling Technology), and monoclonal Ki67 (MIB-1; Dako,
Carpinteria, CA). The next day, we washed the slides in PBST (0.1% Tween-20 in PBS) and
incubated them with biotinylated secondary antibodies in a humidified chamber for 30
minutes at room temperature. At the end of incubation, we washed the slides in PBST three
times (5 minutes). We incubated the slides in ABC solution from Vectastain Elite ABC Kit
(Vector Labs, Burlingame, CA) for 30 minutes followed by washing three times in PBS (5
minutes each) and two times in ddH2O (5 minutes each). We next developed the slides by
incubating the slides in DAB substrate and washed the slides in ddH2O. We counterstained
the slides with Mayer’s hematoxylin for 10 seconds followed by washing under tap water.
We immersed the slides in serial ethanol (70%, 90%, 100%) for 5 minutes each and in
Histoclear for two times (5 minutes each) in order to rehydrate and cover-slipped with
Permount. We scored cyclin E and pCDK2 staining as previously described in our lab (362).
To this end, we determined the intensity of staining independently both in the nucleus and
cytoplasm of the cells. We assigned the staining pattern into four different categories: 0
represent without any detectable staining, 1 represent weak staining, 2 represent moderate
staining, and 3 shows strong staining. Tumors with no staining or only nuclear staining were
considered as LMW-E negative. However, tumors were considered LMW-E positive if they
showed cytoplasmic-alone or combination of cytoplasmic and nuclear pattern. To determine
pCDK2 staining we combined two different scores assigned by the intensity of the staining
(0 to 3) and the percentage of positive cells (0 to 6) for a total score 18. Any tumor tissue
with score above 6 was considered as positive for pCDK2 expression. The scaling system
for percentages included: 0 = 0%, 1 = 1-5%, 2 = 6-10%, 3 = 11-25%, 4 = 26-50%, 5 = 5175%, and 6 = 76-100% and for intensity included: 0: no staining, 1: weak staining, 2:
moderate staining, and 3: strong staining. To determine the percentage of Ki67 positivity, we
counted three different regions of each tumor and counted at least 200 cells in each area
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and calculated the average positivity in each tumor.

2-2l Statistical analysis
We repeated all in vitro experiments in triplicate and used two-sided T test to perform
pairwise comparisons using Prism software 6th version (Prism, San Diego, CA). P<0.05 was
considered statistical significance. The period between performing surgery until any
recurrence from breast cancer was defined as recurrence-free interval and estimated using
the Kaplan-Meier method. We censored cases with death from other medical conditions or
those with secondary malignancies. We compared recurrence-free survival and other
parameters such as Ki67 staining, PEPI score, or LMW-E status using long-rank test.

2-3 RESULTS
2-3a LMW-E informs poor response to neo-adjuvant AIs in HR+ breast cancer patients
To examine the correlation between LMW-E and clinical response to aromatase
inhibitors, we determined cyclin E status in a cohort of patients who underwent neoadjuvant
AI therapy as part of the Z1031 trial. These patients (n=73) were randomized to receive
aromatase inhibitors for a period of 16-18 weeks before undergoing surgery at MD
Anderson Cancer Center. Clinical data and pathologic features are summarized in table 3.
We excluded 11 patients due to lack of follow up ultrasound or unavailable post-treatment
tissue samples (Figure 6). Post-treatment tissue samples isolated at the time of surgery
were subjected to immunohistochemistry analysis using cyclin E antibody to determine
cytoplasmic versus nuclear staining pattern of cyclin E protein. We stratified each tumor into
LMW-E positive if the tumors scored positive for cytoplasmic staining of cyclin E as we have
previously shown that LMW-E localizes mainly to the cytoplasm of breast cancer cells (320,
324). We detected cytoplasmic staining of cyclin E (LMW-E expression) in 32 out of 65
(49%) of breast cancer tumor tissues (Figure 7A). Waterfall plot showed that patients with
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the maximum shrinkage of tumor during neoadjuvant therapy were mainly in the LMW-E
negative category (Figure 7B). In contrast, LMW-E expressing tumors were significantly
correlated with higher remaining tumor volume and lymph node involvement at diagnosis
(Figure 7, C and D). Moreover, long-term follow up of these patients showed higher relapse
from breast cancer in patients who express LMW-E in their tumors (Figure 7E). Other
studies have shown the link between PEPI score (a combination of tumor size, lymph node
status, Ki67 and ER status) and risk of relapse in the neoadjuvant setting (152). We
detected higher PEPI score in patients who express LMW-E in their tumors compared to
those with no LMW-E expression (Figure 7F).
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Figure 6: Remark diagram indicating HR+ post-menopausal patients who were
included to study cyclin E status as part of the (ACOSOG)-Z1031 trial.
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Figure 7: LMW-E correlates with lack of response to neoadjuvant aromatase
inhibitors. (A) Representative immunohistochemistry staining using cyclin E antibody
showing four different phenotypes based on the pattern of cytoplasmic (C) compared to
nuclear (N) staining (B) waterfall plot indicating percent change in tumor size after 16-18
weeks of neoadjuvant AI treatment in patients with LMW-E positive (red) and negative
(green) tumors (C) comparison of change in tumor size between the two groups in panel B
(D) lymph node involvement in ER+ postmenopausal patients with LMW-E positive and
negative tumors (E) recurrence-free survival in ER+ patients with LMW-E positive and
negative tumors (F) comparison of preoperative endocrine prognostic score (PEPI) in ER+
patients with or without LMW-E expression
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We further investigated the significance of LMW-E binding partner, CDK2, in mediating
resistance to neoadjuvant aromatase inhibitor. To this end, we stained tissue samples from
the same patients using phospho-CDK2 antibody and dichotomized tumors into phosphoCDK2 negative or positive based on intensity and the percentage of positive cells. Statistical
analysis showed correlation between LMW-E and cytoplasmic phospho-CDK2 in tumor
samples (Figure 8, A and B). Cytoplasmic phospho-CDK2 expression correlated with
diminished response to neoadjuvant aromatase inhibitors (Figure 8C). Finally, we
interrogated the significance of Ki67 as a tumor proliferation marker in predicting response
to AIs. In these samples, no correlation was detected between post-treatment Ki67 level and
relapse-free survival (Figure 8D). Taken together, these results suggest that LMW-E and
phospho-CDK2 status can inform response to AIs in the neoadjuvant setting.
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Figure 8: Cytoplasmic phospho-CDK2 correlates with LMW-E expression and lack of
response to aromatase inhibitors. (A) Representative immunohistochemistry staining of
remaining tumors following neoadjuvant aromatase inhibitor treatment using cyclin E and
phosphoCDK2 (pCDK2) antibody (B) Correlation between LMW-E and cytoplasmic
phosphoCDK2 expression in tissue samples after neoadjuvant treatment with aromatase
inhibitors (C) Percent change in tumor size after neoadjuvant AI therapy in patients with or
without pCDK2 expressing tumors (D) Comparison of relapse rate between patients with
Ki67-high versus Ki67-low tumors following neoadjuvant treatment with aromatase
inhibitors.
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Table 3: characteristics of ER+ postmenopausal patients treated with neo-adjuvant
aromatase inhibitors (AIs) at MD Anderson Cancer Center

Factor
Age at diagnosis (years):
Median (range)
Neoadjuvant AIs
Anastrozole
Letrozole
Exemestane
Lymph node status
Positive
Negative
Adjuvant chemotherapy
Yes
No
Radiation therapy
Yes
No
Stage
I
II
III
IV
Estrogen receptor
Positive
Negative
Progesterone receptor
Positive
Negative
Her-2 receptor
Positive
Negative
Subtype
Ductal carcinoma
Lobular carcinoma
Mixed ductal and lobular
Mucinous
Unspecified
Recurrence/metastasis
Positive
Negative
Cyclin E staining
Cytoplasmic positive (LMW-E)
Cytoplasmic Negative (No LMW-E)
Unavailable samples

Number (%)
64 (47-84)
26 (35.6)
24 (32.9)
23 (31.5)
30 (41.1)
43 (58.9)
28 (38.4)
45 (61.6)
56 (76.7)
17 (23.3)
0 (0)
50 (68.5)
23 (31.5)
0 (0)
73 (100)
0 (0)
66 (90.4)
7 (9.6)
0 (0)
73 (100)
45 (61.6)
14 (19.2)
12 (16.4)
1 (1.4)
1 (1.4)
7 (9.6)
66 (90.4)
32 (43.8)
33 (45.2)
8 (11)
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2-3b LMW-E expression overcomes inhibition of proliferation by aromatase inhibitors
In order to study the mechanism of LMW-E mediated resistance to aromatase inhibitors,
we developed a model system using aromatase overexpressing MCF7 cells to inducibly
express cyclin E. In this model system, individual clones are able to express full length or
LMW-E isoforms only upon exposure to doxycycline (1ng/ml) (Figure 9A). Moreover, cyclin
E expression was independent of aromatase expression as shown in the Western blot
analysis (Figure 9A). We used empty vector (not able to express cyclin E) and GFP
inducible cells as control for our experiments. In order to detect the effect of aromatase
activity, we challenged aromatase-overexpressing cells (control) to estrogen deprivation
followed by androstenedione treatment. We detected enhanced proliferation by 2.5 fold
compared to estrogen deprivation condition (Figure 9B). This suggests that the cells are
able to generate estrogen through conversion of supplemented androstenedione by
aromatase activity inside the cells. This process represents steroid production in
postmenopausal patients in whom androgen precursors are converted to estrogen by the
activity of aromatase enzyme. Treatment of these cells with AIs (letrozole or anastrozole) in
addition to androstenedione inhibited androstenedione-induced proliferation in a dose
dependent manner (Figure 9, B and C).
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Figure 9: Aromatase inhibitors inhibit androstenedione-induced proliferation. (A)
Example of Western blot analysis showing aromatase and cyclin E using aromatase
overexpressing cells. Aromatase overexpressing MCF7 cells infected with viruses to
inducibly express empty vector (EV), full-length cyclin E (EL), or LMW-E isoforms (T1 or T2)
upon doxycycline challenge (1 ng/ml). (B, C) Aromatase-overexpressing MCF7 cells
(control) were deprived of estrogen for 4 days followed by treatment with androstenedione
(AD; 25nM) with/without letrozole (LET) or anastrozole (ANA) with indicated concentrations.
Cell proliferation was assessed after three days by counting cell numbers. *p < 0.05, **p <
0.01, ***p < 0.001; unpaired t test.
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In order to examine response to LMW-E, we exposed inducible cells to doxycycline
followed by treatment with aromatase inhibitors and assessed proliferation at two different
short-term or long-term assays (3-day and 12-day experiment, respectively). For the 3-day
experiment, the cells were exposed to doxycycline for one day to induce the transgene and
then treated with AIs with/without doxycycline and AIs (letrozole or anastrozole) for three
days. The cell proliferation assay showed that only LMW-E expression enabled the cells to
overcome letrozole or anastrozole inhibition (Figure 10, A and B). Full-length and control
(empty vector) cells showed inhibition of proliferation when exposed to letrozole or
anastrozole (Figure 10, C and D).
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Figure 10: LMW-E but not full-length cyclin E overcomes AI-mediated inhibition of
proliferation. (A, B) Proliferation of LMW-E-inducible cells (T1 and T2) cultured in the
absence of estrogen for 4 days, induced with/without doxycycline (Dox) for 24h and exposed
to 25nM of androstenedione and/or 1μM of letrozole (LET) or 1μM of anastrozole (ANA).
Cells were counted after 3 days of treatment. (C, D) Proliferation of empty vector (EV) or fulllength cyclin E (EL) inducible cells cultured and treated as in A and B. *p < 0.05, **p < 0.01;
unpaired t test
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Next, we extended these experiment by challenging the cells in a 12-day survival
assay. To this end, we challenged the inducible cells and their parental control cells with
estrogen deprivation followed by treatment with doxycycline and AI treatment. Results
showed that 50% inhibitory concentration of letrozole was approximately 15-fold higher
when LMW-E was expressed suggesting resistance to letrozole (Figure 11, A and B). In
sharp contrast to LMW-E, overexpression of full length cyclin E or empty vector cells did not
significantly affect response to letrozole under similar treatment condition to LMW-E (Figure
11, C and D).
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Figure 11: LMW-E but not full-length cyclin E improves survival of cells treated with
letrozole. (A, B) LMW-E inducible cells were deprived of estrogen for four days, challenged
with/without doxycycline for 24 hours and treated with androstenedione plus letrozole
(increasing concentrations), followed by assessment of cell viability at day 12. (C, D) empty
vector (EV) and full-length inducible cyclin E (EL) cells treated and assesses as in A and B.
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2-3c LMW-E overcomes cell cycle inhibition of aromatase inhibitors
In order to understand mechanism of response to cyclin E induction, we assessed cell
cycle when cells were treated with AIs under induced or un-induced conditions. For these
experiments, we deprived the cells of estrogen, challenged with/without doxycycline in order
to induce the transgene and treated with androstenedione and letrozole (or anastrozole) for
three days. Flow cytometry analysis of the control cells revealed that androstenedione
increased S phase percentage of the cells with concomitant decrease in G1 phase
(compare second bar to first one) (Figure 12A). These cells respond to increasing
concentration of AIs by arresting in G1 phase as shown by increase in G1 and decrease in
S phases of cell cycle (Figure 12, A and B). Anastrozole or letrozole were both able to
significantly inhibit S phase at 1μM concentration (Figure 12, A and B). We challenged
inducible cells to the same concentration of AIs and assessed their cell cycle profile in the
presence of absence of LMW-E. Results indicated that LMW-E expression overcome S
phase inhibition of AIs (Figure 12, D and E). This response is attributed to LMW-E
expression but not doxycycline, as doxycycline did not modulate response to AIs in control
(empty vector) cells (Figure 12 C).
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Figure 12: LMW-E expression overcomes AI-mediated cell cycle arrest. (A, B)
Aromatase overexpressing MCF7 cells (control) were deprived of estrogen for total of four
days and treated with androstenedione (AD, 25nM) and increasing concentrations of
letrozole (LET) or anastrozole (ANA) followed by assessment of G1 and S phases by flow
cytometry analysis. (C, D, E) empty vector (EV) or LMW-E inducible cells (T1 and T2) were
estrogen deprived for four days, challenged with/without doxycycline for 24 hours, and
treated with androstenedione (AD) with/without letrozole (LET) or anastrozole (ANA) at 1μM
concentration. Cell cycle analysis was done following AI therapy at day 3. *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001; unpaired t test.
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2-3d LMW-E overcomes cell cycle inhibition through up-regulation of G1 regulators.
To further study mechanism by which LMW-E bypasses the activity of aromatase
inhibitors, we collected cell lysates from inducible cells and subjected them to Western blot
analysis. Treatment of cells with androstenedione increased the level of G1 cell cycle
regulators such as CDK2, pCDK2, Rb, and phospho-Rb proteins (lane 1 and 3, figure 13, A
and B). Letrozole addition blocked induction of the aforementioned G1 regulators (lane 3
and 7 figure 13, A and B). These findings are in line with G1 arrest following AI treatment as
detected in our cell cycle analyses. However, LMW-E expression rescued AI-mediated
inhibition by up-regulation of CDK2, pCDK2, and phosphorylated Rb protein (lane 1 and 2, 7
and 8, figure 13, A and B). Similar findings were detected under treatment with anastrozole
treatment. In vitro kinase assay also confirmed that letrozole inhibited CDK2 kinase activity
while LMW-E overcome such inhibition (Figure 13C). These results show that LMW-E
expressing cells have inactivated Rb protein as a tumor suppressor and thus are unable to
arrest at G1 phase by either estrogen deprivation or aromatase inhibitor treatment.
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Figure 13: LMW-E bypasses aromatase inhibitor inhibition through up-regulation of
G1 cell cycle regulators. (A, B) LMW-E inducible MCF7AC1 cells were deprived of
8 24 hours followed by treatment
estrogen for 4 days, challenged with/without doxycycline for

as shown with androstenedione (AD; 25nM) with/without letrozole (LET; 1μM) or anastrozole
(1μM) for three days. Western blot analysis was performed with antibodies as shown. (C)
LMW-E (T2) cells were treated as in A, Cell lysates were immunoprecipitated (IP) using
antibody against CDK2 followed by analysis of kinase activity using specific CDK2 substrate
(GST-Rb).
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We also validated our results using aromatase overexpressing T47D cell line that stably
express LMW-E (T2) isoform (Figure 14A). Similar to MCF7 cells, we found that treatment
with letrozole inhibited androstenedione-medicated proliferation (Figure 14B). However,
LMW-E (T2) expression bypassed AI-mediated inhibition of proliferation and cell cycle arrest
(Figure 14, C and D).
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Figure 14: LMW-E expression bypasses AI-mediated inhibition of proliferation and
cell cycle arrest in T47D cell line. (A) Representative Western blot analysis of aromatase
overexpressing T47D cells that stably express empty vector (EV) or LMW-E (T2) isoform of
cyclin E (B) Cell proliferation of aromatase overexpressing T47D-empty vector (EV) cells
deprived of estrogen for 4 days followed by treatment with androstenedione (AD; 25nM) plus
increasing concentrations of letrozole (LET) for 3 days. (C) Cell proliferation of empty vector
(EV) or LMW-E (T2) cells deprived of estrogen for 4 days and treated with AD (25nM)
with/without letrozole (1μM) for 3 days (D) S-phase percentage of empty vector and LMW-E
(T2) expressing T47D cells treated as in C with letrozole or anastrozole (ANA) at 1 μM
concentration. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired t test.
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2-3e LMW-E-mediated resistance to aromatase inhibitors is reversible
To examine reversibility of LMW-E-mediated resistance, we challenged inducible
MCF7AC1 cells with doxycycline to express LMW-E and then removed doxycycline followed
by assessment of proliferation and cell cycle. To this end, we collected cell lysates before
and after induction of LMW-E as well as every day following doxycycline removal for 7 days.
Western blot analysis at different time intervals revealed that the level of LMW-E initiated to
drop after 1 to 2 days of doxycycline removal and subsequent to that the levels of other G1
regulators (such as CDK2, pCDK2, Rb and pRB) decreased at a later time (Figure 15A).
Proliferation assay indicated the cells that were induced initially followed by doxycycline
withdrawal (DOX removal) responded to letrozole similarly to the cells that were never
induced (Dox –ve) (Figure 15B). In contrast, LMW-E expressing cells continued to show
significantly higher proliferation when treated with letrozole (DOX +ve) (Figure 15B). Cell
cycle analysis of LMW-E inducible cells under similar condition showed that doxycycline
removal inhibited S-phase under letrozole treatment similar to un-induced cells (Figure 15C).
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Figure 15: LMW-E-mediated resistance to AIs is reversible. (A) Representative Western
blot analysis of LMW-E (T2) MCF7-AC1 cells deprived of estrogen for 4 days, challenged
with/without doxycycline and treated with androstenedione (AD) plus letrozole throughout
the experiment. Doxycycline was withdrawn from the media after induction; cell lysates were
collected every day for 7 days and subjected to Western blot analysis. (B) MCF7A1C1
LMW-E (T2) cells were cultured in estrogen-deficient media and treated as in A followed by
counting cell numbers at indicated times. (C) LMW-E inducible cells were estrogen deprived,
induced and treated as in A and B and subjected to cell cycle analysis at indicated days.
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2-3f LMW-E mediated resistance to aromatase inhibitors is CDK2/Rb dependent
To further explore the role of cell cycle regulators downstream of LMW-E that contribute
to resistance to AIs, we down-regulated CDK2 or Rb independently and examined response
to treatment. We knocked down Rb and CDK2 using two independent shRNAs (Figure 16A)
and examined response to letrozole under un-induced or induced conditions using Western
blot analysis and flow cytometry analysis. Western blot analysis showed that under Rbknockdown condition, the cells respond to LMW-E by induction of CDK2 and pCDK2 (Figure
16B). However, in contrast to scramble cells, LMW-E induction failed to induce Rb or
phospho-Rb when CDK2 was downregulated (Figure 16B). Moreover, knockdown cells did
not show enhanced S phase entry upon LMW-E expression as compared to scramble cells
(Figure 16C). Collectively, our findings show that LMW-E mediated resistance is at least
partially dependent on CDK2 to phosphorylate Rb allowing the cells to bypass G1 phase.
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Figure 16: LMW-E mediated resistance is CDK2/Rb dependent: (A) Western blot
analysis indicating downregulation of CDK2 or Rb in LMW-E (T2) inducible cells using two
independent shRNAs. (B) Representative Western blot analysis of LMW-E (T2) inducible
cells knocked down with shRNA targeting CDK2, Rb, or scramble (control), deprived of
estrogen for 4 days, challenged with/without doxycycline (1ng/ml) for 24 hours, and treated
with/without androstenedione (AD; 25nM) and letrozole (LET, 1 µM) for 3 days. (C)
Comparison of S-phase percentage of LMW-E (T2) inducible cells, knocked down with
shRNA, treated similarly to (B) and subjected to flow cytometry analysis. Results for two
independent shRNAs are shown and compared to scramble. **p < 0.01, ***p < 0.001.
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2-3g Tumors with LMW-E expression do not respond to letrozole
To determine responsiveness of LMW-E expressing tumors to AIs, we developed a
model system by injecting inducible cells into mammary fat pad of 4-6 week-old nude mice.
These mice were ovariectomized before the experiment and supplemented with
androstenedione pellets that provide the precursor for estrogen production by the
aromatase-overexpressing cancer cells. We randomized the mice to different treatments
such that there were no differences in the average volumes at the initiation of therapy
(average 150 mm3). Four treatment arms were considered; two control arms (vehicle and
vehicle plus doxycycline) and two experiment arms (letrozole and letrozole plus
doxycycline). Letrozole was injected subcutaneously and doxycycline was supplemented to
drinking water throughout the experiment. We euthanized the mice and harvested tumors at
the end of experiment when tumors reached the maximum size in the control arm (45 days).
Tumor measurements revealed that letrozole treatment induced tumor shrinkage only when
LMW-E was not expressed (Figure 17, A and B). In contrast, LMW-E expressing tumors
showed continuous tumor growth in spite of letrozole treatment (Figure 17, A and B). The
two control lines of the experiment showed similar tumor growth throughout the experiment
(Figure 17, A and B). In addition, we collected cell lysates from the harvested tumors and
subjected them to Western blot analysis using antibodies targeting G1 cell cycle regulators.
Results confirmed LMW-E expression in tumors of the animals that received doxycycline
(lanes 3,4,7,8 Figure 17C). Letrozole treatment decreased CDK2 and pCDK2 levels in
tumors compared to vehicle treated mice (lanes 1,2 VS 5,6 Figure 17C). However, LMW-E
expression rescued such letrozole-mediated inhibition by up-regulating CDK2 and pCDK2
levels (Figure 17C). Immunohistochemistry analysis revealed cyclin E expression in the
cytoplasm of the tumor cells when exposed to doxycycline representing LMW-E expression
in these tumors (Figure 17D). LMW-E expression corresponded with higher cytoplasmic
pCDK2 levels in tumors as well as higher proliferation as measured by Ki67 level (Figure 17,
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D and E). Collectively, these in vivo experiments suggest that LMW-E expression make the
tumors unresponsive to letrozole treatment.
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Figure 17: LMW-E tumors are unresponsive to letrozole. (A) All nude mice were
ovariectomized and injected with aromatase overexpressing MCF7AC1-T2 inducible cells in
their mammary fat pad. All animals were supplemented with androstenedione pellets, and
randomized to treatment arms; vehicle (hydroxypropyl cellulose) (n = 7), vehicle plus
doxycycline (Dox) (n = 7), subcutaneous letrozole (LET; 10 μg/day; n = 9), or letrozole plus
doxycycline (n = 6). Doxycycline (1 mg/ml) was added to drinking water to express LMW-E
in the tumors. Tumor measurements were performed twice a week and tumor volumes were
compared. (B) Representative tumors harvested from mice treated as in A at the end of the
experiment. (C) Representative Wb indicating expression of cyclin E, CDK2, and pCDK2 in
xenograft tumors (two tumors for each treatment arm) isolated from xenografts treated as in
A. (D) Representative immunohistochemistry analysis of tumors isolated from mice treated
as in A and stained with cyclin E, CDK2, and Ki67 antibodies. Three tumors from each
treatment arm are shown. (E) Comparison of quantitative Ki67 levels from xenograft tumors
isolated from mice treated as in A. percentage of Ki67 value for each tumor was measured
by counting 200 cells from three different areas of each tumor and the average is shown for
each arm. *p < 0.05, **p < 0.01.
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Studies have shown that constitutive activity of ER pathway or increased expression of
aromatase enzyme contributes to resistance to anti-estrogens (207, 264). We performed an
in vivo aromatase assay and quantitative PCR analysis to test whether these alternative
pathways contribute to LMW-E mediated resistance in our model system. Results revealed
that aromatase activity is inhibited by only by letrozole in a dose-dependent manner but not
LMW-E (Figure 18A). In addition, quantitative PCR analysis of two main ER target genes
(progesterone receptor and pS2) showed that the expressions of these two genes are only
regulated by androstenedione or letrozole but not LMW-E (Figure 18, B and C). Our findings
suggest that LMW-E regulates response of AIs mainly through deregulation of cell cycle.
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Figure 18: LMW-E expression does not alter aromatase activity or ER mediated gene
expression. (A) LMW-E (T2) MCF7AC1 cells were deprived of estrogen for 4 days,
exposed to doxycycline for 24 hours, treated with letrozole for 4 hours and subjected to an
aromatase activity assay using radio-labelled androstenedione as a substrate. (B, C)
Quantitative PCR analysis of LMW-E inducible cells (T2), deprived of estrogen for 4 days,
15

challenged with doxycycline (1ng/ml) for 24 hours, and treated with/without androstenedione
(AD; 25nM) and letrozole (LET; 1 µM) for 3 days. Real-time RT-PCR analysis was
performed using primers targeting progesterone receptor (PgR) and pS2 genes. ***p <
0.001.
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2-3h Dinaciclib but not palbociclib can inhibit proliferation of LMW-E expressing cells
The FDA has recently approved Palbociclib for advanced ER+ breast cancer patients in
combination with AIs or Fulvestrant (363). We asked whether pharmacologic inhibition of
cyclin dependent kinases by palbociclib or dinaciclib is effective to reverse LMW-E mediated
resistance. Western blot analysis of T2 inducible cells indicated that LMW-E expression
increased CDK2, and pCDK2 while it did not affect expression of CDK4 or CDK6 (targets of
palbociclib) (Figure 19A). In addition, LMW-E expression increased CDK2 kinase activity
while the activity of CDK4 kinase remained unchanged (Figure 13C and 19B). Next, we
assessed responsiveness of the LMW-E expressing cells to dinaciclib and palbociclib using
a survival assay. To this end, we estrogen deprived the cells for four days before the
experiment and treated them with increasing concentrations of either dinaciclib or palbociclib
under estrogen deprived condition and in the presence or absence of doxycycline. Cell
survival analysis at day 12 revealed that LMW-E expressing cells were responsive to
dinaciclib (Figure 19D), but unresponsive to palbociclib (Figure 19C). In contrast, full-length
cyclin E did affect response to either dinaciclib or palbociclib (Figure 19, E and F). These
results indicate that dinaciclib is a beneficial therapeutic strategy for the LMW-E cells
compared to palbociclib.
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Figure 19: LMW-E expressing cells respond to dinaciclib. (A) Representative Western
blot analysis of LMW-E inducible cells deprived of estrogen, challenged with/without
doxycycline (1 ng/ml) for 24 hours, and treated with/without androstenedione (AD; 25 nM)
plus letrozole (LET; 1 µM) for three days using antibodies as indicated. (B) Representative
kinase assay of LMW-E T2 cells treated as in A, cell lysates were immunoprecipitated with
CDK4 antibody and subjected to kinase assay using CDK2 substrate (GST-Rb). (C, D)
Representative results of cell viability assay using MCF7AC1-LMW-E (T2) inducible cells
deprived of estrogen for 4 days, challenged with/without doxycycline (throughout
experiment) and treated with palbociclib (6 days) or dianciclib (4 days). Drugs were removed
afterwards and media was changed to drug-free estrogen-deprived media until the end of
the experiment at day 12. (E, F) Representative results from cell viability assay of full-length
(EL) inducible MCF7Ac1 cells deprived of estrogen, induced, and treated with palbociclib or
dinaciclib similar to C and D.
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2-4 DISCUSSION
Two different forms of resistance are observed in BC patients who are treated with AIs;
primary (de novo) resistance and secondary (acquired) resistance. In the primary resistance
model, approximately 20% of patients show tumor proliferation is spite of anti-hormone
therapy (193). On the other hand, acquired resistance develops overtime when patients are
treated for a long period of time with AIs (132). In this study, we have examined primary
resistance to AIs using in vitro and in vivo models as well as tumors isolated from patients
undergoing neoadjuvant AI treatment. Our results indicate correlation between LMW-E
expression and lack of response to neoadjuvant AIs. Patients who express LMW-E have
higher chance of relapse from breast cancer. Our in vitro model system showed that AIs
inhibited proliferation, induced G1 cell cycle arrest by decreasing CDK2, pCDK2, Rb and
phospho-Rb levels. However, expression of LMW-E increased CDK2 activity and inactivated
Rb protein allowing the cells to bypass G1 checkpoint. In line with these experiments,
xenograft tumors with LMW-E expression were unresponsive to letrozole treatment.
Our models propose that deregulation of cell cycle is an initial process leading to
activation of other signaling pathways that allow the cells to escape from AI treatment. For
example, AI resistant cell lines show higher expression of aurora kinase A and B (two major
regulators of M phase of cell cycle) and are more sensitive to aurora kinase inhibitors (355).
These resistant cells were able to arrest at G2/M phase of cell cycle when treated with
inhibitors of aurora kinase (355). Similarly, inhibition of PLK1 (a kinase involved in G2/M
transition) inhibited proliferation of resistant cells and induced cell death in vitro (356).
Moreover, combination of PLK1 inhibitor with fulvestrant showed synergistic activity in vivo
(356). These studies suggest that cell cycle targeted therapies are valuable to be
considered in combination with aromatase inhibitors.
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Results from recent clinical trials confirm the beneficial role of combination of cell cycle
inhibitors with aromatase inhibitors. The combination of palbociclib with AIs in advanced
HR+ BC patients has improved progression-free- survival (295, 296). A recently published
study showed that palbociclib combined with anastrozole improved complete cell cycle
arrest as defined by Ki67 less than 2.7% (364). However, anti-proliferative effect of
palbociclib required continued treatment with palbociclib (364). In vitro studies suggest that
the cells adapt to short-term (3 day) palbociclib treatment by sustained cyclin E2 expression
and phosphorylation of Rb protein (365). This adaptation resulted in cell cycle progression
through activity of CDK2. Moreover, examination of palbociclib resistant cells (long-term
palbociclib treated cells) revealed cyclin E amplification as well as cyclin E1 overexpression
at protein level in resistant cells (365). Consistent with these findings, our results indicate
that deregulation of cyclin E pathway through LMW-E generation induce resistance to
palbociclib. LMW-E expression results in higher CDK2 activity, inactivation of Rb protein
through hyperphosphorylation of the protein. Therefore, the cells are not further arrested at
cell cycle in spite of upstream inhibition of CDK4/6 by palbociclib.
Recently published data on patients treated with neo-adjuvant AIs revealed that patients
who were resistant to aromatase inhibitors also showed poor response to chemotherapy
(193). This suggests that additional therapies are needed for this subpopulation of patients.
Our results show that breast cancer cells that are resistant to aromatase inhibitors respond
to a CDK2 inhibitor dinaciclib. Sequential combination of a CDK2 inhibitor (roscovitine)
followed by doxorubicin induced cell death in vitro and controlled tumor growth in vivo using
TNBC cell lines (332). It is worth noting that such combination did not affect HMEC cells in
vitro and was not toxic in animal models (332). A phase one study tested the combination of
dinaciclib (starting dose of 20 mg/m2) followed by epirubicin treatment in 9 patients
diagnosed with advanced breast cancer (349). However, this study was terminated due to
toxicity of this combination including neutropenic fever, syncope and lower doses were not
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further investigated (349). In hematologic malignancies, dinaciclib has reached an advanced
level (366). In a phase III study, refractory chronic lymphocytic leukemia (CLL) patients
received only dinaciclib (dose range 7 to 14 mg/m2 within each cycle) for a total of 12
cycles. Overall response rate was detected in 40% of patients and the most common
adverse effects included neutropenia (35%) and thrombocytopenia (20%) of cases (366).
Monotherapy using dinaciclib was tested in relapsed multiple myeloma patients. Results of
this study defined and the maximum tolerated dose of dinaciclib as 50 mg/m2 (higher than
combination study in breast cancer) (367). In this phase 1/2 study, approximately 10% of
patients showed partial response to dinaciclib treatment (367). Taken together, we propose
that dinaciclib is a valuable drug to be considered in combination of aromatase inhibitors in
HR+ breast cancer patients.
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CHAPTER 3: CELL CYCLE DEREGULATION IN ACQUIRED RESISTANCE TO
AROMATASE INHIBITORS
3-1 INTRODUCTION
Escape from growth suppressors is one of the hallmarks of cancer. Therefore, inhibiting
cell cycle dependent kinases could be a potential therapy against cancer cells. A few studies
have shown the link between cell cycle deregulation and AI resistance (355, 356). Using a
compound screen including 195 kinase inhibitors that can exclusively inhibit proliferation of
AI resistant cells, Hole et al found aurora kinase A and B as potential targets (355). Western
blot analysis indicates that AI resistant cells had higher aurora A and B kinase levels
compared to parental cells. Aurora kinases are cell cycle regulatory proteins playing major
role during mitosis (368). Functionally, aurora kinase A is involved in centrosome maturation
and separation of chromosomes and aurora kinase B regulates cytokinesis (368, 369). Upregulation of aurora kinases is found in different cancers such as ovary, breast and thyroid
cancers (106, 370, 371). Knockdown of Aurora kinases by siRNA or treatment with two
aurora kinase inhibitors (Alisertib and Danusertib) resulted in higher inhibition of proliferation
and G2/M arrest in AI resistant cells compared to parental cells. Results from this study
suggest that a combination of aurora inhibitors with an anti-estrogen could be potentially
effective to reverse AI resistance (355). In a similar study, the authors used two ER+ LTED
models (MCF7 and HCC1428) and screened them with a library of inhibitory RNA that can
target 720 different kinases. They measured output based on inhibition of cell viability as
well as decreased ER activity in an ERE luciferase reporter assay. This screen detected
polo-like kinase 1 (PLK1), a kinase overexpressed in G2 phase of the cell cycle, as the top
target (356). LTED cells had higher PLK1 both at mRNA and protein level compared to
parental cells and higher PLK1 mRNA level correlated with higher Ki67 in post-letrozole
treated tumors isolated from 10 patients. Furthermore, inhibition of PLK1 by siRNA or by two
different inhibitors in LTED cells suppressed proliferation, decreased ER transcriptional
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activity, and induced apoptosis as measured by PARP cleavage and p-Histone H2AX.
Lastly, a combination of fulvestrant with PLK-1 inhibitor (Volasertib) showed synergistic
effect using both cell culture and animal model.
Dynamic alterations in cell cycle regulatory genes along with ER, PR and Her-2
receptors have been detected in AI resistant cells (372). Expression levels of these markers
were examined using two LTED model systems generated from parental MCF7 and BT474
cell lines using IHC and qRT-PCR (372). Results revealed a dynamic pattern of ER
expression throughout a 10 month culture in the absence of estrogen (372). They detected
decreased expression of ER during the first 2-8 weeks of estrogen deprivation with reexpression after 10 months both at mRNA and protein level. In contrast to this, In BT474 cell
line ER level did not change during the first 8 weeks but decreased only after 10 months.
However, consistent decrease in PR level was detected throughout estrogen deprivation in
both cell lines (372). Comparison of microarray gene expression profile of these LTED cells
at multiple time points revealed the highest down-regulation in genes that regulate cell cycle
at an early phase (2 days and 6 weeks) with reversible expression pattern at a later phase
(10 months). This suggests a concomitant dynamic change in the level of ER and genes that
regulate cell cycle and further suggests that targeting components of cell cycle using
available targeted therapies could be an effective strategy in resistant cells. A summary of
studies showing the link between cell cycle and resistance to antiestrogens is shown in table
4.
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Table 4- Studies indicating a link between cell cycle components and resistance to
anti-estrogens
List of Genes

Applied Model
system

Type of Anti-

Reference

estrogen resistance
Aurora kinase A and
B

Polo-like kinase 1
Cyclin B2, cyclin D2
CDK6, CDC25C
Rb protein

Rb protein

Phospho-CDK2

Cyclin E

Cell cycle signature

Letrozole resistant
MCF7
Exemestane resistant
MCF7
MCF7-LTED
HCC1428-LTED
MCF7-LTED
BT474-LTED
Xenograft from Rbknockdown MCF7 &
Rb-knockdown T47D
Tumor tissues from
tamoxifen treated
patients
Letrozole resistant or
tamoxifen resistant
MCF7
Transient
overexpression of
LMW-E
Gene expression
from AI resistant
MCF7 vs parental

Letrozole and

(355)

Exemestane
Aromatase inhibitors

(356)

Aromatase inhibitors

(372)

Tamoxifen

(373)

Tamoxifen

(277)

Letrozole &

(374)

Tamoxifen
Letrozole

(357)

Aromatase inhibitors

(264)
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3-1a Role of CDK2/Rb pathway in AI resistance
Cdk2-Rb pathway is the major regulator of cell cycle. The association between
CDK2/Rb pathway and resistance to anti-estrogens has been the focus of a few studies
(277, 373). Bosco and colleagues studied the link between Rb and tamoxifen resistance.
Using Rb knock down cells, they show that ER+/Rb knocked down cells show higher
proliferation in vitro. In addition, xenograft tumors generated from Rb knock-down cells
become insensitive to tamoxifen therapy (373). In line with these findings, Rb dysfunction in
patient samples is also linked to tamoxifen resistance (277). Lehn and colleagues examined
tumor tissues from 500 post-menopausal breast cancer patients with or without adjuvant
tamoxifen therapy (277). Rb dysfunction phenotype was detected in 17% of cases where
Ki67 staining was high but phospho-Rb staining was low suggesting that these patients
have either lost Rb or have a mutation in the gene. The role of CDK2 in breast cancer and
its significance in resistance to AIs is not well studied. In one study, the authors generated
letrozole and tamoxifen resistant derivatives of MCF-7 cell lines and found higher phosphoCDK2 to CDK2 ratio in resistant cells (374). Treatment of these resistant cells with
roscovitine decreased proliferation of cells, induced cell cycle arrest at G1 (letrozole
resistant) or G2/M (tamoxifen resistant) phase of the cell cycle (374). Western blot analysis
showed that roscovitine decreased phospho-CDK2 (T160), phospho-Rb (S795) and ERα
levels. More importantly, roscovitine decreased tumor volume when these resistant cells
were incorporated subcutaneously into nude mice. This study suggests that tamoxifen and
letrozole resistant cells respond to roscovitine. However. It is important to mention that the
concentration of roscovitine in this study was very high (20-30 μM). Another study in our lab
using transient overexpression of LMW-E in MCF7 cells shows that the cells are able to
bypass cell cycle arrest following letrozole treatment when LMW-E was overexpressed
(357). However, the effect of LMW-E was abrogated when the cells were treated with a
CDK2 inhibitor, roscovitine. Collectively, these finding implicate the role of LMW-E/CDK2
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pathway in breast cancer suggesting that further studies are needed to explore the potential
benefit of CDK2 inhibitors specifically in patients with LMW-E expressing tumors.

3-2 MATERIALS and METHODS
3-2a Generation of resistant cell lines:
We have developed two different model systems to study mechanism of acquired
resistance to aromatase inhibitors. In the first model, we exposed aromatase overexpressing
cells (MCF7AC1) to increasing concentration of individual AIs for at least 10 months before
analysis. To this end, the cells were cultured in phenol-red free DMEM and charcoal-dextran
treated FBS (Corning, Corning, NY) throughout the process and supplemented with AD
(25nM) (Sigma-Aldrich (St. Louis, MO) and increasing concentrations of either anastrozole
or letrozole (Sigma-Aldrich, St. Louis, MO). We maintained the cells in media containing the
maximum tolerated concentration of the AIs (5uM) during the experiments. To generate
control cells in parallel with AI resistant cells, we only supplemented the cells with AD
(25nM) without addition of AIs. In addition, we generated another model by depriving the
cells of estrogen for a long period of time (at least 9 months). This model system is known
as long-term estrogen deprived model system (LTED), mimics acquired resistance to AIs,
and is used in the literature to study acquired resistance to aromatase inhibitors. To study
dynamics of changes in cell cycle profile of the cells, we froze and examined cells at
different time points during the estrogen deprivation process.

3-2b Cell proliferation and viability assay
To examine proliferation, equal number of cells were plated in 6-well plate and treated
as indicated on each figure for three days. At the end of the experiment, we washed the
cells in PBS, trypsinized, and counted using an automated cell counter (Biorad, Hercules,
CA). For cell viability assay, we used the same HTSA assay as described in previous
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chapter. Briefly, equal number of cells were plated in 96-well plates and allowed the cells to
attach. Next, we treated the cells for a specific period of time with each drug as indicated on
each figure, removed the drug, and cultured the cells in drug-free media to complete a 12day experiment. At the end of the experiment, we washed the cells using PBS, stained them
with crystal violet, solubilized using the solubilizing solution, and measured density using a
plate reader (Biotek, Winooski, VT).

3-2c Cell cycle analysis
To study the cell cycle profile of the cells, we treated AI-resistant cells with different
concentrations of AIs as indicated for three days and subjected them to cell cycle analysis
as described in the previous chapter. To this end, we washed the cells in cold PBS,
collected cells and maintained in 70% ethanol overnight at 4°C. The next day, the cells were
precipitated by centrifugation, ethanol was removed and the cells were washed in PBS twice
followed by centrifugation. Cells were stained with propidium iodide (10 μg/mL), 0.5%
Tween-20, ribonuclease A (20 μg/mL) diluted in bovine serum albumin overnight at 4°C,
incubated at 37oC and subjected to cell cycle analysis at MD Anderson Flow Cytometry
core. To examine cell cycle profile of the LTED cells, we cultured cells that were frozen at
different time points simultaneously, stained the cells similar to the condition described for
AI-resistant cells, and subjected them to cell cycle analysis.

3-2d Western blot analysis
AI resistant and LTED cells were treated as indicated on each figure. At the end each
experiment, we washed the cells in PBS, harvested using trypsin, washed in cold PBS, and
precipitated pellets by centrifugation. Cell pellets were lysed by addition of same volume of
RIPA lysis buffet to the pellets followed by several occasional vortexing and ultra
centrifugation for 45 minutes. We collected supernatant and measured protein level using
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the Biorad assay. Thirty five microgram of protein was loaded on each lane of SDSpolyacrylamide gel and subjected to electrophoresis followed by overnight transfer to
immobilon P membrane (Millipore) at 35V in cold room (4°C). The next day, the membrane
was blocked in BLOTTO milk for 30 minutes at room temperature and incubated with
individual primary antibodies for 2 hours followed by multiple cycles of washes in TBST.
Next, the membranes were incubated with appropriate goat anti-mouse or goat anti-rabbit
secondary antibodies conjugated with horseradish peroxidase (Pierce, Rockford, IL) for 1
hour at room temperature. After several wash cycles, we developed the membranes using a
Renaissance chemiluminescence system (Perkin Elmer Life Sciences, Inc., Boston, MA)
using the provided instructions of the company. Primary antibodies used for this assay
included cyclin E (HE12), CDK2, and CDK6 (Santa Cruz Biotechnology, Santa Cruz, CA),
phospho-CDK2 (Cell Signaling Technology, Danvers, MA), P21 (EMD Millipore, Billerica,
MA), P27 (BD Biosciences, San Jose, CA), Rb and CDK4 (BD Pharmingen, San Jose, CA),
pRb (S807/811; Cell Signaling Technology), aromatase (Biorad), actin (Millipore, Billerica,
MA), and vinculin (Sigma-Aldrich).

3-2e Scratch assay
LTED cells were cultured on 6-well plates and were maintained in incubator in order to
form monolayers. Next, the cells were scratched with capturing the image of the monolayer.
Plates were maintained in incubator followed by recapturing of the images at indicated times
to measure the gap between the two layers.

3-2f Establishment of xenograft model system
To assess tumorigenic potential of the cells, LTED and AI-resistant cells were injected
into mammary fat pad of nude mice followed by examination of mammary tissue for tumor
formation. To this end, 4-6 week-old nude mice were purchased from animal facility at
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Experimental Radiation Oncology department of MD Anderson Cancer Center and were
ovariectomized in order to deplete any endogenous source of estrogen. These animals were
not supplemented with any exogenous source of androgen or estrogen to assess
tumorigenicity under hormone independent condition. One week after recovery from
surgery, 5×106 cells (parental MCF7 or LTED) were harvested, mixed with matrigel (1:1
ratio) and injected into mammary fad pad (100ul total volume) followed by examination of
mammary fat pad for tumor formation. In a similar experiment, we examined experimental
metastasis model using LTED, LET-R and parental cells. To this end, 1×106 cells were
injected via tail vein into 4-6 week female nude mice. The mice were sacrificed 30-40 days
after injection, and lungs and liver tissues were collected for examination of metastasis.

3-3 RESULTS
3-3a Development of acquired resistance model to aromatase inhibitors
In order to characterize our model system, we challenged the cells that we cultured in
the presence of AIs as well as the control counterpart to increasing concentration of both
letrozole or anastrozole and assessed cell proliferation and survival. Cell proliferation
analysis after 3-day treatment revealed that long-term cultured cells show significantly
higher proliferation when challenged with either anastrozole or letrozole (Figure 20, A and
B). In addition, a 12-day survival assay showed that long-term anastrozole-treated cells can
tolerate 20 times higher concentration of the drug compared to control cells (IC50 4 M VS
0.2 M, respectively) (Figure 20C). Similarly, long-term letrozole treated cells showed higher
IC50 value when challenged with letrozole in a 12-day experiment (0.9 M VS 0.02 M
respectively) (Figure 20D). These experiments suggest that long-term treated cells are
resistant to individual aromatase inhibitors, further entitled as anastrozole resistant (ANA-R)
or letrozole resistant (LET-R) cells in this chapter.
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To assess proliferation of LTED cells, we cultured LTED cells that had been frozen at
different times simultaneously and measured cell proliferation after three days of culture in
the estrogen-deprived media. Results indicated a trend toward higher proliferation overtime
suggesting that the cells have adapted to estrogen deprivation situation (Figure 20E). We
next injected LTED and control cells into mammary fat pad of nude mice and assessed
tumor formation. These mice were ovariectomized before cell injection without any
exogenous hormone supplementation throughout the experiment. Examination of mammary
fat pad revealed that 12 out of 18 sites injected with LTED cells formed tumors (Figure 20F).
In sharp contrast, none of the mammary fat pads injected with control cells formed tumors
after two weeks. These experiments suggest estrogen-independent tumorigenesis in LTED
cells.
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Figure 20: Establishment of aromatase inhibitor resistance and LTED models. Longterm anastrozole or letrozole treated cells and their control counterparts were deprived of
estrogen and treated with androstenedione (AD 25nM) and anastrozole (1μM) or letrozole
(1μM) followed by counting cell numbers after three days (A, B). Long-term drug treated
cells were derived of estrogen and treated with androstenedione and increasing
concentrations of individual AIs followed by cell viability assay at day 12 (C, D). Parental
and LTED cells, frozen at different times, were cultured simultaneously and assessed for cell
proliferation by counting cell number after 3 days (E). Mice were ovariectomized and
received an injection in mammary fat pad using LTED or parental cells and assessed for
tumor formation at indicated times (F).
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3-3b Deregulation of cell cycle in acquired resistance to aromatase inhibitors
To further investigate the mechanism of acquired resistance to AIs, we used available
databases generated from the resistant cells and subjected them to Gene Set Enrichment
Analysis (GSEA) analysis to identify the profile of resistant cells compared to sensitive cell
lines (264). Results from our analysis revealed enrichment of cell cycle regulatory genes in
the resistant cell lines indicating that cell cycle deregulation could be an important regulator
of resistance (Figure 21A). To further characterize deregulation of cell cycle, we subjected
our resistant cells and their control counterparts to cell cycle analysis. To this end,
anastrozole and letrozole resistant cells as well as control cells were subjected to estrogen
deprivation followed by treatment with AD and different concentrations of AIs. Cell cycle
analysis revealed that control cells arrest at G1 upon treatment with AIs in a concentration
as low as 0.1 μM (Figure 21, B and C). In contrast, the AI resistant cells failed to arrest in G1
cell cycle upon treatment with the drugs. To further study the role of cell cycle, we compared
G1 cell cycle regulatory proteins in resistant and control cell line using Western blot analysis.
Results indicated that control cells responded to anastrozole by decreasing CDK2, Rb and
phospho-Rb levels while these regulators remain unchanged in resistant cells (Figure 21 D).
Collectively, our findings suggest that cell cycle deregulation is a key process in
development of resistance to AIs.
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Figure 21: Cell cycle is deregulated in acquired AI resistant cells. GSEA analysis
indicating enrichment of genes regulating cell cycle checkpoint and phases in LTED cells
compared to parental cells (A). Cell cycle analysis of AI-resistant and control cells deprived
of estrogen for three days and treated with androstenedione (25nM) and increasing
concentration of anastrozole (ANA,μM) or letrozole (LET,μM) for three days followed by cell
cycle analysis (B, C). Western blot analysis of anastrozole resistant and control cells
deprived of estrogen for three days and treated with increasing concentration of anastrozole
with similar doses as in C (D).
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3-3c Estrogen deprived cells show deregulated cell cycle pattern and respond to cell
cycle inhibitors
To further study mechanism of cell cycle deregulation in AI resistant cells, we examined
cell cycle profile of LTED cells at different intervals during estrogen deprivation process over
both short-term (4 day) and long-term (5-9 months) culture. LTED cells that were frozen at
different times were cultured simultaneously and subjected to cell cycle analysis. Results
indicated that cells respond to short-term estrogen deprivation by arresting at G1 phase of
the cell cycle compared to control cells, which is reversed after long-term derivation (Figure
22A). Western blot analysis using the cell lysates collected from LTED cells at different
intervals revealed that short-term estrogen deprivation decreased G1 regulatory proteins
such as CDK2, Rb, phospho-Rb (Figure 22B). However, the levels of the aforementioned
regulators increased significantly when they adapt to a low estrogen situation (5-7 months)
(Figure 22B). In addition, examination of aromatase in the LTED cells showed increased
level of aromatase in the resistant cells. ERα also showed a dynamic change in level along
with cell cycle regulators. To further study the contribution of cell cycle regulation in AI
resistance, we treated LTED and control cells with two cell cycle targeted therapies
dinaciclib (CDK2 inhibitor) and MLN8237 (Aurora-A kinase inhibitor) and assessed cell
viability using the HTSA survival assay. Results showed that LTED cells respond to these
inhibitors as least at a similar dose to parental cells suggesting that these medications can
be considered beneficial under context of AI resistance (Figure 22C). Our results presented
in previous chapter showed that expression of LMW-E results in deregulation of cell cycle
allowing the cells to bypass inhibition of aromatase inhibitors. In our LTED models we
observed the generation of LMW-E as an acute response to estrogen deprivation (4-day)
and after long-term estrogen deprivation (5-7 Months). In addition, using transgenic animal
models of cyclin E, our lab has shown have LMW-E expressing tumors have higher invasive
and metastatic potential (329). We asked whether LMW-E expressing LTED cells have
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higher migratory potential compared to control cells. To this end, we used a scratch assay to
compare the ability of control and LTED cells to fill the gap indicating their migratory
potential. Results showed that LTED cells show higher migration compared to parental cell
line at two different intervals of measurement (24h and 48h). Taken together, results from
LTED model also suggest that deregulation of cell cycle, through up-regulation of G1
regulators or generation of LMW-E, is associated with development of resistance.
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Figure 22: Deregulation of cell cycle is associated with estrogen independence. LTED
cells frozen at different time intervals were cultured simultaneously in estrogen-deprived
media and subjected to cell cycle analysis (A). Western blot analysis of LTED cells at
indicated times, cell lysates were analyzed by Western blot using antibodies as shown (B).
Cell viability assay indicating sensitivity of LTED and control cells to CK2 inhibitor (dinaciclib)
and Aurora-A kinase inhibitor (MLN8237). Cells were pleated in 96-well plates in estrogendeprived media, treated with indicated doses for 72h followed by culture in drug-free media
until assessed at day 12 (C). Scratch assay comparing percentage of wound closure at 24h
or 48h following scratch induction using LTED and control cells, representative image is
shown (D).
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To further explore cell cycle deregulation in AI resistant cells, we subjected our AI
resistant cells and control cells to treatment with/without AIs and examined major G1 cell
cycle regulators in this model. Results indicated that in control cells, treatment with AIs
decreased CDK2, phospho-CDK2, Rb, phospho-Rb, and p21 protein levels while cyclin A,
CDK4, CDK6, and p27 remained either unchanged or elevated. In contrast, AI resistant cells
did not show decrease in protein level of CDK2, phoospho-CDK2, Rb or phospho-Rb
proteins upon drug treatment. Protein levels of CDK4, CDK6 and p27 increased in letrozole
resistant cells upon treatment similar to control cells while CDK4 and p27 levels decreased
in anastrozole resistant ones. Next, we asked whether ER or other signaling pathways such
as PI3K contribute to deregulation of cell cycle machinery in AI resistant cells. To this end,
cell lysates were collected from control and AI resistant cells following treatment with
Fulvestrant (ER down regulator) or PI3K inhibitor (GDC0941) and subjected them to
Western blot analysis (Figure 23B). Results indicated that Fulvestrant decreased Rb and
phospho-Rb levels in both control and AI resistant cells while the levels of cyclin E and
cyclin D were generally unaffected. In a similar fashion, inhibition of PI3K pathway resulted
in down-regulation of Rb and Phospho-Rb suggesting that these two inhibitors could be
beneficial in AI resistant cells by inhibiting Rb pathway.
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A

B

Figure 23: Cell cycle regulatory proteins are altered in AI resistant cells.
Representative Western blot comparing level of cell cycle regulators in AI resistant or control
cells treated with vector, anastrozole (ANA 1 M), or letrozole (LET 1 M) for three days
followed by Western blot analysis using antibodies as indicated on the figure (A).
Representative Western blot indicating level of cell cycle regulators in control, anastrozole
resistant cells (ANA-R), or letrozole resistant (LET-R) ones (B). Cells were treated with
Vehicle (DMSO and methanol), Fulvestrant (1μM) or PI3K inhibitor (GDC0941, 1μM) for 24
hours and followed by Western blot analysis.
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3-4 DISCUSSION
In this study, we aim to understand mechanism of acquired resistance to aromatase
inhibitors by focusing on cell cycle using two different model systems; LTED and cells that
become resistant through long-term culture with AIs. Using these two model systems, we
have shown that in contrast to control cell, resistant cells have deregulated cell cycle profile
as they fail to arrest at G1. Specifically, we showed that resistance cells have higher levels
of CDK2, Rb, phospho-Rb and LMW-E (LTED model) associated with deregulated cell cycle
in comparison to sensitive cell lines. Our results presented in previous chapter indicated that
LMW-E expression bypasses AI-mediated inhibition through a CDK2 dependent manner in a
de novo setting. We further showed that inhibition of CDK2 by dinaciclib reverses resistance
to AIs (de novo model). This signifies that targeting LMW-E/CDK2 pathway could also be a
potential target in the acquired resistant setting. In fact, xenograft tumors derived from
letrozole resistant cell lines showed response to roscovitine (CDK2 inhibitor) further
supporting this hypothesis (374).
Using Western blot analysis on LTED cells derived from MCF7 cell line we indicated a
dynamic change in the expression of ERα throughout estrogen deprivation process. In the
acute phase the cells respond to estrogen deprivation by decreasing ER expression,
however eventually ER expression returns to baseline following a few months of estrogen
deprivation. These results are in line with previous studies using Immunohistochemistry and
qRT-PCR to show down-regulation of ER in the acute phase of estrogen deprivation
following up-regulation after 10 months (372). Evidence from patients treated with
aromatase inhibitors indicates that these dynamic changes are also seen in tumor tissues
isolated from breast cancer patients (375). Miller et al used microarray analysis on tumor
tissues taken before and after 2 weeks of neo-adjuvant letrozole therapy and found 91
down-regulated genes as a response to AI therapy mainly clustered in cell cycle progression
category (375). One possible explanation for the acute response could be that the cells
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switch dependence from ER pathway to other mitogenic pathways such as PI3K/AKT
signaling pathway. For example, Her2 and ERBB3, as two tyrosine kinase receptors that
active PI3K/AKT pathway, are up-regulated in letrozole resistant cells (376). In addition,
treatment of xenograft tumors with an ERBB3 inhibitor (Seribantumab) delayed development
of resistance to letrozole indicating dependence of tumors on this signaling pathway in
response to AIs. On the other hand, up-regulation of ER level after long-term estrogen
deprivation phase may suggest that the tumors enter a hypersensitive state in which they
respond to very low levels of circulating estrogen in the plasma. This raises the question
whether restart of anti-estrogen therapy after a gap of therapy in resistant condition may be
beneficial in patients. In fact, letrozole resistant xenograft tumors showed a significant
response to letrozole after a cycle of being taken “off” treatment suggesting that this could
be a potential treatment strategy (377).
Studies using MCF7 cell line have shown that expression of ERα is synchronized with
different phases of cell cycle suggesting a cell-cycle regulated process (378). In addition,
exogenous expression of cyclin D even in the absence of estrogen is able to induce ER
transcriptional activity (292). In vitro studies using immunoprecipitation assays showed direct
association between cyclin D and ERα (292). On the other hand, in ER positive breast
cancer cells, estrogen induces expression of cyclin D (379). In order to study the interaction
between ERα and cell cycle under AI resistant condition, we treated resistant cells with
Fulvestrant to down-regulate ER and subsequently detected down-regulation of G1 cell
cycle regulators. This suggests that the beneficial effect of Fulvestrant in AI resistant setting
could partially be attributed to cell cycle inhibition.
Our results indicated generation of LMW-E with higher migratory potential in LTED cells
compared to the control cell line. Using mammary epithelial cells our lab has indicated that
expression of LMW-E enriches cancer stem cell population upon serial transplantation and
is linked with invasion. In addition, transgenic animals with LMW-E expression in mammary

131

tissues was linked with higher mammary tumor formation and metastasis (359). Our findings
in LTED cells fit well with previous reports indicating up-regulation of EMT genes in LTED
model (372). In addition, gene expression analysis of post-letrozole treated tumors revealed
upregulation of mesenchymal markers such as VIM and MMP2 and enrichment of the
cancer stem cell phenotype (248). These data suggest that the role of LMW-E and its
significance in invasion and metastasis during the development of AI resistance needs
further investigation. Experiments are undergoing to study biologic significance of LMW-E
using cyclin E knock out model system in LTED cells.
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CHAPTER 4: CONCLUSIONS, FUTURE DIRECTIONS
4-1 MAJOR FINDINGS
HR positive breast cancer constitutes the majority of breast cancer patients, thus antihormonal therapy is considered as an effective strategy for these patients. Aromatase
inhibitors are currently considered as the standard of therapy in HR+ post-menopausal
patients. However, resistance to these therapies develops and is considered a significant
treatment challenge. Cyclin E is deregulated in breast cancer patients and correlates with
poor survival. Thus, we hypothesized that expression of cyclin E contributes to development
of resistance to aromatase inhibitors. The data presented in this dissertation addresses the
following questions:
1- Could Cyclin E be applied as a predictive marker of response to aromatase inhibitors in
HR positive patients?
Immunohistochemistry staining of pre and post-treatment with neoadjuvant AIs
revealed cytoplasmic staining of cyclin E, representing LMW-E, in about 50% of tumors.
Additionally, LMW-E expression was associated with diminished tumor response (higher
volume of remaining tumor), higher lymph node involvement, and increased breast cancer
relapse. Examination of tumor tissues for phospho-CDK2 revealed direct correlation
between expression of cytoplasmic phospho-CDK2 and cytoplasmic cyclin E as well as
diminished response to AIs.
2- Would the deregulation of cell cycle by LMW-E affect response to aromatase inhibitors in
vitro?
Treatment with aromatase inhibitors was able to inhibit AD-induced proliferation and
induce cell cycle arrest. In contrast, LMW-E expression enhanced proliferation of the cells in
spite of AI treatment, bypassed cell cycle arrest, increased CDK2, phospho-CDK2, Rb, and
phospho-Rb levels.
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3- Is the effect of LMW-E/CDK2 pathway on response to aromatase inhibitors reversible?
One important feature of our system is its inducibility, where we can turn off cyclin E
induction (deinduced) and examine response to AIs. Western blot analysis revealed that
CDK2, phospho-CDK2, Rb and phosphor-Rb levels decreased after LMW-E expression is
switched off. In addition, cell cycle analysis of these cells indicated that while LMW-E
expressing cells showed significantly higher S phase, deinduced cells showed similar cell
cycle pattern as uninduced cells. Moreover, down-regulation of CDK2 or Rb independently
abrogated LMW-E medicated resistance to AIs suggesting that CDK2 inhibitors are potential
therapies for LMW-E expressing tumors.
4- Does LMW-E regulate response to aromatase inhibitors in xenograft tumors?
Letrozole treatment significantly induced tumor regression in xenograft tumors derived
from aromatase overexpressing MCF7 cells. However, LMW-E expressing tumors showed
significantly higher tumor volume when treated with letrozole. LMW-E expression in tumors
was associated with higher expression of cytoplasmic CDK2 and Ki67 expression.
5- Is dinaciclib or palbociclib effective to reverse LMW-E medicated resistance to AIs?
CDK2 level and CDK2 kinase activity increased upon LMW-E expression while CDK4
level remained unchanged. In addition, LMW-E expressing cells responded to dinaciclib but
not palbociclib.

4-2 LIMITATIONS OF THE STUDY
One limitation of the current study is the overexpression of aromatase inside the breast
cancer cells, whereas the main source of aromatase in women is peripheral tissues such as
adipose tissue. In this model system, we deprived the cells of estrogen and provided them
with androstenedione (estrogen precursor) that can be converted to estrogen by the activity
of aromatase. While this system differs from the status of aromatase production in postmenopausal women, it recapitulates the same phenomenon. Our data clearly show that the
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cells respond to androstenedione and subsequently to letrozole or anastrozole treatment. In
addition, clinical trials have confirmed similar results originally generated from this preclinical model system indicating that it is a clinically relevant model (380).

4-3 FUTURE DIRECTIONS
Our results indicated that LMW-E expression bypassed AI inhibition in vitro through
deregulation of cell cycle. In addition, examination of tumor tissues from patients who
received AIs in the neoadjuvant setting revealed that cyclin E and phospho-CDK2
expression could predict response to AIs. LMW-E expression in tumors correlated with
higher volume of remaining tumor, lymph node involvement, as well as higher relapse from
breast cancer throughout the long-term follow up. Our in vitro results using cyclin E inducible
model revealed that LMW-E mediated resistance is reversible by switching off cyclin E
expression (doxycycline removal) or down-regulation of CDK2. In addition, LMW-E
expressing cells responded to dinaciclib suggesting that targeting CDK2 is a potential
therapy for LMW-E expressing tumors. One potential application of this project is to further
investigate dinaciclib (or other clinically relevant CDK2 inhibitors) in animal models and in
early phase clinical trials. We established a xenograft model of cyclin E expressing tumors
using aromatase overexpressing cell line and indicated that LMW-E expressing tumors are
unresponsive to letrozole. It is necessary to test whether dinaciclib can inhibit tumor growth
in these LMW-E expressing tumors. Another strategy is to interrogate response to AIs after
switching off LMW-E expression by removing doxycycline from the drinking water. It is
speculated that LMW-E expressing tumors would shrink in response to combination of AI
treatment and dinaciclib. In addition, we anticipate that tumors would regress when LMW-E
is turned off upon doxycycline removal.
Another therapeutic application of this project is to use dinaciclib in early phase clinical
trials for patients with LMW-E expressing tumors. Preoperative treatment with AIs in
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selected ER+ breast cancer patients is a feasible approach to study response to treatment
and identifying markers of resistance (190, 191). This alternative treatment approach has
increased the chance of breast conservative treatment in HR+ post-menopausal patients
with stage II/III disease (193, 381). Using this approach, we propose that patients with early
resistance to AIs who express LMW-E be treated with dinaciclib in the neoadjuvant setting
to assess tumor response before undergoing surgery. Analysis of the data from ACOSOG
Z1031B trial revealed that only two out of 35 patients who were defined as resistant to neoadjuvant AIs (Ki67>10%) experienced pathologic complete response when underwent neoadjuvant chemotherapy suggesting that these patients were resistant to chemotherapy.
Using immunohistochemistry analysis, we detected LMW-E expression in approximately
50% of ER+ post-menopausal patients who received neoadjuvant AIs at MD Anderson
Cancer Center as part of the Z1031 trial indicating that majority of these patients may be
considered candidates for dinaciclib treatment. Dinaciclib as monotherapy has been shown
to be safe and generally well tolerated in clinical trials (347, 350). Combination of dinaciclib
with epirubicin, however was found to be toxic in TNBC patients (349). Further studies are
required to study the efficacy of dinaciclib combined with AIs specifically in patients with
LMW-E expressing tumors.
Another potential application of our findings that needs further investigation is use of
dinaciclib in patients who are unresponsive or develop resistance to palbociclib. Addition of
palbociclib to letrozole has shown to increase progression-free survival in HR+/Her2negative breast cancer patients (295, 296). In a case series study, we have shown
unexpectedly rapid progression of breast cancer within four months upon discontinuation of
palbociclib treatment indicating that alternative treatments are required (382). In addition,
overexpression of cyclin E1 level through gene amplification has been detected in breast
cancer cells that developed resistant to palbociclib in vitro (365). These results are in line
with our findings that LMW-E expressing cells are unresponsive to palbociclib but respond to
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dinaciclib (chapter 2). Thus, dinaciclib can be used in patients who progress on palbociclib
or alternatively with palbociclib to prevent development of resistance to palbociclib.
In the third chapter of this project, we focused on understanding the mechanism of
resistance to aromatase inhibitors in the acquired setting. To this end, we generated two
model systems: LTED and ER+ cells that developed resistance to individual aromatase
inhibitors in vitro. Further experiments are still undergoing using these two model systems in
our lab, however our current data suggest deregulation of cell cycle in the acquired resistant
setting. These two model systems are valuable tools to further explore resistant
mechanisms to aromatase inhibitors.
Our preliminary results in the LTED model system showed higher tumorigenic potential
of LTED cells when transplanted into mammary fat pad and higher migration potential in
vitro. These results are in line with another study indicating higher invasion in LTED model
system (383). Of particular note, we detected generation of LMW-E in the LTED cells
compared to parental cells. In transgenic animal models, overexpression of LMW-E in the
mammary tissue correlated with increased tumor formation and higher metastasis (329). In
addition, in bladder cancer cell lines and human tissue samples, expression of LMW-E was
associated with invasive phenotype and poor survival (384). Therefore, it is intriguing to
study invasive potential of resistant cells using in vitro assays and an experimental model of
metastasis through injection of resistant cells into tail vein followed by examination of
metastatic sites (undergoing experiments). One experimental approach to address the
significance of cyclin E in our model system is to knock out cyclin E using the Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) system (ongoing
experiment) followed by examination of biologic effects using specific assays such as
proliferation, invasion and metastasis. This system has been established in our lab and
consists of two components including a guide RNA (gRNA) that can be designed to
specifically recognize cyclin E sequence and a non-specific endonuclease (Cas9) that will
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cut the specific sequence. This approach will help us investigate significance of cyclin E by
knocking out cyclin E in experimental models.
Another field of research that needs further investigation is the role of CSC in mediating
resistance to AIs. CSCs exist as a subpopulation of tumor cells with self-renewal capacity
that can survive the pressure of chemotherapy or radiation (235, 236). In one study,
examination of post-letrozole treatment tumors revealed enrichment of CSCs (248). One
possible theory in the context of HR+ breast cancer is the existence of a subpopulation of
ER-ve cells with stem cells features that are less dependent on estrogen to survive. These
cells may silent ER expression upon treatment in order to survive anti-estrogen treatment.
Indeed, in vitro analysis revealed that AI resistant cells showed higher Her-2 expression and
treatment of resistant cells with anti-Her-2 therapy decreased population of cancer stem
cells (249). In line with this, we detected a dynamic change in the expression of ERα
throughout estrogen deprivation process reaching a nadir at 1 month after estrogen
deprivation in LTED cells (see chapter 3). Therefore, understanding the role of cancer stem
cells and targeting specific pathways that contribute to resistance could have therapeutic
implication. Of particular note, we detected LMW-E expression in the LTED model that may
play role in stem cell behavior of these cells. Introduction of LMW-E but not full length cyclin
E into the hMEC doubled cancer stem cell population (CD44high/CD24low) and resulted in
tumorigenicity when injected in vivo (328). Moreover, serial transplantation of the cells in
vivo enriched the population of CSCs indicating the link between LMW-E and cancer stem
cell phenotype. Therefore, the role of LMW-E in the mediating resistance to AIs needs
further investigation.
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4-4 SIGNIFICANCE
Almost 75% of all breast cancer patients express hormone receptor and thus require
hormonal therapy. Aromatase inhibitors are considered the first line therapy in hormone
receptor positive patients who already reached menopause. However, resistance to AIs is
considered as a clinical challenge in treatment. In addition, specific biomarkers of response
are required to identify resistant patients in the early phase of treatment. Herein, we show
that cytoplasmic expression of cyclin E (LMW-E) and phospho-CDK2 can identify a subset
of patients that are resistant to aromatase inhibitors. In addition, our results show that
targeting CDK2 by dinaciclib is a potential therapeutic strategy to inhibit LMW-E expressing
tumor cells providing evidence that dinaciclib has therapeutic implication in HR+ patients
with LMW-E expressing tumors.
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